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Abstract 
Cancer is a complex, but also devastating disease, which today, more than ever, is 
present in our lives and society. Practically every person has a close relative or friend, 
or has been themselves affected by this disease. Although the incidence of cancer has 
been increasing rapidly, it is not a modern illness. Cancer has been detected in several 
archaeological findings, from dinosaurs to mummies (1–3). Most recently, in February 
2019, a report was published about the oldest indication of cancer ever found in 
vertebrates. It describes the finding of osteosarcoma in a Middle Triassic stem-turtle 
(1). As discussed in the article, the reason why this disease can be found virtually from 
the beginning of life, is because it is an unfortunate side effect of cell development 
during life and evolution (1). The authors of the paper put it most adequately, in my 
opinion, as they say: "Cancer is not a modern physiological defect but rather a 
vulnerability that is deeply rooted in vertebrate evolutionary history" (1). 
Cells are constantly renewing, dividing and adapting themselves to survive. These 
adaptations can provide an evolutionary advantage and, sometimes, be passed on and 
change the species. However, sometimes mistakes occur that lead cells to lose 
replication control and cancer arises. The fact that cancer arises from errors or changes 
during cell development makes it very complex, adaptable and difficult to understand 
and treat. This complexity can be observed in the different tissues, types and sub-types 
of the disease, which often manifest themselves as almost completely different entities, 
with different causes, development and outcomes. Moreover, the fact that it is your 
body attacking itself, and not a foreign organism, makes it difficult to detect and treat, 
but also hard for patients and society to understand and accept it. Curiously, cancer 
findings in fossils are a rare discovery, one of the reasons for this is the degradation of 
soft tissue in time, which makes detection in these tissues impossible (1). Other reasons 
are environmental and genetic changes.  
As constant technological developments have, on one hand, increased our lifespan 
allowing for more cell replication and stress exposure, which increases the chances of 
mutation. On the other hand, they put us in contact with carcinogens such as growth 
hormones, pesticides, pollution and radiation that contribute for an increased incidence 
of cancer. Moreover, better understanding and diagnostics tools allow cancer patients 
to be identified more often and rapidly than ever. 
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One of the environmental causes for cancer is radiation, such as, for example, solar UV 
light, which is one of the main causes of malignant melanoma, one of the most 
aggressive malignancies in humans (4). It has a high incidence worldwide, which is 
unfortunately expected to increase, with a global mortality rate of 20% (5). Case 
numbers can be correlated with tropical, sunny regions and ozone layer holes, as is the 
case of Australia, as well as phenotypic features such as pale white skin, blond or red 
hair and blue eyes, and familial history (4,6,7). Since skin cells are designed to have a 
protective role, they are very adaptable and resistant to apoptosis induced by DNA 
mutation, characteristics which are preserved in and often used by malignant cells for 
their survival (6). Therefore, the malignant transformation, metastasis and drug-
resistance development that follows are all complex, multifactorial processes dependent 
on many variables, which present tremendous challenges for the development of 
curative therapy. Although there have been many therapeutic improvements, most 
drugs only interfere with the growth of primary tumours (8–10). As a result, patients 
develop metastatic melanoma, which is one of the most aggressive and drug resistant 
neoplasm that sadly leads to death in the majority of cases, usually due to resistance to 
treatment (4). 
Resistance development is a complex, multipart process, not yet fully understood. In 
this work our main interest is the environment-mediated drug resistance (EM-DR), 
which is an innate, transient protective effect that the microenvironment provides to 
cells. It is an important phenomenon because it allows for the development of acquired 
drug resistance, i.e. genetic adaptations in response to prolonged therapy.  
One type of EM-DR is cell adhesion-mediated drug resistance (CAM-DR), which is 
mediated by the attachment of cell membrane proteins, such as integrins and syndecans, 
to components of the extracellular matrix (ECM), which triggers survival cell-
signalling pathways. The mitogen-activated protein kinase (MAPK) pathway has been 
associated with melanoma development, progression and resistance and intensively 
studied (11,12). For this reason, we decided to focus this work in the study of an 
associated but less studied pathway in melanoma, the FAK/PI3K/AKT signalling 
pathway, which is also known to lead to cell survival.  
 
 
Abstract 
 
29 
 
With this purpose, we have investigated the sensitivity of melanoma cells to cisplatin 
treatment under different integrin-activating experimental conditions. Cells were 
seeded on surfaces coated with ECM components - fibronectin and collagen - and 
treated with Mn2+; a known integrin activator, previously to cisplatin addition. A 
PI3K/mTOR inhibitor was also used, in order to interfere in cell signalling. After the 
treatments, cell sensitivity to cisplatin was evaluated using a colorimetric cytotoxicity 
test. Moreover, β1 integrin-deficient cells were generated and tested, together with 
syndecan-4 knockdown cells, with the purpose of assessing the importance of these 
adhesion molecules for the cells in the context of cisplatin resistance. Finally, the 
activation of the FAK/PI3K/AKT signalling pathway was observed under these 
experimental conditions through flow cytometry. 
This work provides a view into one of the CAM-DR mechanisms used by melanoma 
cells to protect themselves from cisplatin stress. It shows the importance of integrins, 
syndecans and the ECM in this context, as well as in cell plasticity and the complexities 
of resistance formation.  
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1. Introduction 
Melanoma 
The last report from the International Agency for Research on Cancer (GLOBOCAN – 
WHO), on September 2018, showed over 18 million new cases of cancer worldwide, 
more than half leading to death; this number is expected to rise to 29.5 million by 2040 
(5). In Germany and Brazil there were 608,742 and 559,371 new cases (this number is 
expected to duplicate by 2040); and 247,462 and 243,588 deaths by cancer in 2018, 
respectively (5).  
 
Figure 1. Cancer incidence in the world in 2018 and 2040 projection according to report released 
by the World Health Organization (5). 
Malignant melanoma, specifically, has an incidence of 287,723 new cases worldwide 
with a mortality rate (MR) of about 20% (5). In Germany, 31,432 (MR 11,5%) people 
are affected and in Brazil 7,407 (MR 28%), unfortunately these numbers are expected 
to increase in the next two decades (5).  
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Figure 2. Melanoma incidence in the world in 2018 and 2040 projection according to report released 
by the World Health Organization (5). 
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The 5-year survival rate of melanoma is low, only 14% of patients survive (4). 
Malignant melanoma is one of the most aggressive malignancies in humans and is 
responsible for 60–80% of deaths from skin cancer (4). This results from the lack of 
deeper understanding of the genetic alterations and signalling pathways of malignant 
transformation events, metastasis process, and chemotherapy and radiotherapy 
resistance mechanisms.  
Normal melanocytes originate from the neural crest as pluripotent cells that suffer 
induction through bone morphogenic protein signalling; induction causes neural crest 
stem cells to undergo epithelial–mesenchymal transition (EMT), lose adhesion to 
neighbouring cells and gain migrative capacities (4,6,7). Mature melanocytes produce 
pigment through very complex cell machinery in vesicles called melanosomes. The 
pigment produced has been classified as eumelanin (brown/black) and pheomelanin 
(red/blond), which have been associated with an innate higher oxidative stress in the 
skin, independent of UV radiation; but also have shown to carry a non-functional 
polymorphic variant of the melanocortin receptor 1 (MC1R) that is involved in melanin 
production as protective response to UV radiation (4,6,13). Moreover, skin 
pigmentation can also be constitutive or adaptive. The former refers to the amount and 
type of pigment synthesized, as well as the maturation process of the melanosomes, 
while the latter refers to melanin production as a protection mechanism triggered by 
UV radiation (6). UV exposure can cause DNA damage (usually C  T) to the most 
superficial skin layers, this leads to p53 stabilization and upregulation of pro-
opiomelanocortin (POMC) (6,14). POMC is cleaved forming various derivates 
including β-endorphin, which is responsible for sun-seeking behaviour; and melanocyte 
stimulating hormone (MSH) (14). MSH is secreted in order to activate its receptor, 
MC1R, in other underlying melanocytes (6). This leads to cAMP induction and 
consequent upregulation of microphthalmia-associated transcription factor (MITF), 
which regulates the melanocyte lineage. This protective role of the melanocytes renders 
them innately programmed to adapt to DNA damage and stress; this is known as 
melanocyte plasticity and is preserved in and often used by malignant cells for their 
survival.  
Malignant transformation and drug-resistance development of melanocytes is a 
complex process, which involves interactions of environmental and genetic factors 
leading to loss of regulation of cell proliferation, apoptosis and cell-cell interactions. 
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Thus, the risk for melanoma depends on various factors, such as genetic and 
environmental influences, some risk factors include UV exposure, pale white skin, 
blond or red hair and blue eyes phenotypes, as mentioned above, but also large and 
irregular atypical or dysplastic nevi, and family history (10% of cases) (4,6,7). The 
many genetic alterations that occur in the melanocytes during malignant transformation 
have been thoroughly analysed and reviewed by the melanoma Cancer Genome Atlas 
Program (TCGA), and only a few examples will be discussed in this work (15). 
One of the familial melanoma mutations is in the CDKN2A gene, which regulates cell 
cycle and p53, a known cancer related protein (4,16,17). Other melanoma-susceptibility 
genes include CDK4, RB1 and MITF. As previously mentioned, MITF is a melanocyte-
specific transcription factor involved in melanin production, thus melanocytes are 
highly dependent on MITF for their UV protective function (6). However, MITF is 
involved in many other essential cell processes, such as differentiation, proliferation 
and survival (6,18). Interestingly, MITF dependence is retained in malignant 
transformation of melanocytes, where this gene is mutated (2-8% of amelanotic 
tumours), overexpressed or upregulated (18,19). Several mechanisms are involved in 
the regulation of MITF expression and/or activity in cancer, including epigenetic and 
microenvironmental signals, as well as transcription factors and signalling pathways; 
for example, MITF deregulation can often be observed with BRAF mutation, which is 
consistent with the role of MITF as an oncogene in melanoma cells, highly dependent 
on and as a factor for familial melanoma (6,20–23). Moreover, ERK mutations can also 
cause MITF deregulation (18).  
The abovementioned BRAF and ERK are known components of the MAPK signalling 
pathway, which is upregulated in melanoma, and one of the most important malignancy 
drivers. It is initiated by tyrosine kinase (RTK) or G-protein coupled receptors (GPCR), 
which recruit and activate the protein RAS (H-, K- or N- isoforms). Activated RAS 
then binds to RAF (A-, B- or C- isoforms), inducing RAF dimerization and activation. 
RAF is then able to phosphorylate and activate MEK, which then phosphorylates and 
activates its downstream effector ERK that, in turn, is able to regulate cell cycle 
progression. Therefore, this signalling pathway is often mutated in melanoma cells. 
BRAF-activating mutation is usually a cytosine to tyrosine exchange, usually 
associated with UV-radiation (6,24). It is the most common of such mutations, present 
in 40–50% of melanomas (16,17,24–26). Found in another 15–30% of cases are NRAS 
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mutations, which can also be connected to UV-radiation damage (16,17,24,27,28). 
Interestingly, NRAS and BRAF mutations seem to be mutually exclusive. On the other 
hand, BRAF-activation mutation correlates with ERK mutation, overexpression and 
constitutive activation (4,29).  
The high prevalence of BRAF and NRAS mutations in malignant melanoma has drawn 
therapeutic and research efforts upon this signalling pathway, while the PI3K/AKT 
pathway has been considered secondary. However, this is a major regulator of cell 
behaviour and its mutation and deregulation is an essential part of cancer cell 
transformation and the maintenance of the malignant phenotype (30). The PI3K/AKT 
pathway is one of the most studied in cancer and has been shown to be one of the most 
affected by genetic alterations caused by tumour development, growth, resistance and 
metastasis (31). Also, in melanoma, the effectors of this pathway have been shown to 
be mutated or genetically altered. The most common PI3K/AKT activating mutations 
in melanoma are NRAS (15 - 20%) and the loss or mutation of the PI3K regulator, 
PTEN (up to 30%) (15,31,32). These two mutations are concomitantly exclusive, 
probably because of their redundant role as PI3K/AKT activators. Furthermore, PTEN 
mutation is usually accompanied by BRAF mutation, thereby concomitant de-
regulation of MAPK pathway, results in concurrent activation of both pathways 
(16,31,33–36). 
Moreover, PI3K and AKT can be found to be mutated or overexpressed in other cases 
(6,24,37). For example, 40% of melanomas present upregulation of AKT due to 
mutations, upregulation of upstream kinases or loss of function of regulating proteins 
(15,31). TCGA has shown an association between AKT overexpression and NRAS 
mutated phenotype (40%), although some studies have shown higher AKT activation 
in cells with PTEN loss (15,38). AKT point mutations are considered rare (1-2%), but 
can be observed in melanoma, often associated to PI3K mutations (15,31). Curiously, 
although point mutations in AKT subtype 1 could be observed in all cancer types, AKT 
isoform 3 is only mutated in melanoma cells, which could be used as a specific drug 
target in patients that carry this mutation (31,37,39–41). Additionally, point mutations 
of the PI3K gene can be found in 2% to 6% of melanomas (15,31,42,43). 
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Figure 3. Molecular and immunologic signalling in melanoma. Depicted summary of the complex and 
intertwined signalling present in melanoma cells. Adapted from Sullivan et al. (16). 
The primary therapeutic treatment option is the surgical removal of the malignant 
melanoma tissue with a sentinel lymph node biopsy (SLNB) in order to evaluate the 
presence of cancer cells on the lymph node(s) where the melanoma is most likely to 
disperse. Early surgical removal of primary tumours and lymph node resection is an 
effective treatment, but up to 20% of patients may go on to develop metastatic disease, 
which has a very poor prognosis (44–46). This occurs because standard 
chemotherapeutics, that display a proven success record against many different cancers, 
are ineffective on metastatic melanoma (44–46). The plasticity of skin cells to adapt 
and protect themselves from UV stress gives them an almost innate metastatic potential. 
Thus, melanoma recurrence is often manifested in a metastatic spread of the primary 
tumour. Until 2010, dacarbazine was the only treatment for melanoma, sometimes 
administrated with interleukin 2 (IL-2) as an adjuvant (only approved in the USA) 
(6,17). In the last decade, however, therapy for metastatic melanoma has advanced 
significantly. The new therapeutic approaches can be divided into immunomodulation, 
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as for example, IL-2 itself or more relevant, monoclonal antibodies blocking CTLA-4, 
PD-1 or PD-L1, which have been shown to decrease immune tolerance, consequently 
inducing tumour regression by intensifying T-cell attack (16,17). Other approaches 
target mutated signalling pathway components, that make use of the abovementioned 
mutations to select adequate targeted therapy in the form of inhibitors. Two BRAF 
inhibitors, for instance, have shown promising clinical results and have been approved 
for treatment of patients with BRAF-mutant melanomas (16,17,25,47,48). Inhibitors 
have also been developed against other MAPK pathway proteins, which are often 
mutated or over-expressed/activated in melanoma, such as the MEK inhibitor 
AS703026 (NCT01693068); MEK inhibitor MEK162 (NCT01763164, NCT01320085, 
NCT01337765); MEK inhibitor AZD6244 (NCT00866177, NCT00338130) and ERK 
inhibitor LTT462 (NCT02711345) (49–51). Inhibitors of members of the PI3K/AKT 
signalling pathway have also been developed: PI3K inhibitor BEZ235 (NCT01343498, 
NCT01195376, NCT01337765, NCT01337765, NCT01285466, NCT00620594, 
NCT01508104), AKT inhibitor GSK2110183 (NCT01653912, NCT01531894, 
NCT01476137), AKT inhibitor AZD5363 (NCT02465060, NCT03310541, 
NCT01226316), AKT inhibitor GDC0068 (NCT01562275, NCT02536391, 
NCT02536391), AKT inhibitor MK2206 (NCT01519427, NCT01480154). 
Despite all the treatment advances listed above, the American cancer society still 
recognizes chemotherapy as a non-usual treatment for melanoma in palliative setting, 
to relieve symptoms and extend patient survival in extreme cases where other 
treatments have failed (52). Especially, by using direct infusion of the drug into the 
tumour or electrochemotherapy, which consists of applying an electric field to the cell 
membrane to increase its permeability (53–55). Electrochemotherapy is well-
established in the treatment of superficial neoplastic lesions such as melanomas, usually 
in cases if unresectable tumours as a palliative measure (53–55). The chemotherapeutic 
arsenal of agents includes cisplatin, carboplatin, paclitaxel, and dacarbazine (4). 
Moreover, metastatic development and treatment resistance is still a big issue which 
prevents permanent curative results. Sadly the majority of metastatic melanoma 
patients still dies within a few years of metastasis development (6,56). For this reason, 
even though the response to chemotherapeutic drugs is only moderated, studies have 
been made to try to combine these older treatment options to the newer inhibitors and 
overcome drug resistance (45,57–59). 
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Cisplatin 
As mentioned above, the global incidence of melanoma has been increasing. New 
therapies offer exciting prospects for improved survival and have supplanted the role 
of chemotherapy as first- and second-line therapy in melanoma treatment. However, 
the development of resistance against such therapies is a major problem and the need 
for additional effective melanoma therapy remains. Cytostatic compounds, such as 
cisplatin are still used in extreme cases and can be combined with the newer agents to 
enhance their effect (52). Platinum compounds, such as cisplatin, are the most effective 
chemotherapeutics for a number of major cancers, but have been considered ineffective 
on metastatic melanoma, even though they show a similar average response rate as 
dacarbazine (about 14%), which has been considered standard treatment for melanoma 
for three decades (44,46). 
Cisplatin was synthesized for the first time by Michele Peyrone in the 19th century, but 
it was not until 1960 that its cytostatic effect was identified (60,61). The effect of the 
compound was attributed to two active platinum complexes: [Pt IV (NH3)2Cl4] and its 
cis isomer [Pt II (NH3)2Cl2], which became known as cisplatin. Shortly thereafter the 
first in vivo assays was conducted, where cancer infected mice were treated with 
cisplatin showing tumour reduction (62). Already in 1971, the first clinical trials were 
performed and, in 1978, the FDA approved cisplatin as a cancer therapy drug (63,64). 
Due to the severe effects of cisplatin, such as neuro-, oto- and nephrotoxicity, some less 
toxic analogues, such as carboplatin, have since been synthesized (65–67).  
The structure of cis- diamminedichloridoplatinum(II) is formed by a square planar 
coordination complex with platinum in the middle and two ammines and chlorides in a 
cis-position (shown in 1) (68,69). The neutral charge of the structure, caused by the 
balance between the two negatively charged chlorides and the two positive platinum 
atoms, makes cisplatin hard to dissolve in water (64). In contact with water the parent 
species, depicted in 1, is hydrolysed into five dissociation products: chlorido-aqua (2), 
diaqua (3), chlorido-hydroxido (4), hydroxido-aqua (5), and dihydroxido (6) (68,70). 
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Figure 4. Hydrolysis of cisplatin. In aqueous environments, cisplatin (1) hydrolyses into chlorido-aqua 
(2), diaqua (3), chlorido-hydroxido (4), hydroxido-aqua (5), and dihydroxido (6). Adapted from Khateeb 
et al. (70).  
This dissociation process is dependent on the total drug and chloride concentration and 
pH, and influences the amount of reactive species that can actually induce cytotoxicity 
(68). For this reason, the final intravenous formula to be injected in patients is stabilized 
with saline solution (NaCl 0.9 % (w/v)) that preserves the dichloride parental species 
at 89 - 97% of the solution, conditions similar to the blood and extracellular situations 
(85%) (68,69). Upon arrival at the cells, cisplatin complexes infiltrate the cell through 
different mechanisms, which are still under debate. Passive diffusion has been accepted 
as the main cisplatin absorption mechanism for decades (71). Cisplatin absorption is 
slow and dependent on many parameters, such as pH and intracellular ion concentration 
(63). However, other uptake mechanisms such as transporters and ion channels have 
also been associated with cisplatin absorption (72). The most important of which, is the 
copper-transporter CTR1, which has been shown to be downregulated in cisplatin 
resistant cells (73). 
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Once inside the cell, intracellular conditions lead to hydrolysis of about 50% of the 
dichloride form, from 85% to 44%, leading to a rapid increase in the mono- and diaqua 
complexes (hydroxido-aqua (2%), chlorido-aqua (24%) diaqua (less than 1%) (68). 
These aqua complexes are very reactive electrophile species, hence, they display high 
affinity for structures with nucleophilic cores such as DNA (71). Cisplatin causes DNA 
adducts by binding to the N7-position of the imidazole ring of the DNA purine bases 
adenine and guanine, thereby resulting in DNA-protein crosslinks, interstrand 
crosslinks, as well as the more toxic intrastrand crosslinks (69). These adducts lead to 
abnormal bending of the DNA molecule, which can be detected by cell repair 
machinery, which activates apoptotic signals leading to cell death (74).  
 
Figure 5. Cisplatin DNA adducts. Cisplatin binds to the DNA leading to abnormal bending and apoptosis 
(75). 
However, cisplatin cell uptake, DNA damage and cytotoxic effect mechanisms are 
often deregulated in cancer cells that develop treatment resistance. Chemoresistance is 
a complex and important obstacle for patient treatment. Therefore, understanding the 
mechanism and effects of such events is imperative to improve clinical approaches and 
will be discussed below. 
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Chemoresistance 
Although there have been many developments in cancer pharmacotherapy, which 
mostly interfere with the growth and development of primary tumours, drug resistance 
still presents itself as one of the major obstacles to the complete cure of most cancers 
(8–10). The lower sensitivity of tumour cells to chemotherapeutic treatment is a grave 
limitation, in light of the restricted dose escalation due to unwanted cytotoxic side-
effects in patients. 
Constant therapeutic advances increase the chance of cancer patients achieving 
complete remission status. Unfortunately, this often does not mean the patient is a 
hundred percent disease free, but it refers to the absence of detectable tumours. This 
means that a small group of cells, usually 109 - 1011 cells, which could potentially form 
a new tumour, can remain undetected in the body (76–78). These cells are called 
minimal residual disease (MRD) and can endure treatment stress through innate 
survival mechanisms, such as quiescence, which enable the development of drug 
resistant cell expansion (8,10,79). This leads to treatment resistant disease relapse and 
usually the death of the patient. This presents a major challenge for physicians trying 
to ensure patient survival. Although melanoma can be treated by surgical resection, 
metastatic melanoma is one of the most aggressive and drug resistant neoplasm with 
poor overall survival. The new BRAF inhibitors, combination therapies and 
immunotherapies offer exciting prospects for improving survival, but not all patients 
respond positively and the development of resistance is a major problem (80,81), hence 
the need for effective additional melanoma therapy. In order to overcome this problem, 
we need more efficient diagnostic tools that are able to identify this small number of 
cells and also new therapies to specifically target MRD resistant cells.  
Many efforts have been made to understand this phenomena, first identified in 
hematopoietic cancers, and that consists of a three-step process: first there is tumour 
cell homing to the bone marrow, which bears fibroblasts and extracellular matrix 
components that act as a sanctuary that facilitates survival (78). This microenvironment 
protection leads to transient environment-mediated drug resistance (EM-DR) and 
finally, the development of microenvironment-independent resistance or acquired drug 
resistance, through which tumour cells suffer genetic modifications in response to 
prolonged therapy, leading to insensibility to treatment (77,78,82). 
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The exact harbouring location for epithelial tumours is still uncertain, MRD population 
is not uniform; it features cellular and geographic heterogeneity, they can allocate in 
the bone marrow but do not necessarily do so (10,79). The cells disassociate from the 
main tumour and become circulating tumour cells (CTC) that travel through the blood 
stream in a process denominated leukemic phase (76,83). Efforts have been made to 
effectively use the detection of these few CTC in the blood to prevent metastasis, MRD 
and resistance. This has been called liquid biopsy (76,83).  
However, not all CTC are treatment resistant, not all of them have the potential to form 
MRD niches, or initiate new tumours (8,79). Only a small subpopulation of CTC with 
stem-like properties is inherently refractory to treatment (8,9,79,84). These cells have 
been consistently identified in several different tumours. For example, in melanoma, 
Rambow et al. called them neutral crest stem cells (NCSC), Menon et al. had already 
observed similar melanoma cells that they called induced drug-tolerant cells (IDTCs), 
and Sharma et al. studied drug-tolerant persister (DTP) cells in lung cancer (8,9,79). 
The most interesting fact about these cells is that the resistance mechanisms are 
transient and mutation independent; this means that these are quick responses to 
environmental stress, such as anti-cancer treatment, but also pH changes, starvation and 
hypoxia, mediated by epigenetics and/or interactions with the extracellular matrix and 
its compounds (9,78). Since these adaptations do not interfere in the genetic code of the 
cell, that is, there are no mutations, this transient resistant state can be reverted after a 
so-called “drug – holiday” period (8,9). This consists of suspending treatment for a 
specific amount of time until the resistance mechanisms are turned off. Then, the drug 
regime can be reinstated and previously resistant cells will die (8,9). The exact amount 
of time needed as “holiday” is tumour, treatment, and it seems patient/host, dependent. 
However, the previously discussed liquid biopsy could be a powerful tool to analyse 
resistance development, in real-time, in a non-invasive way, and help decide the best 
moment to reinstate treatment and which treatment protocol to use (8,9,76,83). 
Resistance is a natural adaptation process used by living beings to survive 
environmental changes/stress. Thus, it is not surprising that tumour cells make use of a 
number of potential molecular mechanisms to adapt and circumvent chemotherapeutic 
treatment. There is a vast array of different adaptations used by cancer cells to try to 
avoid the cytotoxic effects of cisplatin, which are very complex and often intertwined, 
some of these adaptations will be explained in the section below. Even though cellular 
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events are often dependent and associated with each other, cisplatin resistance 
mechanisms are classically divided into: 
- Pre-target 
- On-target 
- Post-target 
- Off-target. 
 
Figure 6. Cisplatin resistance mechanisms. Summarized depiction of tumour cells numerous cisplatin 
circumventing molecular mechanisms, that are typically divided into: pre-target (blue), post-target 
(yellow), off-target (orange), on-target (purple). Adapted from Wantoch von Rekowski (85). 
 
Pre-Target Resistance 
Pre-target resistance consists of cell protective mechanisms used by tumour cells to 
avoid cisplatin binding to DNA. They involve (i) decreasing drug uptake; (ii) cisplatin 
sequestration and facilitated extrusion; and (iii) increased efflux rate. 
Reduced cisplatin uptake is usually achieved by cancer cells through downregulation 
of the copper influx-transporter CTR1 and/or reduction of LRRC8 protein expression, 
which reduces the activity of the VRCA complex. 
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CTR1 is formed by three monomers, each containing three trans-membrane domains 
with cytosolic C-terminals (73,86,87). It is usually involved in copper ions influx into 
the cytoplasm but can be used by cisplatin to enter the cell. It has been shown that, after 
being internalized, cisplatin interacts with the CTR1 transporter in two different 
residues (Y103 and C189) responsible for transporter endocytosis and membrane 
placement, respectively, thereby cisplatin uptake itself automatically induces 
downregulation of CTR1, and therefore resistance (73,86,87). 
VRAC or volume-regulated anion channel family is responsible for, but not restricted 
to, cell volume restauration under osmotic cell swelling conditions, and therefore, its 
activity is pH dependent and can be influenced by cisplatin chloride anions. Alkaline 
conditions, for example, have been shown to increase its activity, which is regulated by 
the leucine-rich repeat-containing 8 (LRRC8) protein family (88). It seems possible that 
the acidic conditions innate from tumour milieu might be associated with 
downregulation of VRAC. Osmotic cell swelling, as well as ROS, have been shown to 
increase cisplatin accumulation in the cell, which shows that the LRRC8 – VRCA 
complex is involved in the influx of cisplatin (87). Thus, the downregulation of both 
LRRC8 proteins expression and VRAC activity have been associated with cisplatin 
resistance. This complex also affects cell cycle progression, apoptosis and proliferation. 
In fact, VRAC activity has been shown to affect cell cycle in a chloride concentration 
dependent manner (89). LRRC8 downregulation is also involved in post-target cisplatin 
resistance by preventing activation of apoptotic signals, through p53, MDM2, p21 and 
CBP 9 and 3, following cisplatin treatment (87). 
Another pre-target resistance mechanism makes use of the extrusion mechanisms of the 
cell which consist of tagging substances to suffer exocytose. For example, nucleophilic 
species, such as glutathione, can be conjugated to cisplatin by glutathione S-transferase 
(73,86). The expression of both glutathione and its conjugating enzyme have been 
shown to be upregulated in cisplatin resistant cancers (90). With respect to melanoma, 
organelles that synthesize, store, and transport melanin in melanocytes, known as 
melanosomes, have been shown to sequester and extrude cytotoxic drugs, thereby 
decreasing drug concentration and damage to the cell (91,92). Examples of some 
melanosome proteins that have been shown to be overexpressed and assist in cisplatin 
resistance in melanoma cells are the premelanosome protein (gp100/PMEL), G-protein 
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coupled receptor 143 (GPR143) and, of course, MITF, which is also involved in 
cisplatin off-target resistance (see below) (91,92). 
An additional mechanism of cisplatin pre-target resistance consists of increasing the 
efflux rate of the drug by upregulating the expression and activity of efflux transporters. 
As mentioned above, copper transporters play a role in cisplatin influx, logically copper 
transporters are also involved in the cisplatin outflow. ATP7A and B are ATPases 
responsible for copper and platinum ATP-dependent transport through the cell 
membrane (73,86,87). Interestingly, the effect of ATP7A/ATP7B in cisplatin resistance 
not only depends on its overexpression, but also seems to be location specific. For 
example, Kalayda et al. have shown that these enzymes concentrate on the trans-Golgi 
network in sensitive ovarian cancer cells (A2780) and translocate to peripheral vesicles 
in the resistant cell-sub type (93). Similar to CTR1 copper influx transporters, the 
accumulation of cisplatin in the cell leads to ATP7A/ATP7B overexpression and 
recruitment to the plasma membrane, and therefore resistance.  
Multidrug resistance-associated protein 2 (MRP2) also called cMOAT or ABCC2, is 
another ATP-dependent efflux transporter that has been shown to be overexpressed in 
cisplatin-resistant cancers, including melanoma (73,94). This effect is specific to 
platinum-derived drugs and allows resistant cells to evade G2 cycle arrest and apoptosis 
due to lower concentration of cisplatin adducts in the cell (94). 
On-Target Resistance 
There are three main modes of action of on-target resistance, (i) increased DNA repair 
rate; (ii) cells become able to tolerate DNA lesions; or (iii) impaired recognition of 
DNA damage. 
One of the main downstream effectors of increased DNA repair is the polymerase 
family PARP. They play an important role in various cellular processes, including 
modulation of chromatin structure, transcription, replication, recombination, and DNA 
repair, especially in the G2 cell cycle phase (95). PARP is part of some of the main 
DNA repair machinery involved in cisplatin resistance, such as base excision repair 
(BER), nucleotide excision repair (NER) and the homologous recombination repair 
(HRR). Interestingly, PARP has been shown to be generally upregulated in melanomas, 
including naïve tumours, which suggests that this is not an adaptation to DNA 
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damaging agents, but a part of the malignant transformation, likely used to tolerate other 
mutations (96). For this reason, PARP inhibitors have been developed and used in 
tumour therapies alone or in combination with DNA damaging agents, such as cisplatin 
(95).  
NER is formed by several different proteins that recognize, extract and repair 
monofunctional adducts and intrastrand crosslinks. One of such proteins is the 
xeroderma pigmentosum group A (XPA), a key protein in the NER pathway, which has 
been shown to be overexpressed and promote resistance of melanoma tumour cells to 
cisplatin-based drugs by facilitating the DNA repair process (97,98). Moreover, 
increased XPA can induce off-target cisplatin resistance by activating PARP1 (97). The 
endonucleases complementation group 1 (ERCC1) and xeroderma pigmentosum group 
F (XPF or ERCC4) are also members of the NER system and have been shown to be 
upregulated in melanoma cells in response to exposure to cisplatin (98–101). ERCC1-
XPF complex inactivation or inhibition renders melanoma cells sensitive to cisplatin 
(102).  
A different cisplatin-DNA-damage repair system is the homologous recombination 
repair (HRR), which is mostly active in the S phase of the cell cycle and can fix double-
strand breaks. Inhibition or mutation of HRR proteins sensitize cells to cisplatin (73). 
Some proteins that belong to the HRR system are BRCA1, BRCA2 and RAD51, which 
are frequently mutated in breast, ovarian and skin cancers (73,98). BRCA mutation and 
lack of function confers synthetic lethality in response to PARP inhibition (103). The 
PARP inhibitor Olaparib traps PARP onto DNA repair intermediates, causing 
obstruction of replication forks, which is normally resolved by BRCA (103). However, 
when BRCA is mutated, it loses its function, and this obstruction leads to cell death 
(103).  
On the other hand, the RAD51 inhibition mechanism involves a different mode of 
action called replicative bypass, which enables cells to tolerate DNA lesions and move 
forward with the cell cycle. Upon encountering interstrand crosslinks during 
replication, following cisplatin treatment, melanoma cells downregulate RAD51 and 
increase the activity of translesion synthesis (TLS) DNA polymerase zeta (REV3) (98). 
Translesion synthesis polymerases are able to insert bases on a damaged template to 
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allow replication to proceed. Other TLS polymerases involved in the recognition of 
GpG abducts and replicative bypass are POLH and REV7 (73). 
The MMR DNA damage detection system is able to recognize, but not repair DNA. 
Once a lesion is detected apoptotic signals are initiated. Two proteins from this system, 
MSH2 and MLH1, which recognize GpG interstrand adducts, are often mutated or 
downregulated in cisplatin resistant tumours, including melanoma (73,104–106). 
Similarly to other mechanism mentioned above, it has been observed that naïve tumours 
present normal MSH2 expression levels, and that the downregulation of this protein is 
an adaptive response subsequent to cisplatin treatment (73). In the case of MLH1, 
mutations in this protein have also been associated with replicative bypass (107).  
Post-Target Resistance 
Cisplatin post-target resistance involves many different cell alterations that are deeply 
intertwined and involve (i) defects in the apoptotic signalling pathway and (ii) faulty 
cell death machinery. In this context, different protein alterations can affect cells 
distinctively.  
There are two main signalling pathways, which are responsible for sending messages 
from the cell membrane to the nucleus and dictate cell fate. The famous MAPK and 
PI3K/AKT signalling pathways emit pro- or anti-apoptotic signals, through the BCL-2 
protein family, depending on a variety of different factors, such as cell type, cell 
confluence, stress conditions, etc. (108). Moreover, these pathways regulate each other 
in order to keep a healthy balance in the cell (108). Thus, the deregulation of one or 
both pathways is a complex, though recurrent, phenomenon in tumour cell resistance 
(108).  
As mentioned above, the PI3K/AKT pathway is one of the most deregulated in all 
cancer types, over 50% of cancers present upregulation of AKT due to mutations, 
upregulation of upstream kinases or loss of function of regulating proteins (30). In 
melanoma, several genetic and epigenetic activating modifications could be identified 
in the members of this cascade as part of treatment resistance development (31). For 
example, Survivin, a caspase-inhibitory protein, has been shown to be upregulated 
following cisplatin treatment in different tumour entities, in a PI3K/AKT dependent 
manner (73,109). Moreover, clinical studies using Survivin or PI3K inhibitors (YM155 
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and BEZ235 respectively) alone or combined to platinum-based chemotherapy, have 
shown good results (NCT01009775, NCT00281541, NCT00818480, NCT01343498, 
NCT01195376, NCT01337765, NCT01285466, NCT00620594, NCT01508104). 
As discussed above, the MAPK pathway is often overexpressed and upregulated in 
melanoma. This is associated with a worse prognosis, and usually generated by point 
mutations, such as BRAF and NRAS mutations, that cause the pathway to be 
constitutively active (16,17,110,111). This pathway has been targeted directly by many 
specific inhibitors, however, it is also involved in the resistance mechanisms of 
cytostatic drugs, such as cisplatin. ERK phosphorylation, for example, has been shown 
to be increased in response to cisplatin treatment (51). Additionally, the signals 
transmitted by MAPK and PI3K/AKT pathways often converge into the BCL-2 protein 
family, that has been reported to be deregulated in cisplatin resistant tumours, including 
melanoma, causing faulty cell-death machinery (17,73,104,112). Its pro-apoptotic 
members, such as BAX and BAK are often downregulated, while their counterparts, 
BCL-2, BCL-XL and MCL-1 are overexpressed (16,73,108). 
The expression of anti-apoptotic genes from the BCL-2 family can also be increased by 
MITF. As mentioned above, MITF is overexpressed or upregulated in 2-8% of 
amelanotic tumours, as part of malignant transformation of melanocytes (18,19). Once 
activated, MITF can activate the expression of almost one hundred genes and regulate 
multiple biological processes in melanoma cells, such as differentiation, proliferation, 
migration, senescence, metabolism and plasticity, as well as survival (113–117). The 
latter is achieved by increasing the expression of anti-apoptotic genes including BCL-
2A1, BCL-2 and BIRC-7 and could influence cell chemoresistance (115).  
Finally, one of the best studied proteins of the cell-death machinery, the tumour-
suppressive protein (p53), which is responsible for DNA repair and apoptosis initiation 
followed by cellular stress. It has been broadly studied in vitro and in clinical settings 
and its mutation and inactivation is classically associated with drug-resistance, 
including cisplatin (118–122). The mutation and inactivation of p53 is present in several 
tumour types, including melanoma, where it has been shown to be inactivated in 
approximately 90% of patients (118–122). p53 mutations are often observed 
concomitantly to NRAS mutation (15%), and thus have been associated with NRAS-
driven melanoma progression (122–124). p53 inactivation in melanoma cells can also 
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be caused by off-target phenomena such as overexpression of p53 regulators MDM2 
and/or MDM4, or CDKN2A deletions (50%) (125–127). For this reason, several 
attempts have been made to reactivate p53, such as through PRIMA-1 (p53 
Reactivation of Massive Apoptosis) and its methylated form PRIMA-1Met (APR-246), 
which have been successfully used, in combination with chemotherapy, in a variety of 
cancers, showing promising results (128–130). These are only some examples of the 
many genetic alterations that can lead to constitutive activation of these two very 
important pathways, which influence cell survival and can lead to drug resistance. 
Off-Target Resistance 
Off-target resistance mechanisms consist of alterations in the expression or activation 
of molecules that do not interact directly with cisplatin but ensure cell survival by 
activating signalling pathways that enable most of the genetic adaptations mentioned in 
the sections above. Adhesion molecules and membrane receptors play a major role in 
this by interacting with the extracellular matrix and activating protective signals; this is 
known as cell adhesion mediated drug resistance (CAM-DR) (77,78,82).  
Cancer cells often modify the ECM by overexpressing molecules that can interact with 
cell receptors and induce survival. This is the case for the matrix proteins, Collagens, 
which have been observed to be overexpressed and induce CAM-DR in several cancer 
types (131–136). Cells can also overexpress or upregulate cell receptors that interact 
with the ECM. Receptors tyrosine kinase (RTK) are most commonly involved in this 
process. One of the most important genetic alterations in malignant melanoma involves 
receptor tyrosine kinases and the upregulation of downstream MAPK and PI3K/AKT 
pathways, both of which play major roles in melanoma progression (4,31). For 
example, deregulation of the receptor AXL causes MAPK-mediated stabilization of the 
abovementioned MDMX–MDM2 heterocomplex, and thus p53 inactivation in 
melanoma cells (137). Another receptor known to be mutated in 20% of melanomas, 
activating the PI3K/AKT pathway is ERBB4 (31). Moreover, the overexpression of 
HER-2 of the ERBB growth factor receptor family, has been associated with PI3K/AKT 
dependent cisplatin resistance through an interesting mechanism that depicts 
environment-mediated drug resistance perfectly: at first contact with cisplatin, HER-2 
activates basal levels of PI3K/AKT pathway, which induce cell-cycle arrest and 
survival through cyclin-dependent-kinase inhibitor 1A (CDKN1A or p21)(138–140). 
Introduction 
 
49 
 
This protects the cell from DNA damage and gives the cell time to adapt to treatment 
stress. As cisplatin stress persists, PI3K/AKT pathway activity increases, not 
exclusively, as a result of HER-2 overexpression (138). This leads to CDKN1A 
translocation from the nucleus to the cytoplasm, thereby generating a high proliferative 
cisplatin resistant phenotype (acquired drug resistance) (138,141). 
However, other membrane receptors that do not possess kinase activity, such as 
integrins and syndecans, can also be activated by components of the ECM, such as 
fibronectin (FN), laminin (LM) and collagen (Coll), and induce resistance. Integrins, 
especially the β1 integrin subunit, have been primarily associated with CAM-DR in 
blood cancers, since this was the first type of cancer in which environment-mediated 
drug resistance has been studied, as mentioned above (142–146). β1 integrin has later 
been associated with CAM-DR in several different solid tumours, in which resistance 
to chemo- and targeted therapy is induced by β1 integrin contact with ECM compounds, 
such as FN, the main component of bone marrow; and Coll I, the main ligand for β1 
integrin and a major matrix protein of tumour microenvironment (147–152).  
This binding causes β1 integrin up-regulation, and thus increases activation and 
expression of important components of the MAPK and PI3K/AKT signalling pathways 
such as ERK, MEK, ILK, FAK, PI3K, AKT and upregulation of anti-apoptotic proteins 
such as BCL-2, BCL-X, Bim, MCL-1 and Survivin and downregulation of BAX (147–
152). But, so far, there are not many studies connecting β1 to melanoma 
chemoresistance. Recently, Iyoda et al. were able to demonstrate multiple drug 
resistance induced by FN in melanoma and breast cancer cells mediated by Bim (153). 
Moreover, even though the relation between β1 integrin and Coll I in melanoma 
migration and metastasis has been established since the ‘90s, there is only one report, 
in uveal melanoma, linking these molecules in the context of chemoresistance, which 
demonstrates the lack of studies about this interaction (154–158). 
In light of these facts, we have concentrated our efforts in investigating the adhesion 
molecules, integrin, and its co-receptor, syndecan. They interact with the PI3K/AKT 
pathway and have been associated with tumour malignancy. The importance of these 
molecules for cancer progression and resistance, as well as their relation to the 
PI3K/AKT pathway and each other, will be discussed below. 
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Extracellular matrix 
The extracellular matrix (ECM) is a complex non-cellular environment responsible for 
structural support and stability to cell tissues as well as information exchange between 
the intra- and extracellular spaces. Cells interact with the ECM through adhesion 
molecules, mainly integrins and syndecans, which recognise and bind to specific ECM 
components and carry out these messages. Interestingly, almost all ECM elements 
present binding sites for these two proteins (159). These bonds affect cell adhesion, 
polarity, motility, proliferation, differentiation and survival (159–162). For example, 
although, malignant transformation leads to anchorage-free survival, integrin adhesion 
to components of the ECM regulates the expression of pro and anti-apoptotic proteins 
from the BCL-2 family, such as BAX and BCL-2, through FAK/PI3K signalling, 
promoting cell survival (163,164). As previously mentioned, ECM also offers 
protective response to cancer cells against cytostatic drugs (147–152). β1 integrin 
binding to the ECM triggers FAK (focal adhesion kinase) signalling that inhibits p53 
through degradation by MDM2 (165,166). 
Thus, ECM properties such as composition and physical-chemical properties, namely 
rigidity, elasticity, topology, and pH, impact cells in different ways (162,167–170). For 
example, matrix stiffness has often been associated with tumorigenesis and increased 
cell cycle progression, especially in breast cancer, by adhesion-mediated FAK 
activation, which initiates proliferation signals through phosphorylation of PI3K and 
RAS, resulting in ERK activation and nuclear translocation, and cyclin D1 induction 
(171–175). Mechanotraction also downregulates PTEN expression, thereby 
upregulating PI3K/AKT signalling, which leads to cell growth and survival (176). The 
ECM is a versatile and dynamic milieu composed of water; fibrous proteins, such as 
vitronectin, LM, FN and Coll; glycoproteins; and proteoglycans; soluble factors; 
polysaccharides and glycosaminoglycans (160).  
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Figure 7. Extracellular matrix influences in cancer progression and maintenance. Cells bind their 
adhesion molecules, for example discoidin domain receptors (DDR), integrins, syndecans and laminin 
receptor, to ECM components such as Coll, FN and laminin resulting in a vast array of cell signals that 
impact cell behaviour, survival and growth (162). 
Collagen 
Collagens account for 30% of total protein mass in mammals (177). They constitute the 
largest matrix protein family with at least 28 members and are defined by the presence 
of triple-helical domains, which can comprise almost all of their structure (96% for Coll 
I), or very little of it (less than 10% for Coll XII) (177,178). They interact with other 
collagens and components of the ECM, as well as glycoprotein, proteoglycans, cell 
surface receptors and adhesion molecules, such as integrins, and contribute to tissue 
integrity, tensile strength, organization and function (178).  
Coll fibrils are a classical example of a quaternary protein structure. The amino acid 
structure of Coll is translated and folds into α-helices (secondary protein structure) that 
vary in size from 662 - 3152 amino acids (177). α-helix chains can present several 
isoforms, which define Coll type, each of these isoforms can suffer alternative splicing 
or use alternative promoters generating further variability and affect Coll function 
(177). The triple helices represent the tertiary protein structure and are formed by three 
left-handed α-helix chains twisted into a right-handed coil (177). The triple-helical 
general sequence is formed by Gly-Pro-X or Gly-X-Hyp repeats, X representing other 
amino acids, although 3-hydroxyproline residues have been identified in Coll I, II, III, 
and V/XI (177,179). This structure is mainly stabilized by glycine, but also inter-chain 
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hydrogen bonds (25). Fibrillar collagens can associate in various ways to form 
quaternary structures: Coll fibrils that may contain non-fibrillar counterparts (fibril-
associated collagens with interrupted triple-helices - FACIT) (177). For example, 
cartilage fibrils are made of Coll II, XI and IX (FACIT) or II and III, while skin fibrils 
are rich in Coll I and III and cornea I and V (177,180,181). Besides FACIT, non-fibrillar 
Coll includes multiplexins and membrane collagens, and besides the ability to form 
fibrils, fibrillar collagens present one major triple-helical domain while non-fibrillar 
bear many (177,178). The most common Coll is type I, it forms hexagonal-like 
structures by associating groups of five Coll I molecules into supertwisted fibrils, which 
interdigitate with other fibrils (177,178). Coll assemblies can be observed by electron 
microscopy as rods of 75 nm – 425 nm of length, as depicted below (177).  
    
Figure 8. Collagen structure. The amino acid structure of Coll is translated and folds into α-helices 
(represented in red, green and blue). A. Three α-helix chains twist into a triple helix (182). B. Coll fibrils 
observed under microscope (183). 
The function of Coll in the cell is diverse and dependent on several factors. These 
factors include, first, the previously mentioned wide Coll family diversity and genetic 
modifications (177,184). Second, some collagens (IX, XII, XIV, XV, XVIII) function 
as core proteins for glycosaminoglycans and, therefore, are considered proteoglycans 
(177,184). They can suffer glyco- or proteolytic cleavage, usually by glycosylases, and 
matrix metalloproteinases (MMPs) or sheddases, respectively, this leads to the release 
of bioactive fragments that influence cell behaviour (177,184,185). Third, 
conformational changes caused by interactions with other collagens or ECM 
A B 
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compounds, denaturation or binding to cell receptors leading to the generation of 
mechanical forces, as is the case for integrins (177,184). For example, it has been 
suggested that integrins and FN, together with Coll V and XI, could be involved in 
fibrillogenesis of Coll I and II (177,186). Coll and FN have been shown to co-localize 
in the ECM, and there seems to be a mutual cooperation between them (187). FN 
displays Coll binding (FNI6 FNII1-2FNI7-9, see Figure 10.) and is involved in the 
deposition of Coll, as mentioned above (187,188). Simultaneously, Coll provides 
structural support that regulates FN stretching (189). 
Besides acting as mechanosensors, integrins are involved in several cell functions 
which are often related to attachment to the ECM. The integrins that show most affinity 
to Coll are β1 integrins. They are responsible for cell attachment and survival in 
physiologic conditions, however, in cancer cells other integrin subunits maybe 
involved. In normal fibroblasts, β1 integrin can lead to apoptosis in response to 
contraction of Coll I 3D matrices, through the inhibition of the FAK/PI3K/AKT 
pathway (190). However, the same cells survive following activation of the same 
integrins and pathway on Coll I coating (no mechanotension) (190). On the other hand, 
in melanoma cells, Coll I 3D matrices have been shown to lead to cell survival by 
activating β3 integrin (191). Initial attachment seems to be made by β1 integrins, but 
extensive incubation in Coll stimulates cells to digest the Coll, exposing its RGD 
binding site where β3 integrin can attach and lead to cell survival (191). Overexpression 
of Coll has been associated with CAM-DR in cisplatin-resistant ovarian and lung 
cancers (131–133,136). Moreover, Bérubé et al. were able to show the presence of the 
CAM-DR in uveal melanoma cells, where there is a correlation between β1 integrin 
binding to Coll IV, FN and laminin, and cisplatin resistance (158). β3 integrin also 
seems to be involved in this process to some extend (158). Additionally, Coll IV has 
been shown to bind and activate integrin α1 (192). Coll I has been shown to carry 
different binding sites for heparan sulfate and heparin than for integrins, which means 
this Coll can bind to integrins and glycosaminoglycan chains of proteoglycans 
simultaneously, thereby facilitating integrins – syndecans clustering, for example (178). 
Fibronectin 
Fibronectin (FN) is a very ubiquitous ECM adhesion protein; it is known by its ability 
to bind simultaneously to a variety of ECM compounds, such as collagens and growth 
factors, cell surface receptors and adhesion molecules, such as integrins and 
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proteoglycans (187,188,193). Binding to these molecules and/or mechanotension can 
lead to conformational alterations in FN, which impact cell behaviour, such as 
migration and adhesion (187,188,193). FN also presents a quaternary protein fold, it is 
composed of two approximately 230 – 270 kDa subunits, connected by a pair of 
disulphide bonds, at their C-termini, forming a dimeric glycoprotein (187,188,193). 
Each subunit is composed by twelve Type I repeats, two Type II repeats, and 15-17 
Type III repeats (187,188,193). These repeats present similar but distinct structures, the 
main difference being that type I and type II repeats are stabilized by intramodular 
disulphide bonds, while type III repeat is formed by an antiparallel 7-stranded β-barrel 
structure that is not stabilized by disulphide bonds, rendering the molecule more 
flexible and sensitive to chemical or mechanical changes (187,188,193).  
 
Figure 9. Fibronectin structure and domains. Adapted from Gee et al. (194). A. Linear depiction of 
FN, which is composed of two approximately 230 – 270 kDa subunits, connected by interchain 
disulphide bonds, at their C-termini, forming a dimeric glycoprotein. Each subunit is composed by twelve 
Type I repeats (FNI represented by grey squares), two Type II repeats (FNII represented by grey circles), 
and 15-17 Type III repeats (FNIII represented by blue diamond). The RGD integrin binding site can be 
identified in pink at the cell binding region of the molecule. Finally, the amino-terminal 70-kDa fragment 
contains assembly and gelatin-binding domains and is routinely used in FN binding and matrix assembly 
studies. B. 3D molecular structure of FN. FNIII is formed by an antiparallel 7-stranded β-barrel 
structure, which is not stabilized by disulphide bonds like FNI and FNII, giving the molecule flexibility. 
FN is secreted as soluble, covalent dimer (fibres) that associate into supermolecular 
structures (fibrils) through non-covalent bonds that involve Type I repeat 1-5 and Type 
III repeat number 1 (187,188,193). Fibril formation is mediated by integrins that enable 
the cross talk between FN fibres and the actin cytoskeleton, coordinating FN fibril 
architecture with cell shape and intracellular signalling (188,193,195). Integrins’ main 
binding site is the RGD motif on FNIII9-10, but they can also bind to the CS1 segment 
of the alternatively spliced V region on FNIII (196–198). The main subunit involved in 
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FN fibril assembly is integrin α5β1 (188). Its binding to FN RGD motif generates FAK-
mediated intracellular signalling, which is essential to FN fibril formation (188,199). 
This leads integrins to cluster and form adhesion complexes that create contractile 
forces, exposing FN binding site and allowing fibres approximation and interaction 
with each other (188). Other cell-adhesion molecules such as α4β1, αvβ1, αvβ3 and 
αIIbβ3 can also induce fibril formation under specific stimuli, such as activation by 
Mn2+ or specific antibodies (188). Moreover, the proteoglycans syndecan-1 and 2 seem 
to also be able to contribute to FN association (188). 
FN function and affinity to ligands is controlled by several factors, such as structure 
variability by alternative splicing, which mainly affects subunit size and the presence 
of specific binding sites; environmental factors, such as contractile forces and pH; and 
conformational changes in the protein structure (187,188,193). For instance, alternative 
splicing can alter integrin α4β1 and syndecan ability to bind to FN (197,198,200,201). 
Moreover, the FN quaternary structure is rendered inactive for transportation in the 
blood stream (187). Additionally, FN relaxed or stretched state can dictate binding 
affinity to specific integrin types; for example relaxed FN promotes integrin α5β1 
binding, while stretched conformation favours integrin αvβ3 adhesion (187). This 
integrin subtype switch can have consequences in cell decision-making, such as 
proliferation in detriment of migration, which will be discussed in the chapter about 
integrin herein. 
This shows that integrins interaction with FN affects several different cell processes 
besides FN fibril formation. Integrin binding to FN generates survival and proliferation 
intracellular signalling, which involves FAK, PKC, Src, paxillin, and PI3K/AKT (202). 
For example, it has been shown that β1 and β3 integrin activation upon FN and 
vitronectin binding, respectively, leads to FAK phosphorylation and upregulation of 
BCL-2 pro-survival gene through PI3K-AKT pathway (203). Moreover, blocking of 
the FN heparin binding site has shown to inhibit αv and α2 melanoma cell adhesion to 
FN and Coll IV, and reduce cell viability and metastatic potential through 
downregulation of FAK and ERK 1/2 (204). Finally, FN has been associated with 
CAM-DR in acute myeloid leukaemia, breast and skin cancers (153,205–208). In 
addition, blocking of FNIII14 has been shown to inactivate β1 integrin and upregulate 
pro-apoptotic Bim protein (153,205–208). 
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Another family of cell surface receptors are the proteoglycans syndecans (Syn). They 
are formed by a central protein core that presents glycosaminoglycans attached to it 
(178). Even though they will be discussed in depth later, at this point, it is important to 
point out the relation between syndecans and FN. FN presents three major heparin 
binding-sites, but the best characterized is Hep II, located in the C-terminal (FNIII12-14) 
(178). Syn can bind to this site through its glycosaminoglycan chains, which enhances 
integrin-mediated cell spreading and intracellular signalling (159,178). Additionally, 
Hep II presents a RGD sequence that can bind to integrins, reinforcing the concept of 
cooperation between Syn and integrins in cell attachment (178,187,202). 
Glycosaminoglycans 
Glycosaminoglycans are linear polymers of complex sugars, some examples are 
hyaluronan, heparin (Hep), heparan sulfate, chondroitin sulfate. They are formed by 
repetitive disaccharide units, constituted by one hexosamine, glucosamine or 
galactosamine, united by a glycoside bond to a non-nitrogenized sugar residue, uronic 
acid, β-D-glucuronic acid or α-L-iduronic acid, or even, a neutral sugar such as D-
galactose (209). Glycosaminoglycan synthesis is complex and involves a large number 
of transferases and modifying enzymes, whose role is to regulate their fine structural 
properties, such as sulfation in specific positions of their molecule (210,211). The 
reducing portion of the glycosaminoglycan chain, consisting of 50 to 200 repeating 
disaccharides, is covalently bound to the core protein by a link tetrasaccharide, common 
to all glycosaminoglycans, thereby forming a proteoglycan (209). The only exception 
is hyaluronan, which is an ECM soluble molecule. Proteoglycans act as adhesion 
molecules that can bind to other compounds of the ECM, as well as other adhesion 
molecules, such as integrins (212–215). They present a wide variety of distribution and 
biological functions such as tissue organization, adhesion, motility and proliferation, 
which will be discussed below.  
The abovementioned heparins are special glycosaminoglycans produced by mast cells 
with anti-coagulative activity, for this reason they have been widely used as anti-
thrombotic agents since 1939 (216). They are similar to heparan sulfate, but generally 
present a very high amount of iduronic acid, N- and O- sulfation. Hep chain length can 
vary from 6.000-30.000 Da and researchers have observed that sugar chain length 
impacts its ability to bind to its ligand thrombin (216,217). This occurs because this 
glycosaminoglycan facilitates the interaction between anti-thrombin and factor Xa, 
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firstly by tightly binding to anti thrombin through a specific pentasaccharide; this leads 
to allosteric changes in the anti-thrombin, which facilitate factor Xa binding; secondly, 
by loosely connecting to the enzyme and thrombin and allowing anti-thrombin to slide 
along its sugar chain and approach the complex (32). Thus, there is a minimum length 
of the Hep chain that allows this interaction, this length is seven sugar units following 
the pentasaccharide (216,218). This discovery gave rise to two important concepts: 
unfractionated heparin (UFH), which refers to all Hep molecules isolated from a 
sample; and low molecular weight heparins (LMWH), which refers to small Hep 
molecules that still preserve catalytic activity (216,218). Many have been developed 
through the decades, to improve patient treatment, one example being Tinzaparin, 
which has molecular weight of 6.500 Da and is one of the biggest LMWH (218). Studies 
have shown that Tinzaparin has antitumoral properties, such as antimetastatic and 
impairing neovascularization effects (219–221). LMWH has also been associated with 
overcoming chemoresistance (222–225). In our group, Schlesinger et al. have shown 
that heparin can reduce metastatic activity in melanoma, by blocking α4β1 integrin 
(226,227). In addition, Pfankuchen et al. showed that the heparin tinzaparin can induce 
resistance against cisplatin treatment in ovarian carcinoma (224,228). 
Integrins 
Cellular functionality in general is determined by adhesive interactions between cells 
and their local microenvironment, which allows cells to integrate and detect external 
changes and influence cell phenotype as well as malignant transformation. Integrins are 
a key molecule in these exchanges, since they are ubiquitous cell-membrane proteins 
involved in cell adhesion and signalling. Integrins are heterodimeric transmembrane 
glycoproteins formed by α and β-subunits, which mediate interactions between cells 
and their extracellular environments. 18 α- and 8 β-subunits have been mapped on the 
human genome; composing 24 integrins, they form the biggest family of cell adhesion 
molecules presenting a large array of ligands and functions (145,229,230). Subunits α 
and β are each formed by a small cytoplasmic region (40–70 amino acids), which 
interacts with intercellular messenger proteins; a transmembrane section; and a large 
extracellular portion, for ligand binding. The transcription of the subunits is performed 
separately, then they undergo modification with high mannose N-linked 
oligosaccharides to ensure their correct folding and, finally, are assembled in the 
endoplasmic reticulum (ER), and transported into the Golgi apparatus (231,232). 
Integrins are highly glycosylated proteins, and their glycosylation pattern is known to 
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affect integrin heterodimerization, stabilization, cell membrane placement, function 
and affinity to ECM compounds and other ligands (217,233–235). Aberrant 
glycosylation of integrins has been observed in different cancer types, including 
melanoma (217,236,237). The main alteration is the glycosylation pattern of β1 
integrin, which has been shown to be involved in melanoma malignant transformation 
and to affect integrin affinity to ECM compounds (217,236–239). 
The β-subunit is formed by a cysteine-rich membrane proximal-β tail (βTD), followed 
by four epidermal growth factor (EGF) segments, hybrid and PSI 
(plexin/semaphorin/integrin) domains and, finally, a βI-like N-terminus, which 
contains the MIDAS divalent-cation-binding site. The α-subunit is formed by two calf 
domains, followed by a tight and a folded seven-bladed β-propeller, which harbours 
four to five divalent-cation-binding sites and can contain an immunoglobulin-like 
domain. Since the affinity of integrins to their ligands is dependent on the above 
mentioned divalent-cations (Ca2+, Mg2+ and particularly Mn2+) (240), it has been 
reported that Ca2+ binds to the heterodimer to keep it inactive until it has been 
transported to the plasma membrane (241). Integrin activation is dependent on ligand 
binding, which changes the conformation of such receptors. Inactive integrins present 
a folded conformation with the tails of each subunit close together. Upon stimuli, 
integrins go into an extended conformation, with separated tails, that presents 
intermediate or high ligand affinity (242). 
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Figure 10. Integrin structure and activation. A. Integrins present one inactive and two active states 
(intermediate and high affinity). Integrin activation follows ligand binding that induces conformational 
change. B. Integrins are transmembrane proteins formed by an α and a β chain. The β-subunit is 
formed by a cysteine-rich membrane proximal-β tail (βTD), followed by four epidermal growth factor 
(EGF) segments, hybrid and PSI (plexin/semaphorin/integrin) domains and, finally, a βI-like N-terminus, 
which contains one of the metal ion-dependent adhesion sites (MIDAS). The α-subunit is formed by two 
calf domains, followed by a tight and a folded seven-bladed β-propeller, which harbours four to five 
divalent-cation-binding sites and can contain an immunoglobulin-like domain. C. Upon ligand bidding 
and conformational change to the high affinity state integrins can form cooperative clusters that can 
mature into focal adhesions (243). 
Integrin activation is dependent on the above-mentioned cation, particularly, Mn2+, 
which can directly affect integrin conformation to the high affinity extended state (242). 
Once activated, it can bind to components of the ECM (242). Each integrin heterodimer 
interacts, preferentially, with different ECM molecules such as Coll, FN, and LM 
among other substances, as depicted bellow (217,242). Integrin binding to ECM is 
essential to cell survival, since integrin dissociation from the ECM leads to integrin -
mediated cell death by anoikis (242). 
A B 
C 
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Figure 11. Integrin and their ligands. Integrin heterodimers are formed by α and β-subunits, a variety 
of 18 α- and 8 β-subunits compose 24 integrins, which mediate interactions between cells and their 
extracellular environments. Each integrin heterodimer interacts, preferentially, with different 
extracellular matrix molecules such as Coll (depicted in green as CN), fibronectin (FN, depicted in blue), 
and laminin (LN, depicted in pink), among other substances such as tenascin (TN), vitronectin (VTN), 
thrombospondin (TSP) (244). 
Integrin binding to the ECM, or to adjacent cell surface receptors has three different 
functions. First, to regulate the cytoskeleton and ECM fluidity, through physical 
attachment in association with other proteins, such as talin, forming integrin adhesion 
complexes, that generate mechanotransduction signals, which influence cell 
positioning, division and protein expression (245). Second, to form clusters on the cell 
surface, often in association with syndecans, which affect the expression and 
concentration of integrin on cell surface, as well as affinity to ligands (246,247). 
Syndecans have often been described as co-receptors for integrins in the interaction 
with ECM molecules in physiological and tumoral situations, but the relationship 
between these two cell adhesion molecules goes far beyond that, this will be discussed 
in depth in the next section. Third, activate specific signalling pathways by 
phosphorylating kinases, such as focal-adhesion kinase (FAK), proto-oncogene 
tyrosine-protein kinase (Src), Rho-family GTPases, integrin-linked kinase (ILK) and 
lipid kinases, all of which control cell division, migration, differentiation and survival 
(229,230,248,249); or by acting as cell ligands and interacting with surface receptors, 
such as growth factor receptors (GFR), or specific immunoglobulins, such as VCAM. 
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This can affect cell proliferation, survival and angiogenesis through PI3K/AKT 
pathway, ERK signalling and Rho GTPase – Rac1 cascade (229,230). 
 
Figure 12. Integrin adhesion regulation of cell survival and apoptosis. Integrins attachment and 
activation of specific signalling pathways determines cell-fate. Integrin activation and affinity to the 
ECM can lead to cell survival, while integrin detachment initiates anoikis apoptotic signals. (250). 
All these roles of integrins within the cell, associated with the fact that malignant cell 
transformation often alters the expression of integrins, has led them to be associated 
with cancer progression, contributing to proliferation, survival, invasion, 
neoangiogenesis and metastasis (189,195). However, the role of each integrin subunit 
in different cancer types has been object of controversy. As each integrin subunit has 
different, specific functions, their association with different heterodimer counterparts 
influences their specificity to different ECM molecules or receptors and affects 
function. Moreover, different integrin subunits can cooperate or regulate each other to 
adapt to modify their microenvironment in a rapid, complex process, not yet fully 
understood. These changes can be a response to genetic modification, in the case of 
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malignant transformation, cell density, ECM stiffness, or stress, such as pH variation 
or the presence of anti-tumour drugs in the tissue. A key integrin subunit in this 
haemostasis behaviour is β1 integrin. Preferably binding to Coll and FN, β1 integrin 
can associate with at least 12 α–subunits to ensure cell survival, migration and 
metastasis, by regulating focal adhesions assembly between the cell and ECM. This 
integrin subunit has been associated with poor prognosis and metastasis in several 
cancer types, including melanoma (252–254). Highly metastatic MV3 melanoma cells 
present increased expression and activation of β1 containing integrins and use them to 
reorganize Coll matrices and migrate (255–257). Lydolph et al. have shown that β1 
integrins can be activated by Mn2+ ions, increasing adhesion in a Rho dependent and 
heparan sulfate independent manner, and that the activating status of β1 integrins 
controls cell tendency towards migration or proliferative behaviour (focal adhesion 
formation) (254). Furthermore, as mentioned above, β1 integrin has been linked to drug 
resistance in hematopoietic and solid tumours (142–144,147–149). But, so far, there 
are not many studies connecting β1 integrin to melanoma chemoresistance, except for 
the report from Bérubé et al. about uveal melanoma mentioned above. β1 integrin 
binding to their ECM ligands leads to integrin-mediated cell survival by activation of 
several signalling cascades including the FAK/PI3K/AKT pathway (250,252,258). For 
example, it has been shown that β1 and β3 integrin activation upon FN and vitronectin 
binding, respectively, leads to FAK phosphorylation and upregulation of the BCL-2 
pro-survival gene through the PI3K/AKT pathway (203). For this reason, we thought 
this would be an interesting target to investigate CAM-DR. 
As mentioned above, different integrin subunits can cooperate or regulate each other 
depending on environmental signals, this is the case for β1 and β3 integrin. There seems 
to be a very complex regulation between these subtypes. It has been suggested that β1 
integrin is involved in strong adhesion and proliferation, while β3 integrin expression 
favours endothelial to mesenchymal transition and metastasis (259–261). While this is 
true for β3 integrin, which has been associated with metastasis in many tumour types, 
including melanoma (191,260–264), β1 integrin has also been shown to drive tumour 
migration by modifying the ECM, especially Coll and FN fibres, in solid tumours. This 
can be observed for example in the previously mentioned MV3 melanoma cell lines 
that show high metastatic potential and increased levels of β1 integrins (255–257). As 
mentioned before, other melanoma cells have been shown to survive in Coll I 3D 
matrices by activating β3 integrin (191). Initial attachment seems to be made by β1 
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integrins, which are able to modify the Coll fibres, exposing its RGD binding site where 
β3 integrin can attach and lead to cell survival (191). It has also been suggested that the 
conformation state of FN fibres can favour expression and activation of either integrin 
subtype, thereby impacting cell behaviour and fate (265–267). Moreover, reports have 
shown that breast cancer cells, but not normal mammary cells, compensate for β1 
integrin downregulation by upregulating β3 integrin expression, which makes sense, if 
we observe the similarities between these two integrins, especially that both of them 
are able to bind to ECM components and form focal adhesions, which regulate survival 
through FAK activation (191,260,262,264). For example, the main ligand for β3 
integrin is vitronectin, which can also bind to Coll and induce melanoma cell survival 
(160,191). 
It has been suggested that the switch to β3 integrin makes  cells more aggressive and 
resistant to stress, since this integrin can induce survival upon cell detachment, through 
non-canonical FAK-independent signalling pathways (260,261). It has also been 
associated with RTK independency and cancer stem cell phenotype, which is 
knowingly treatment resistant (261,268,269). Moreover, β3 integrin invasion and 
metastasis in different cancer types, including melanoma by activating the FAK 
signalling pathway (191,260–264). Thus, even though the regulating mechanisms that 
control the balance between β1 and β3 integrin expression are not fully understood, 
they are certainly accurately regulated by cancer cells and seem to adapt to 
environmental changes, survive and proliferate. 
Syndecans 
Syndecans are an important adhesion protein family, often described as co-receptor for 
integrins and as ubiquitously expressed. The syndecans belong to the so-called heparan 
sulfate proteoglycans (HSPG), since they constitute a family of type I transmembrane 
proteins, which present glycosaminoglycans, most commonly heparan sulfate, 
covalently bound to their ectodomain. Syndecans’ core proteins range from 20-40 kDa 
and are divided into three parts: the extracellular domains or ectodomains, which are 
very sequence-divergent among the four syndecans, apart from the conserved GAG 
covalent attachment sites, where usually heparan sulfate, but also chondroitin sulfate, 
can be found; the transmembrane region, which is highly conserved and, finally, the 
small cytoplasmic domain, which is composed of two highly conserved regions (C1 
and C2), and a variable region (V), which is unique to each syndecan (246,247,270). 
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The V region of syndecan-4 is quite well understood and of great importance, its Tyr180 
regulates the effect of proteoglycans on integrin internalization and function. Also the 
serine residue, adjacent to this tyrosine, harbours the phosphorylation site for PKCδ 
(270). 
 
Figure 13. Syndecan subtypes and structure. Syndecans are transmembrane proteins that range from 
20-40 kDa and are divided into three parts: ectodomain (blue), where usually heparan sulfate (orange), 
but also chondroitin sulfate (brown) are bound; the transmembrane region (pink), which is highly 
conserved; and the cytoplasmic domain, which is composed of two highly conserved regions (C1 and C2 
in grey), and a variable region (V in green), which is unique to each syndecan (270). 
Syndecans have been known to work as receptors on the cell membrane, in a GAG-
dependent manner. The long sugar chains enable these HPSG to concentrate or reach 
disperse ligands from the ECM. Their importance has been shown in several studies 
where blocking or digestion of such GAG disrupts syndecan interaction with FN, 
fibroblast growth factor-2 (FGF2) and vascular endothelial growth factor (VEGF) 
(271,272). However, there are also reports of direct interactions between syndecan core 
protein and integrins in a GAG independent manner (273–275). These various 
interactions with multiple ligands render proteoglycans responsible for a variety of cell 
processes, such as regulating adhesion, motility and cellular proliferation; activity of 
cytokines, growth and angiogenic factors and enzymes; and interacting with tyrosine 
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kinase receptors and integrins (212,246,247,276,277). Thus, they are involved in tissue 
organization, development and repair, inflammation and tumour progression (276,278). 
 
Figure 14. Syndecan – integrin cooperation. Syndecans have been extensively associated with 
integrins as co-receptors, they can activate or increase integrin bidding affinity interacting with them 
directly or indirectly through the ECM, leading to outside–in signalling. Syndecans – integrin interaction 
can also lead to outside-in activation through Src/FAK (246). 
Syndecans have been extensively associated with integrins as co-receptors, and 
therefore inherent in tumour progression through regulation of matrix remodelling, cell 
adhesion and migration. Syndecan-1 aberrant expression has been associated with poor 
prognosis in several tumours (270). This proteoglycan has also been demonstrated to 
co-localize with α2β1 integrin in breast cancer to enhance integrin-mediated adhesion 
through actin organization on Coll, in a heparan dependent manner (247). Moreover, 
syndecan-4 altered expression has been shown to enhance cancer progression in breast 
cancer, melanoma and hepatocarcinoma. In melanoma, for example, downregulation of 
syndencan-4 blocks FGF2 signalling, increasing cell metastatic potential and 
decreasing adhesion (270). 
Regarding cell adhesion and migration, syndecans have a very specific and important, 
yet not completely understood, synergic function with integrins; they have a unique role 
in focal adhesions, which are points of strong attachment formed by membrane 
receptors that attach to actin filaments (stress fibres), such as integrins and syndecans, 
interacting with ECM molecules (212,276,279,280). The number of focal adhesions, 
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their size, and their stability, influences cell anchorage and migration. First, it was 
believed that only the combinatorial interactions of syndecan-4 and integrin β1 could 
form focal adhesion. Currently, it is known that integrin αvβ3 and αvβ5, and integrins 
α2β1 and α6β4 can cooperate with syndecan-1 to adhere to vitronectin and laminin, 
respectively (273,274,281,282). However, since syndecan-4 is obliquely expressed in 
all cell tissue, its involvement with integrin β1 in focal adhesion is the most understood, 
and their interaction has been shown to be the most important combination for ECM-
mediated cell survival (283). 
The combinatorial interactions of syndecan-4 and β1 integrins involve a series of 
downstream signalling events, which are also not fully understood. It seems that the 
syndecan-4 V region recruits phosphatidylinositol 4,5-bisphosphate leading to protein 
kinase Cα (PKCα) activation and integrin β1 engagement, which promotes 
phosphorylation of RhoA and Rho kinases, stress fibre recruitment and focal adhesion 
assembly, enabling migration and adhesion to FN, Coll and laminin (246,284,285).  
The synergy between integrin and syndecan-4 and integrin β1 helps such proteins 
regulate each other, for example syndecan-4 influences β1 integrin endocytosis and 
recycling, thereby assuring the balance between migration and attachment (246). 
Integrin and syndecan-4 interaction spans well beyond physical cell attachment since 
these interactions trigger intracellular survival signals. Since integrins and syndecans 
lack enzymatic activity, they activate these pathways by recruiting non-receptor 
kinases, such as PKC, Src, FAK and PI3K/AKT. In fact, syndecan-4 signalling through 
PKCα has been shown to regulate AKT activation by determining the localization of 
the mTOR complex 2 (mTORC2), which is responsible for the phosphorylation of AKT 
at S473 residue, and PDK1 (3 – phosphoinositide-dependent protein kinase 1), the 
kinase responsible for the T308 phosphorylation of this protein (286–288). 
FAK / PI 3-Kinase / AKT Signalling Pathway  
As previously mentioned, integrins can activate several different signalling pathways, 
which control cell survival, growth, migration and differentiation, such as the 
PI3K/AKT cascade, which can be activated as a result of integrin clustering via 
phosphorylation of focal adhesion kinase (FAK). 
FAK is a cytoplasmic tyrosine kinase formed by an amino-terminal FERM domain, a 
central kinase region, proline-rich domains and a C-terminal focal adhesion-targeting 
Introduction 
 
67 
 
(FAT) domain (289). FAK expression is associated with p53 and NF-κB (290,291). 
FAK overexpression or upregulation is often linked to tumour progression and survival, 
since this kinase can be activated by integrins upon extracellular stimuli, and trigger 
survival signals through PI3K/AKT cascade, for example (292). 
Although FAK can be activated by different stimuli, the best characterized involves 
integrin clustering upon binding to the ECM. This causes FAK dimerization and FAK 
auto-phosphorylation at Y397, which leads to Src protein kinases recruitment, binding 
and phosphorylation of FAK at Y576 and Y577, generating an active FAK–Src 
complex. The FAK-Src complex activates PI3K/AKT signalling through 
phosphatidylinositol-3,4,5-diphosphate [PtdIns(3,4,5)P2] (PIP2) (289,292–294). In 
head and neck cancer, the blockade of integrin-FAK signalling by integrin β1 
antibodies sensitized cells to radiotherapy and delayed tumour growth in vivo (295). 
Moreover, it has been described that integrin activation in ovarian cancer induces 
resistance to paclitaxel and prevents cell-death in an integrin – FAK – AKT-dependent 
manner (296,297). Furthermore, FAK inhibitors have been shown to enhance cancer 
cell sensitivity to cytotoxic drugs (297,298).  
FAK activation can be regulated by an intramolecular occlusion, by which the FAK 
FERM domain binds to the kinase domain, blocking accessibility to Y397 and auto-
phosphorylation. FAK FERM conformational changes can be triggered by interactions 
with phosphoinositide lipids (PIPs), cell binding to ECM (integrins, syndecans), FERM 
binding to receptor tyrosine kinases (RTK), pH alterations and increased cell-ECM 
tension (289,299–302). The latter has been observed in breast cancer mouse models in 
which FAK Y397 phosphorylation and tumour progression increased upon Coll fibre 
crosslinking (301,302). 
As mentioned above, phosphatidylinositol 3-kinase (PI3K) and its downstream effector 
AKT are frequently inappropriately activated and associated with malignancy in several 
different tumours, including melanoma (303–306). PI3K are heterodimers formed by a 
p85 regulatory subunit, which inhibits the p110 catalytic subunit. PI3K activation 
occurs when this inhibition is relieved by a conformational change, induced by the 
engagement of phosphotyrosines on p85 Src-homology 2 (SH2) domain 
(158,158,304,305). This also translocates PI3K to the plasma membrane, where its 
substrate PIP2 resides. 
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FAK phosphorylation creates a motif at the FAT domain, which allows interaction with 
the SH2 domain of PI3K. This can be triggered by cell membrane receptors such as 
integrins and receptor tyrosine kinases (RTK), whose modulation is also dependent on 
integrins (31,158). Thus, integrins play a crucial role in the incorrect activation of PI3K. 
As mentioned above, another PI3K over-activation mechanism is the loss of the PTEN 
tumour suppressor gene, which is considered to be part of the malignant transformation 
of melanoma cells, reported in up to 30% of cases (16,31,33–35,304). PTEN is 
responsible for dephosphorylating PIP3, consequently terminating PI3K signalling. 
(304). 
Accumulation of PIP3 generated by PI3K recruits AKT to the cell membrane and 
allows its phosphorylation by PDK1 (3 – phosphoinositide-dependent protein kinase 1) 
on T308 phosphorylation site, which results in partial activation of AKT (30,307). 
However, to be fully active, AKT must be phosphorylated into two critical residues: 
T308 and S473, since phosphorylation of S473 stabilizes T308 phosphorylation. The 
kinase responsible for S473 phosphorylation is, in most cases, the mTOR complex 2 
(mTORC2) (289,304,308,309). Once activated, AKT phosphorylates several 
substrates, such as FOXO, mTORC1 and GSK3, which are involved in various cellular 
processes, including cell growth, proliferation, survival, and metabolism, all of which 
are crucial for the establishment and maintenance of the tumorigenic phenotype (30).  
 
Figure 15. Integrin FAK/PI3K/AKT signalling pathway. FAK auto-phosphorylation upon integrin 
activation creates a motif at the focal adhesion-targeting domain of FAK, which allows interaction with 
the SH2 domain of PI3K. Accumulation of PIP3 generated by PI3K recruits AKT to the cell membrane 
and allows its phosphorylation by PDK1 (3 – phosphoinositide-dependent protein kinase 1) on T308 
phosphorylation site, and phosphorylation of S473, in most cases, by the mTOR complex 2 (mTORC2). 
The integrin-linked kinase (ILK) acts as a co-activator of AKT, together with PI3K, upon integrin 
activation. FAK - PI3K – AKT signalling leads to cell survival and drug resistance.
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2. Aim 
Minimal residual disease (MRD) has first been identified in hematopoietic cancers. 
This phenomenon consists of a three-step process, of which environment-mediated 
drug resistance (EM-DR) is the most essential. Extracellular matrix components shelter 
cells from chemotherapeutic stress through a vast array of mechanisms that ensure cell 
survival and enable cells to go to the next step, acquired drug resistance. Drug-
resistance development of melanocytes is a complex process, which involves 
interactions of environmental and genetic factors leading to loss of regulation of cell 
proliferation, apoptosis and cell-cell interactions. 
Cell membrane proteins that adhere to the extracellular matrix and to other cells, and 
lead to survival in face of chemotherapeutic stress are pivotal in this assemblage. The 
most important of these proteins are integrins. Their importance in cell-cell and cell-
matrix vital interactions is recognized and well understood. Furthermore, their impact 
on cell malignant transformation is established, although the mechanisms of such 
process are still under investigation. Moreover, integrins can directly activate focal 
adhesion kinase (FAK) that can phosphorylate PI3K and activate PI3K-AKT signalling.  
However, a potential role of integrins to chemoresistance of highly metastatic 
malignant melanoma has not yet been elucidated. Therefore, this project aims to 
provide an insight into the resistance phenomena of melanoma cells; investigate a 
potential link between beta-1 integrin and melanoma anti-apoptotic PI3K-AKT 
pathway, in response to cisplatin treatment; as well as elucidate the potential synergistic 
role of syndecans and integrins in underlying mechanisms of chemoresistance. 
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3. Material and Methods 
Materials 
Chemicals and primary compounds 
Chemical substances 
Denomination Manufacturer 
(3-(4,5-dimetiytiazol-2-yl)-2,5-
diphenyltetrazoliumbromate), MTT 
AppliChem GmbH, Darmstadt, Germany 
4′,6-diamidino-2-phenylindole, DAPI Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
Acetone Merck Chemicals GmbH, Schwalbach, 
Germany 
AlamarBlue™  Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
Annexin V-FITC Apoptosis Detection Kit Bender MedSystems GmbH, Vienna, 
Fromtria 
Bacillol® AF Paul Hartmann AG, Heidenheim, 
Germany 
BEZ235 (Dactolisib) Selleck Chemicals, Munich, Germany 
Bovine Serum Albumin, BSA Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
Carbon dioxide, CO2 AIR LIQUIDE Deutschland GmbH, 
Düsseldorf, Germany 
CASY®ton Schärfe Systems GmbH, Reutlingen, 
Germany 
Cell Extraction Buffer Thermo Fisher Scientific Inc., Waltham, 
USA 
CellTiter-Fluor™ Promega GmbH, Mannheim, Germany 
cis- diamminedichloridoplatinum(II), cisplatin Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
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Clarity™ ECL Western Blotting Substrate Bio-Rad Laboratories GmbH, Munich, 
Germany 
Collagen I (rat tail) Roche Diagnostics GmbH, Mannheim, 
Germany 
Dimethyl sulfoxide, DMSO Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
Dulbecco’s Modified Eagle Medium, DMEM PAN Biotech GmbH, Aidenbach, 
Germany 
Dulbecco's Phosphate-Buffered Saline, DPBS, 
without calcium, without magnesium, sterile 
PAN Biotech GmbH, Aidenbach, 
Germany 
Ethanol 96% (v/v) Merck Chemicals GmbH, Schwalbach, 
Germany 
Foetal bovine serum, FBS, F7524 Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
FuGENE® HD transfection reagent Promega GmbH, Mannheim, Germany 
Gigasept® Instru AF Schülke & Mayr GmbH, Norderstedt, 
Germany 
Glycine AppliChem GmbH, Darmstadt, Germany 
Halt™ Protease Inhibitor Cocktail (100X) Thermo Fisher Scientific, Waltham, USA 
Hydrochloric acid 1M Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
Isopropanol 100% Merck Chemicals GmbH, Schwalbach, 
Germany 
L-Glutamine Solution (200mM) PAN Biotech GmbH, Aidenbach, 
Germany 
Liquid nitrogen, LN2 Linde AG, Düsseldorf, Germany 
Manganese(II) chloride, MnCl2 Merck Chemicals GmbH, Schwalbach, 
Germany 
Melsept® SF B. Braun AG, Melsungen, Germany 
Methanol 99,9% Merck Chemicals GmbH, Schwalbach, 
Germany 
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Milk powder Carl Roth GmbH, Karlsruhe, Germany 
Paraformaldehyde Carl Roth GmbH, Karlsruhe, Germany 
Penicillin / Streptomycin Solution (10.000 
I.E./mL / 10 mg/mL) 
PAN Biotech GmbH, Aidenbach, 
Germany 
Phenylmethylsulfonyl fluoride, PMSF Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific Inc., Darmstadt, 
Germany 
Polybrene® (hexadimethrine bromide) Santa Cruz Biotechnology Inc., 
Heidelberg 
Precision Plus Protein™ Unstained Standards Bio-Rad Laboratories GmbH, Munich, 
Germany 
Precision Protein™ StrepTactin-HRP 
Conjugate 
Bio-Rad Laboratories GmbH, Munich, 
Germany 
Proteome Profiler™ Human Soluble Receptor 
Array 
R&D Systems Europe Ltd., Abingdon, 
UK 
Puromycin  Carl Roth GmbH, Karlsruhe, Germany 
Roti®-CELL PBS/EDTA Solution Carl Roth GmbH, Karlsruhe, Germany 
RPMI-1640® medium PAN Biotech GmbH, Aidenbach, 
Germany 
Sample Laemmli buffer, 2× concentrate Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
Sodium azide, NaN3 Carl Roth GmbH, Karlsruhe, Germany 
Sodium carbonate, Na2CO3 AppliChem GmbH, Darmstadt, Germany 
Sodium chloride, NaCl Grüssing GmbH, Filsum, Germany 
Sodium hydroxide Solution 1M, NaOH Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
Sodium hydroxide, NaOH Grüssing GmbH, Filsum, Germany 
TRIS-Base AppliChem GmbH, Darmstadt, Germany 
Tri-sodium citrate dehydrate, C6H5Na3O7 * 2 
H2O 
Merck KGaA, Darmstadt, Germany 
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Triton X-100 Carl Roth GmbH, Karlsruhe, Germany 
Trypsin/EDTA 0.25% Solution PAN Biotech GmbH, Aidenbach, 
Germany 
Tween™ 20 AppliChem GmbH, Darmstadt, Germany 
VitroGel 3D-RGD The Well Bioscience, Newark, USA 
Transfection plasmids 
Transfection system  Manufacturer 
Control shRNA Lentiviral Particles-A Santa Cruz Biotechnology Inc., 
Heidelberg, Germany 
Integrin β1 shRNA (h) Lentiviral Particle: sc -
35674 - V 
Santa Cruz Biotechnology Inc., 
Heidelberg, Germany 
Primary Antibodies 
Antibody  Epitope Host and Isotype Manufacturer 
β1 Integrin (P5D2) human β1 Integrin from 
epidermal keratinocytes 
Mouse, 
monoclonal, IgG1 
Santa Cruz 
Biotechnology 
Inc., Heidelberg, 
Germany 
β3 Integrin (B-7) Against amino acids 
635-730 of the C-
terminus of human β3 -
Integrin  
Mouse, 
monoclonal, IgG1 
Santa Cruz 
Biotechnology 
Inc., Heidelberg, 
Germany 
β-actin (C4) whole length of β-actin 
from avian gizzard 
actin  
Mouse, 
monoclonal, IgG1 
Santa Cruz 
Biotechnology 
Inc., Heidelberg, 
Germany 
AKT1 (C – 20) Against the C-terminus 
of human AKT1 
Goat, polyclonal, 
IgG 
Santa Cruz 
Biotechnology 
Inc., Heidelberg, 
Germany 
p-AKT1 (Thr 308) Against amino acid 
sequence containing 
Rabbit, polyclonal, 
IgG 
Santa Cruz 
Biotechnology 
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Thr 308 phosphorylated 
human Akt1 
Inc., Heidelberg, 
Germany 
ERK-1/2  ERK1 and ERK2 Rabbit, 
polyclonal, IgG 
Cell Signalling 
Technology, 
Frankfurt am 
Main, Germany 
p-ERK-1/2 
(Thr202/Tyr204) 
Double-phosphorylated 
Thr202 and Tyr204 or 
simple-phosphorylated 
Thr202 of ERK1 and 
ERK2 
Rabbit, 
monoclonal IgG1 
Cell Signalling 
Technology, 
Frankfurt am 
Main, Germany 
FAK (C – 20) Against the C-terminus 
of human FAK 
Rabbit, 
polyclonal, IgG 
Santa Cruz 
Biotechnology 
Inc., Heidelberg, 
Germany 
p-FAK (2D11) Against the amino acid 
residues surrounding 
Tyr397 of human FAK 
Mouse, 
monoclonal, 
IgG1 
Santa Cruz 
Biotechnology 
Inc., Heidelberg, 
Germany 
GAPDH (GT239) Against the central 
region of human 
GAPDH 
Mouse, 
monoclonal, 
IgG2b 
Gene Tex Inc, 
Irvine, USA 
p-MEK-1/2 
(7E10) 
Amino acids of the T-E-
Y Sequence 
Mouse, 
monoclonal, 
IgG1 
Santa Cruz 
Biotechnology 
Inc., Heidelberg, 
Germany 
PI3K p85α (Z – 8) Against amino acids 333-
430 of human PI 3-
kinase p85α 
Rabbit, 
polyclonal, IgG 
Santa Cruz 
Biotechnology 
Inc., Heidelberg, 
Germany 
p-PI3K p85α (Tyr 
508) 
Against a short amino 
acid sequence containing 
Tyr-508 phosphorylated 
PI3-kinase p85α of 
human origin. 
Goat, polyclonal, 
IgG 
Santa Cruz 
Biotechnology 
Inc., Heidelberg, 
Germany 
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Secondary Antibodies 
Antibody  Epitope Host and Isotype Manufacturer 
Donkey F(ab´)2 Anti 
Goat IgG  
Goat-IgG 
light chain 
Donkey, polyclonal, 
F(ab´)2 fragment, 
Alexa Fluor488 
Abcam plc, 
Cambridge, UK 
Donkey Anti-Mouse IgG Mouse-IgG Donkey, polyclonal, 
Alexa Fluor488 
Abcam plc, 
Cambridge, UK 
Donkey Anti-Rabbit IgG Rabbit-IgG Donkey, polyclonal, 
Alexa Fluor405 
Abcam plc, 
Cambridge, UK 
Donkey Anti-Goat IgG Goat-IgG Donkey, polyclonal, 
FITC 
Santa Cruz 
Biotechnology Inc., 
Heidelberg, 
Germany 
Donkey Anti-Goat IgG Goat-IgG Donkey, polyclonal, 
HRP conjugated 
Santa Cruz 
Biotechnology Inc., 
Heidelberg, 
Germany 
Goat Anti-Rabbit IgG Rabbit-IgG Goat, polyclonal, 
HRP conjugated 
Santa Cruz 
Biotechnology Inc., 
Heidelberg, 
Germany 
mIgGκ BP Mouse-IgGκ 
light chain 
Binding protein, HRP 
conjugated 
Santa Cruz 
Biotechnology Inc., 
Heidelberg, 
Germany 
Reagents solutions 
Antibody solutions 
Antibody (dilution) Composition Amount 
β1 Integrin (1:200) 
sodium azide 10 mg 
BSA 500 mg 
β1 Integrin (P5D2) 50 µL 
TBS-T 10 mL 
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β3 Integrin (1:200) 
sodium azide 10 mg 
BSA 500 mg 
β3 Integrin  50 µL 
TBS-T 10 mL 
β-actin (C4) (1:200-1000) 
sodium azide 10 mg 
BSA 500 mg 
β-actin (C4) 10-50 µL 
TBS-T 10 mL 
AKT1 (C – 20) (1:100) 
1% BSA solution 100 µL 
AKT1 (C – 20) 1 µL 
p-AKT1 (Thr 308) (1:100) 
1% BSA solution 100 µL 
p-AKT1 (Thr 308) 1 µL 
ERK-1/2 (1:200) 
sodium azide 10 mg 
BSA 500 mg 
ERK-1/2 50 µL 
TBS-T 10 mL 
p-ERK-1/2 
(Thr202/Tyr204) (1:200) 
sodium azide 10 mg 
BSA 500 mg 
p-ERK-1/2 (Thr202/Tyr204) 50 µL 
TBS-T 10 mL 
FAK (C – 20) (1:100) 
1% BSA solution 100 µL 
FAK (C – 20) 1 µL 
p-FAK (2D11) (1:100) 
1% BSA solution 100 µL 
p-FAK (2D11) 1 µL 
GAPDH (1:20000) 
sodium azide 10 mg 
BSA 500 mg 
GAPDH (GT239) 0.5 µL 
TBS-T 10 mL 
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p-MEK-1/2 (1:200) 
sodium azide 10 mg 
BSA 500 mg 
p-MEK-1/2 (7E10) 50 µL 
TBS-T 10 mL 
PI3K p85α (Z – 8) (1:100) 
1% BSA solution 100 µL 
PI3K p85α (Z – 8) 1 µL 
p-PI3K p85α (Tyr 508) 
(1:100) 
1% BSA solution 100 µL 
p-PI3K p85α (Tyr 508) 1 µL 
TCF4 (1:200) 
sodium azide 10 mg 
BSA 500 mg 
TCF4 50 µL 
TBS-T 10 mL 
Donkey Anti Goat IgG 
Alexa Fluor488 (1:200) 
1% BSA solution 200 µL 
Donkey F(ab´)2 Anti Goat IgG Alexa 
Fluor488 
1 µL 
Donkey Anti-Mouse IgG 
Alexa Fluor 488 (1:200) 
1% BSA solution 200 µL 
Donkey Anti-Mouse IgG Alexa 
Fluor488 
1 µL 
Donkey Anti-Rabbit IgG 
Alexa Fluor 405 (1:200) 
1% BSA solution 200 µL 
Donkey Anti-Rabbit IgG Alexa Fluor 
405 
1 µL 
Donkey Anti-Goat IgG 
FITC (1:200) 
1% BSA solution 200 µL 
Donkey Anti-Goat IgG FITC 1 µL 
Donkey Anti-Goat IgG 
HRP conjugated (1:1000) 
Milk powder 1 g 
Donkey Anti-Goat IgG 1 µL 
Streptactin from Precision Plus 
Protein™ WesternC™ Pack 
0.5 µL 
TBS-T 20 mL 
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Goat Anti-Rabbit IgG 
HRP conjugated (1:1000)  
Milk powder 1 g 
Goat Anti-Rabbit IgG 1 µL 
Streptactin from Precision Plus 
Protein™ WesternC™ Pack 
0.5 µL 
TBS-T 20 mL 
mIgGκ BP (1:1000) 
Milk powder 1 g 
Anti-Mouse binding protein 1 µL 
Streptactin from Precision Plus 
Protein™ WesternC™ Pack 
0.5 µL 
TBS-T 20 mL 
Buffers and solutions 
Denomination Composition Amount 
Blocking –solution  
Milk powder 5 g 
TBS - T to final Vol. 100 mL 
BSA – Solution 0.5% 
BSA 250 mg 
Sodium azide 50 mg 
DPBS 50 mL 
BSA – Solution 1% 
BSA 500 mg 
Sodium azide 50 mg 
DPBS 50 mL 
   
BSA – Solution 3% 
BSA 1.5 g 
Sodium azide 50 mg 
DPBS 50 mL 
Cisplatin stock solution (5 
mM)  
Cisplatin 15 mg 
DPBS to final Vol. 10 mL 
Cisplatin work solution  
(1 mM) 
Cisplatin stock solution (5 mM)  0.200 mL 
DPBS 0.800 mL 
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Cisplatin work solution 
(3,1mM) 
Cisplatin stock solution (5 mM)  0.600 mL 
DPBS 0.400 mL 
Cryopreservation medium 
DMSO 5 mL 
FBS 45 mL 
Electrode buffer 10X 
Glycine 72 g 
TRIS-Base 15 g 
SDS 5 g 
Purelab® water to final Vol. 500 mL 
Electrode buffer 1X 
Electrode buffer 10X 100 mL 
Purelab® water 900 mL 
Ethanol 10% 
Ethanol 96% 10.4 mL 
DPBS to final Vol. 100mL 
Glycine solution (0,1 M) 
Glycine 375 mg 
DPBS to final Vol. 50 mL 
Luminol - peroxide 
solution 
Clarity Western peroxide reagent 4 mL 
Clarity Western luminol reagent 4 mL 
Lysis buffer 
PMSF stock solution (0.3 mol/L) 34 µL 
Halt™ Protease Inhibitor Cocktail 
(100X) 
500 µL 
Cell Extraction Buffer 10 mL 
Manganese(II) chloride  
stock solution (100 mM) 
Manganese(II) chloride 0.629 mg 
Purelab® water to final Vol. 50 mL 
Manganese(II) chloride  
work solution (10 mM) 
Manganese(II) chloride S. Sol 5.0 mL 
Purelab® water to final Vol. 50 mL 
MTT solution (5 mg/mL) 
MTT salt 50 mg 
DPBS to final Vol. 10 mL 
NVP-BEZ235, Dactolisib  
stock solution (1 mM) 
NVP-BEZ235 1 mg 
DMF to final Vol. 2.13mL 
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NVP-BEZ235, Dactolisib  
work solution (5 µM) 
NVP-BEZ235 stock solution 
(1 mM) 
50 µL 
DPBS 9.950 mL 
NVP-BEZ235, Dactolisib  
work solution (1 µM) 
NVP-BEZ235 stock solution 
(1 mM) 
10 µL 
DPBS 9.990 mL 
Paraformaldehyde 
solution 2 % 
Paraformaldehyde 1 g 
DPBS to final Vol. 50 mL 
PMSF stock solution  
(0.3 mol/L) 
PMSF 250 mg 
DMSO 4.783 mL 
Protein standard solution  
(0,2 mg/mL) 
BSA 2 mg 
Purelab® water to final Vol. 10 mL 
Puromycin 5 mg/mL 
Puromycin  50 mg 
DPBS 10 ml 
Selection medium 
RPMI 1640 500 mL 
FBS 50 mL 
Penicillin / Streptomycin Solution 10 mL 
Puromycin (2.75 µg/mL) 152.6 µL 
RPMI complete medium 
RPMI 1640 100 mL 
FBS 50 mL 
Penicillin / Streptomycin Solution 10 mL 
TBS 10x 
Sodium chloride 40 g 
TRIS-Base 60.06 
Purelab® water to final Vol. 500 mL 
Adjust pH to 7.3 with 1 M 
Hydrochloric acid 
 
TBS 1X 
TBS 10X 100 mL 
Purelab® water 900 mL 
TBS - T TBS 10X 100 mL 
Tween™ 20 2 mL 
Purelab® water to final Vol. 1 L 
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Transduction medium RPMI complete medium 2.5 ml 
Polybrene® (10mg / ml) 1 ul 
Transfer buffer 10X Glycine 72 g 
TRIS-Base 15 g 
Purelab® water final Vol. 0.500 mL 
Transfer buffer 1X Transfer buffer 10X 100 mL 
Purelab® water 900 mL 
Triton stock solution 0.1 
% 
Triton X-100 50 µL 
DPBS 50 mL 
Triton work solution 0.001 
% 
Triton stock solution 0.1 % 500 µL 
DPBS 50 mL 
Disposable materials 
Denomination Manufacturer 
CASY®cups Schärfe System GmbH, Reutlingen, 
Germany 
Cell culture bottles, 250 mL, 75 cm², PS Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Cell culture bottles, 50 mL, 25 cm², PS Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Cell culture bottles, 550 mL, 175 cm², PS Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Cell culture bottles, 650 mL, 175 cm², 
CELLCOAT Collagen Type I 
Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Centrifuge tube, 15 mL, PP, sterile Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Centrifuge tube, 50 mL, PP, sterile Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Combitips advanced®  
1.0 mL; 0.5 mL; 0.1 mL 
Eppendorf AG, Hamburg, Germany 
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Cryovial tube PP, with screw cap, sterile Greiner Bio-One GmbH, Frickenhausen, 
Germany 
CytoOne® 24-Well-Platte, TC-treated Starlab GmbH, Ahrensburg, Germany 
CytoOne® 96-Well-Platte, TC-treated Starlab GmbH, Ahrensburg, Germany 
Disposable pipetting reservoirs Argos Technologies, Inc., Illinois, USA 
Disposable syringes Injekt® Solo (10 mL) B. Braun Melsungen AG, Melsungen, 
Germany 
Disposable syringes Injekt® Solo (20 mL) B. Braun Melsungen AG, Melsungen, 
Germany 
Filter paper 50/PKG, Mini T/B Bio-Rad Laboratories GmbH, Munich, 
Germany 
Gel- Pipette tips MµltiFlex Round Sorenson BioScience Inc., Salt Lake City, 
UT, USA 
Micro plate, 96-Well, PS, V-bottom, 
transparent 
Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Micro tube (0.6 mL) Corning B. V. Life Sciences, Amsterdam, 
Holland 
Micro tube (1.5 mL) Sarstedt AG & Co., Nümbrecht, Germany 
Micro tube (2.0 mL) Sarstedt AG & Co., Nümbrecht, Germany 
Mini-PROTEAN® TGX™ stainfree Bio-Rad Laboratories GmbH, Munich 
Nunc™ F96 MicroWell™ Polystyrolplate, 
black  
Thermo Fisher Scientific GmbH, 
Langenselbold, Germany 
Nunc™ F96 MicroWell™ Polystyrolplate, 
white 
Thermo Fisher Scientific GmbH, 
Langenselbold, Germany 
Pasteur pipette, Glass Brand GmbH & Co. KG, Wertheim, 
Germany 
Pipette tips  (101-1000 µL), blue Starlab GmbH, Ahrensburg, Germany 
Pipette tips  (1-10 µL), transparent Starlab GmbH, Ahrensburg, Germany 
Pipette tips  (1-200 µL), yellow Starlab GmbH, Ahrensburg, Germany 
Pipette tips  (5 mL) Plastibrand®, 
transparent 
Brand GmbH & Co. KG, Wertheim, 
Germany 
Material and Methods 
 
83 
 
Roti®-PVD, 0.45 µm Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Serological pipette (10 mL) Sarstedt AG & Co., Nümbrecht, Germany 
Serological pipette (25 mL) Sarstedt AG & Co., Nümbrecht, Germany 
TC-Platte 6 Well, Standard, F Sarstedt AG & Co., Nümbrecht, Germany 
Equipment 
Equipment Manufacturer 
Accu-Jet®  BRAND GmbH & Co. KG, Wertheim, 
Germany 
Accu-Jet® pro BRAND GmbH & Co. KG, Wertheim, 
Germany 
Analytical balance Kern 770 Kern & Sohn GmbH, Balingen-
Frommern, Germany 
Analytical balance Mettler Toledo Classic 
Plus AB135-S 
Mettler-Toledo GmbH, Giessen, 
Germany 
Analytical balance Sartorius basic BA210S Sartorius AG, Göttingen, Germany 
Analytical balance Sartorius R160P Sartorius AG, Göttingen, Germany 
Aspiration system BVC 21 NT Vacuubrand GmbH & Co. KG, 
Wertheim, Germany 
Cell counter CASY® 1 Model TT Schärfe System GmbH, Reutlingen, 
Germany 
Centrifuge AllegraTM 25R  Beckmann-Coulter GmbH, Krefeld, 
Germany 
Centrifuge Avanti J-25 Beckmann-Coulter GmbH, Krefeld, 
Germany 
Centrifuge Micro 200 R Andreas Hettich GmbH & Co. KG, 
Tuttlingen, Germany 
Centrifuge Mini Spin Eppendorf AG, Hamburg, Germany 
Centrifuge Universal 32 R Andreas Hettich GmbH & Co. KG, 
Tuttlingen, Germany 
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Centrifuge Universal 320 R Andreas Hettich GmbH & Co. KG, 
Tuttlingen, Germany 
ChemiDoc™ XRS+ System Bio-Rad Laboratories GmbH, Munich, 
Germany 
CO2-incubator ICO105med Memmert GmbH + Co. KG, Schwabach, 
Germany 
CO2-Incubator MCO-170 AIC (UV) Panasonic Healthcare Co., Kadoma, 
Japan 
CO2-Incubator NuAire™ DH AutoFlow NuAire Inc., Plymouth, MN, USA 
Drying cabinet 60°C Heraeus Holding GmbH, Hanau, 
Germany 
Freezing container, Nalgene® Mr. Frosty Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
FLUOstar OPTIMA fluorescence scanner BMG Labtech, Offenburg, Germany 
sigmaGuava® easyCyte HT Merck KGaA, Darmstadt, Germany 
Laboratory shaker KS-15 Edmund Bühler GmbH, Hechingen, 
Germany 
Laminar-Air-Flow - Heraeus HeRASafe 
HSP 12 
Heraeus Holding GmbH, Hanau, 
Germany 
Laminar-Air-Flow - Holten safe 2010 Heto-Holton A/S, Allerød, Denmark 
Light microscope Axiovert 200  Carl Zeiss Microscopy GmbH, Jena, 
Germany 
Light microscope Wilovert 30 Helmut Hund GmbH, Wetzlar, Germany 
Light microscope Wilovert Standard HF/K Helmut Hund GmbH, Wetzlar, Germany 
Magnetic stirrer MR 3001 Heidolph Elektro GmbH & Co. KG, 
Kelheim, Germany 
Magnetic stirrer RCT basics IKA®-Werke GmbH & CO. KG, 
Staufen, Germany 
Mini-PROTEAN® Tetra Cell and Blotting 
Module with PowerPac 300 
Bio-Rad Laboratories GmbH, Munich, 
Germany 
Multipette® M4 Eppendorf AG, Hamburg, Germany 
Material and Methods 
 
85 
 
Multiscan® EX Thermo Scientific GmbH, Langenselbold, 
Germany 
Multiwellreader FLUOstar™ OPTIMA BMG Labtech GmbH, Offenburg, 
Germany 
Multiwellreader POLARstar™ OPTIMA BMG Labtech GmbH, Offenburg, 
Germany 
PARAFILM® M BRAND GmbH & Co. KG, Wertheim, 
Germany 
pH-Meter S20 SevenEasy™ pH Mettler-Toledo GmbH, Giessen, 
Germany 
Pipette (10 µL) Ranin  BRAND GmbH & Co. KG, Wertheim, 
Germany 
Pipette (10 µL) Research® Eppendorf AG, Hamburg, Germany 
Pipette (100 µL) Research® Eppendorf AG, Hamburg, Germany 
Pipette (100 µL) Transferpette® S BRAND GmbH & Co. KG, Wertheim, 
Germany 
Pipette (1000 µL) Research® Eppendorf AG, Hamburg, Germany 
Pipette (1-5 mL) Finnpipette® Thermo Fisher Scientific GmbH, 
Langenselbold, Germany 
Pipette (200 µL) Transferpette® S-12 BRAND GmbH & Co. KG, Wertheim, 
Germany 
Pipette (200 µL) Transferpette®-12 
electronic 
BRAND GmbH & Co. KG, Wertheim, 
Germany 
Purelab® Flex water treatment filter ELGA LabWater, Celle, Germany 
Purelab® Plus water treatment filter ELGA LabWater, Celle, Germany 
Repeating pipette HandyStep® electronic BRAND GmbH & Co. KG, Wertheim, 
Germany 
Repeating pipette HandyStep® S BRAND GmbH & Co. KG, Wertheim, 
Germany 
Shaking incubator Unimax® 1010 Heidolph Instruments GmbH, 
Schwabach, Germany 
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Spatula, various Carl Roth GmbH, Karlsruhe, Germany 
Steri-Cycle® CO2 cell incubator Thermo Electron GmbH, Dreieich, 
Germany 
Thermomixer comfort (IsoTherm 1.5 mL) Eppendorf AG, Hamburg, Germany 
Tweezers, diverse Carl Roth GmbH, Karlsruhe, Germany 
Ultrasonic bath Sonorex® Super RK 103 H BANDELIN electronic GmbH & Co. KG, 
Berlin, Germany 
Vacuum- Chemistry pumping unit PC5 Vacuubrand GmbH & Co. KG, Germany 
Volumetric flask BLAUBRAND®, 
Klasse A (10 mL, 50 mL, 100 mL, 250mL, 
500mL) 
Carl Roth GmbH, Karlsruhe, Germany 
Vortex-Genie 2 Scientific industries, New York, USA 
Software 
Denomination/Version Developer 
Ascent Software™ v2.6 © Thermo Labsystems Oy 1996-2002 
ChemSketch Ultra v14.01 © ACD/Labs 2012 
Image Lab v6.0 © Bio-Rad Laboratories 2010 
InCyte™ © Merck KGaA 
Microsoft Office v14.0.7190.5000 © Microsoft Corporation 2010 
Microsoft Visio v14.0.7188.5002 © Microsoft Corporation 2010 
Optima v.2.20R2 © BMG Laptech 
Prism 5 for Windows v5.00 © GraphPad Software Inc. 1992-2007 
ZEN 2012 v.1.1.2.0 © Carl Zeiss 
Zotero 5.0.44 © Roy Rosenzweig Center for History 
and New Media 
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Cell Culture 
The MV3 cell line (kindly donated by Dr. Reiner Zeisig, EPO Berlin) was established 
from a xenotransplantation in nude mice of lymph-node metastases from a 76-year-old 
male patient that suffered from a primary cutaneous amelanotic malignant melanoma 
(310). These undifferentiated cells present aneuploid karyotype, cell polymorphism, 
large abnormal nucleoli and multinucleated cells (310,311). They are also known to 
display high affinity to Coll type I and IV and increased expression of integrin β1 and 
CD44, which have been linked to various steps of the metastatic cascades and tumour 
malignancy (257,312,313).  
MV3 Syn-4 knockdown (MV3 Syn-4 kd) was established by Dr. Patrick Schmitz from 
Dr. Bendas’ group using lipid-based shRNA-plasmid (Mission®shRNA, Sigma-
Aldrich) transfection (314). Cells stably expressing anti Syn-4 shRNA were selected 
under permanent puromycin treatment (314). Syn-4 expression was measured via 
western blot (315). 
MV3 cell lines were kept in RPMI 1640 medium supplemented with penicillin (10 
IU/mL), streptomycin (100 µg/mL) and 10% FBS. The cell medium of transfected cells 
was also supplemented with puromycin (2.75 µg/mL).  
NW1539 and Mel_1956 cells are novel and recently established melanoma cell lines, 
which are currently under further characterization. They were kept in DMEM medium 
containing 10 mM HEPES buffer, L-arginine (84 mg/L), L-glutamine (584 mg/L), 
penicillin (10 IU/mL), streptomycin (100 µg/mL), and 10% FBS. 
All cells were kept at humidified atmosphere, at 37°C, containing 5% CO2. All media 
was stored at 2oC - 8oC and used at room temperature, media supplements (antibiotics, 
FBS, L-glutamine and HEPES buffer) were stored at -20oC until use. 
Cells were grown to 80 – 90% confluence before sub-cultivation and media was 
changed every 2-3 days depending on consumption, which was evaluated by the colour 
of the pH marker. For sub-cultivation, old media was aspirated, and cells were washed 
once with DPBS at room temperature. Then cells were detached, using a commercial 
solution of 0,025 % EDTA, for 3-5 min, at 37 °C. Detached cells were collected with 
the appropriate full media into centrifugation tubes and centrifuged at 4°C, 310 g for 5 
min, after which supernatant was aspirated and cell pellet suspended in 5mL fresh full 
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media. Cell suspension was then counted (see below) and seeded into the new desired 
cell culture container. Since cell culture is inherently subject to fluctuations and 
excessive cultivation and detachment results in the genetic diversification of the cell 
line, every sub-cultivation was counted as one passage, to create a record of the age of 
the cells used. When cells were deemed too old (over 20 – 25 passages) or presented 
abnormal growth or morphology, they were discarded, and a new cell vial was thawed 
(see below). 
CASY® cell counter was used to determine cell concentration in our suspension. The 
equipment isolates cells by aspirating them through a capillary, which generates an 
electric field that can measure cell resistance and thus, cell concentration. 20 μL of cell 
suspension obtained after centrifugation was transferred to a CASY® cup containing 10 
mL of CASY® ton (dilution 1: 500). Cell concentration in this new suspension was 
measured using the CASY® cell counter. Since each cell, depending on its size, 
specifically modifies the resistance, in addition to the absolute cell count, the device 
also presents a cell population size distribution. Particularly small particles represent 
cell metabolites, contaminants or dead cells, which are automatically removed from the 
cell count by the device. Based on the number of viable cells measured, it is possible to 
deduce cell concentration in cell suspensions and seed cells in the desired density. 
Cell lines can be maintained for many years in liquid nitrogen through cryopreservation. 
This assures scientists fresh supplies of the studied cell lines to replace cells that have 
been in culture for too long and present numerous passages or abnormal growth or 
morphology. For this purpose, once detached, cells were resuspended in media and 
counted. As described above, they were centrifuged again, and cell pellet collected in 
cryopreservation medium for a final concentration of 1 million cells per mL. This 
solution was distributed into previously identified cryovials and stored overnight in a 
freezing container filled with 96% ethanol at 80oC. In the following morning, the cell 
vials were transferred to liquid nitrogen for long term storage. The ethanol in the 
freezing container and dimethyl sulfoxide (DMSO) present in the freezing medium 
cause cells to freeze slowly and prevent the formation of water crystals that could 
rupture cell membranes and lead to cell death. When necessary, cryopreservation vials 
were thawed by taking cells from the nitrogen tank and quickly resuspending them in 
warm, full medium. Subsequently, cells were centrifuged to remove toxic DMSO and 
cell debris and seeded into the desired cell-culture containers. 
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Transduction 
Transduction is the specific name given to viral transfections, in other words, the 
introduction of foreign DNA by means of viral particles into a host cell (316). The 
underlying principle is based on the ability of viruses to introduce and integrate their 
genetic material into the genome of target cells. This allows scientists to take advantage 
of the natural mechanism of survival of viruses to introduce genetic modifications in 
culture cell lines (316). These modifications can induce gene silencing as well as 
overexpression (316). In the present case, we aimed to silence the β1 integrin gene and 
thus protein expression. 
For this purpose, modified lentiviruses were used. These viral particles have had the 
desired DNA sequence integrated into their genome, creating a viral vector (316). Since 
the viruses are no longer capable of replication, it is necessary to incubate the cells with 
enough virus particles to ensure that the desired gene sequence is effectively integrated 
into the host genome (316). Typically, the integrated gene sequence will contain 
multiple copies of the desired DNA segments, to allow a proportionally high level of 
target RNA; in our case a small hairpin RNA (shRNA) directed against the β1 integrin 
gene sequence to inhibit protein translation (316,317).  
Small or short hairpin RNAs, known as shRNAs, are artificial constructs used for 
molecular biology because of their double strand stable structure (316,317). In the 
nucleus, the sequence introduced by the virus into the cell genome is transcribed by 
RNA polymerase III or II, depending on the promoter used in the vector, generating a 
double strand RNA molecule bound by a loop (hairpin) (see Figure 16) (316,317). This 
RNA molecule is processed by Drosha and results in a pre-shRNA, which is exported 
into the cytoplasm where it can be cleaved by Dicer into a double-stranded siRNA 
(316,317). An enzyme complex of argonaut proteins and the RNA-induced silencing 
complex (RISC) bind to the double-stranded siRNA and convert it into two single-
stranded RNAs (316,317). The sense strand (passenger) is degraded, while the antisense 
strand (guide) recognizes the complementary target messenger RNA (mRNA) and can 
direct RISC to bind to the target (316,317). Depending on complementarity, RISC 
cleaves the mRNA through argonaut proteins with endonuclease activity, or represses 
mRNA translation into protein (316,317). In both these cases, this leads to reduced 
target protein expression. In our case, the produced guide siRNA is complementary to 
the mRNA that encodes β1 integrin protein, thus blocking β1 integrin translation. This 
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process is referred to as knock-down, as it results in greatly reduced production of 
functioning β1 integrins.  
 
Figure 16. Cell transduction with lentivirus and shRNA processing. DNA sequence for shRNA is 
introduced into the cell by lentivirus particles. After inserted into cell DNA, the sequence is transcribed 
into a hairpin shRNA, which is processed by Drosha, exported to the cytoplasm and cleaved by Dicer 
into a siRNA. The siRNA binds to the RISC – argonaut complex and sense strand (green) is degraded, 
while the antisense strand (blue) recognizes, binds to and cleaves the complementary target mRNA. 
Modified from Cojocari (318). 
Typically, most viral vectors also contain a sequence that allows the detection and/or 
selection of successfully transduced cells. The most common are the so-called reporter 
genes that code for the synthesis of a fluorescent protein, which can be visualized under 
a fluorescence microscope or selected through fluorescence cell sorting; or an enzyme 
that can modify the media (ex. lac-Z) (316). Antibiotics resistance genes can be 
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considered as a type of reporter gene, since they enable cells to produce enzymes that 
can deactivate toxic substances (antibiotics) present in cell media. This confers 
transduced cells resistance to a specific antibiotic and allows selection of transduced in 
detriment of non–transduced cells (316). Moreover, continuous treatment with the 
antibiotic creates selective pressure because it pressures cells to keep the foreign, 
introduced DNA and not lose their transduced properties, even if the transcription of 
the DNA introduced is uncomfortable to the cell (toxic, lacks important protein, high 
energy costs) (316). It is crucial that the toxicity of the antibiotics in a specific cell line 
to be determined prior to transduction, this can be done by using a kill curve method 
(see below) (316). 
Besides the shRNA sequence, the viral vector used contains a sequence for puromycin 
resistance. Puromycin is a nucleoside antibiotic that inhibits protein biosynthesis in 
eukaryotic cells. The successfully transduced cells are capable of producing puromycin 
N-acetyltransferase (PAC), which deactivates the puromycin added to the cell medium 
(319). The cells can be selected accordingly in puromycin-containing medium. Thus, 
puromycin-added medium is referred to as the selection medium.  
In order to exclude possible misleading effects generated by the cell transduction 
process and not by protein downregulation, wild type MV3 cells were also transduced 
with viral particles that are identical to the knockdown vectors, except that they encode 
a scramble sequence that results in a siRNA with no function (Control shRNA 
Lentiviral Particles A) (316). This is particularly important in lentiviral transfections 
because these viruses have the ability to integrate into sections of transcriptionally 
active chromatin. On the one hand, this is an advantage because it allows the genetic 
modification to be passed on to progeny cells, but, on the other hand, increases the risk 
of insertional mutagenesis, which can be reduced by using an integrase-deficient 
lentivirus (316).  
Even though, my colleagues that performed the syn-4 knockdown had already tested 
the best concentration of puromycin for the MV3 cells, I decided to repeat this step and 
make a puromycin kill curve for these cells to ensure that the concentration used was 
still suitable. For this purpose, the cells were seeded at 60% confluence, in 24-well 
plates, and let adhere overnight. On the following day, a curve with increasing 
concentration of puromycin, including the concentration previously used, was added to 
cell medium. Cells were monitored for one week, in the end of which, we could confirm 
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that optimal dose (lowest dose of puromycin that killed all cells) was the previously 
established one: 2.75 µg/mL. We could also observe a minimum dose, in the presence 
of which none or a few cells were affected after one week, and a maximum puromycin 
dose, in the presence of which all cells died within three days. Thus, the selection 
medium for all transfected cells (MV3 Syn-4 kd, MV3 β1 kd and MV3 scramble) is the 
same (complete RPMI 1640 plus puromycin 2.75 µg/mL). 
For transduction, a fresh cell vial of MV3 cells was thawed and cells were kept in 
normal cell culture conditions for one week. On the first transduction day, cells were 
seeded in a 96-well plate at a density of 1000 cells / well and let adhere overnight. On 
the second day, complete cell medium was substituted by 100 μL / well of transduction 
medium (Polybrene® 4µg / mL in complete cell medium). Polybrene serves as a 
polycationic reagent that saturates negative charges between the cell surface and the 
viral capsid. In the next step, the viral particles were thawed and carefully resuspended. 
In one well, 4 μL of integrin β1 shRNA (h) lentiviral particles were added to the 
medium, the same procedure was carried out for the control shRNA lentiviral particles 
in another well. In addition to these two wells, two additional wells were used as 
controls. In order to exclude a harmful influence of the polybrene on the cells, the first 
well of the controls was mixed only with polybrene-containing medium. The second 
well was incubated with cell medium, without supplements and switched together with 
the other samples 24 hours after the transduction to complete medium. The addition of 
puromycin on the fourth day enabled stable clones to be selected. 
The medium with the infectious viruses of this approach was used again to transduce 
another approach in the same way (referred to as clone 2 in the following statements). 
Over a period of four weeks, the cells were further cultured and repeatedly transferred 
to larger growth plates and cell culture bottles until a cell count of approximately 106 
was reached and cryovials could be made. The polybrene control grew in full medium 
analogously to normal cells. As expected, the puromycin control died after a one-week 
incubation period. After transduction, MV3 β1 kd and MV3 scramble were submitted 
to the kill curve assay again and optimal and maximum doses were confirmed.  
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Plate Coating  
As described, the extracellular matrix plays an essential role in the activation of 
integrins and the interaction between this protein and syndecans. To observe the 
influence of ECM components on CAM-DR, cells were grown in commercially pre-
coated Coll I bottles, as well as plates manually coated with FN or Coll I, in our 
laboratory, using commercial stock solutions. 
Coll and FN at a 10 μg / cm2 density were used for all experiments. Based on the 
density, coating area (cm2) and volume (μL), the concentration of work solution (μg / 
mL) required was calculated using equation 1: 
𝑤𝑒𝑙𝑙 𝑎𝑟𝑒𝑎 (𝑐𝑚2) 𝑥 𝑐𝑜𝑎𝑡𝑖𝑛𝑔 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 (µ𝑔/𝑐𝑚2)
𝑣𝑜𝑙 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 (µ𝐿)
= 𝑤𝑜𝑟𝑘 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (µ𝑔/µ𝐿) 
Equation 1. Calculation of the concentration of Coll or FN based on desired density. 
Based on the number of wells to be coated and the volume required per well, the total 
volume of work solution can be calculated, in this step an excess amount of 10% was 
added to make up for pipetting mistakes.  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑤𝑒𝑙𝑙𝑠 𝑥 𝑣𝑜𝑙 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 (𝑚𝐿) = 𝑡𝑜𝑡𝑎𝑙 𝑤𝑜𝑟𝑘 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑣𝑜𝑙 (𝑚𝐿) 
Equation 2. Calculation of total volume of work solution based on the number of wells to be coated. 
Taking this into account, we can calculate the amount of Coll or FN (mg) to form the 
work solution: 
𝑤𝑜𝑟𝑘 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑚𝑔/𝑚𝐿) 𝑥 𝑡𝑜𝑡𝑎𝑙 𝑤𝑜𝑟𝑘 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑣𝑜𝑙 (𝑚𝐿)
= 𝑤𝑜𝑟𝑘 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑐𝑜𝑙𝑙/𝐹𝑁 𝑎𝑚𝑜𝑢𝑛𝑡 (𝑚𝑔) 
Equation 3. Calculation of the mass of Coll or FN required for the work solution, based work 
solution total volume. 
Finally, the volume of stock solution needed to be diluted with PBS to form the work 
solution can be calculated: 
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𝑤𝑜𝑟𝑘 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑐𝑜𝑙𝑙/𝐹𝑁 𝑎𝑚𝑜𝑢𝑛𝑡 (𝑚𝑔)  
𝑠𝑡𝑜𝑐𝑘 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑚𝑔/𝑚𝐿)
=  𝑠𝑡𝑜𝑐𝑘 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑣𝑜𝑙 (𝑚𝐿) 
Equation 4. Calculation of stock solution volume based on amount of coating protein required. 
The amount of PBS is then calculated by subtracting the volume of stock solution from 
the total volume of work solution. Then, the specific volume was pipetted into each 
well and plates were incubated, for at least 1 hour for Coll, and 4 hours for FN, at 37oC; 
wells were briefly rinsed once with DPBS before cell seeding. Coll plates can be dried 
under the laminar air flow after washed with DPBS and kept sterile at 4oC for up to a 
month. 
Establishment of 3D cell culture model 
Throughout the years, mainly due to ethical problems, there has been a constant search 
for science models that accurately mimic the in vivo environment, but do not necessarily 
demand animal research (320,321). Solid tumours grow three-dimensionally in vivo and 
it has been known that cells behave and express different proteins in 3D models, which 
suggests this model mimics the in vivo environment more accurately if compared to 2D 
cultures (320,322). In line with this, 3D cell culture models were developed. There are 
two types of 3D models: spheroids and embedding. The spheroid technique is based on 
cell aggregation properties; when cells are cultured in suspension or in a non-adhesive 
environment. Cells are forced to form a 3D structure by adhering amongst themselves 
due to environmental conditions, such as agitation, hanging drop system or non-
adherent bottom conditions, such as agarose or non-adherent U-bottom plates 
(320,321). These models present the advantage of enabling the observation of the cells 
and their capability to adhere to themselves and produce ECM, without the interference 
of artificial ECM added by the researcher (320,321). However, there are a couple of 
disadvantages, for example, the cells in the bottom of the sphere are still in contact with 
plastic or agarose and might grow two-dimensionally, also it is hard to control sphere 
size and stability, lose spheres might disaggregate in time (320,321). The embedding 
model consists of resuspending the cells in an extracellular protein (Coll) or ECM 
proteins mixture (Matrigel®, VitroGel™ 3D) before it can polymerize into a gel. 
However, it is important to ensure that the gel is not dense to the point that the cells are 
petrified into it and cannot receive nutrients. The advantage of this system is that the 
cells are round, completely in contact with ECM and still present cell-cell contact, 
exchanges and interactions (320,321).  
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Figure 17. 3D Model techniques schema 
After testing many different 3D cell culture model approaches, we opted for the 
embedding of the cells in a commercial hydrogel mixture called VitroGel™ 3D - RGD, 
since this technique showed the most success and least variability. Cells were detached 
from cell bottles and counted as described above, then cell pellet was resuspended in 
complete cell medium and mixed 1:1 with VitroGel™ 3D – RGD, diluted in DPBS 
(1:3), for a final concentration of 102 cells/µL or 2×102 cells/µL, according to 
instructions of the manufacturer for melanoma cells. VitroGel-cell solutions were 
distributed 50µL/well in black clear flat bottom 96-well plates in accordance to our 
established resazurin cytotoxicity assay protocol (see below). Plates were incubated for 
15 min, at 37oC, before addition of 40µL/well of complete cell medium. On the 
following day, a 10µL/well of cisplatin logarithmic concentration curve was applied to 
the cells and resazurin cytotoxicity assays were performed as described below. 
Cytotoxicity assays 
Cell cytotoxicity assays are based on the ability of mitochondria to metabolize 
substances upon ATP spending, usually generating a coloured or fluorescent product. 
There are many different assays based on this concept. One of which is the thiazolyl 
blue tetrazolium bromide (MTT), which measures the cytotoxic effect of cisplatin. This 
assay is based on the capacity of the mitochondria to convert tetrazolium salt (3-(4,5-
dimetyltiazol-2-yl)-2,5-diphenyltetrazoliumbromate) into formazan crystals (316,323). 
This process is carried out by the succinate dehydrogenase enzyme and requires ATP; 
therefore, it can only be performed by viable cells. The resulting formazan crystals can 
be solubilized in dimetylsulfoxide (DMSO) creating a purple solution whose colour 
intensity can be measured by spectrophotometry and is proportional to the amount of 
living cells (316,323).  
3D Model
Spheroid
Agitation 
Hanging Drop
Agarose /U-bottom
Embedding
Collagen
Hydrogel Mixture 
(VitroGel™ 3D)
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Figure 18. Conversion of MTT salt to formazan 
Another example is the alamarBlue™ assay, which was performed using a commercial 
resazurin solution to measure the 3D cell culture assays. Resazurin is a blue, non-toxic, 
cell-permeable, non-fluorescent reagent, which can passively enter cells (316,323). In 
viable cells, it is then converted to resorufin, a highly fluorescent compound that can 
be detected by fluorescence plate reader (316,323).  
 
Figure 19. Conversion of resazurin to resorufin 
For the cell cytotoxicity assays, cells were first seeded at two different cell densities in 
triplicates (B, C, D 5000 cells / well and E, F, G 10000 cells / well) onto  the 60 inner 
wells of black clear bottom (resazurin) or transparent (MTT) flat bottom 96-well plates, 
with or without coating, as described above, and let to adhere overnight. The outer wells 
(A and H) were filled with 90µL DPBS per well, to avoid medium evaporation (see 
plate scheme). Cells were usually let to adhere overnight, and appropriate treatment 
was given on the following day. 
For treatment with manganese (Mn2+), cells were incubated for 5 minutes with 1 mM 
solution of manganese chloride (MnCl2), for final concentration of 100µM Mn
2+ per 
well. After incubation, cell medium was discarded, and new cell medium added to all 
cell plates, before cisplatin addition.  
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BEZ235 (NVP-BEZ235, Dactolisib) is an imidazole[4,5-c]quinolone derivative dual 
pan-PI3K/mTOR inhibitor developed by Novartis, which is currently in phase I/II 
clinical trials for use as co-adjuvant anti-tumour therapy (308,324,325). It binds, 
reversibly and competitively, to the ATP-binding cleft of PI3K and mTOR, working as 
potent and selective inhibitor of PI3K pathway. BEZ235 presents very low affinity to 
other down or upstream effectors, such as FAK, AKT and PDK1, but has been shown 
to interfere in 50% of AKT phosphorylation in a reversible manner (308). It interferes 
in cell proliferation, and it has been shown to lead to apoptosis, when associated to 
platinum derivatives and taxanes (326,327). 
 
Figure 20. Structure of dual pan-PI3K/mTOR inhibitor BEZ235 (NVP-BEZ235, Dactolisib) 
For this reason, cells were treated with 500 nM and 100 nM of BEZ235, for 30 minutes, 
before different concentrations of cisplatin were added. 
Administration of 10 μg tinzaparin (500 μg/mL) was performed at two different time 
points, 0 h, which means tinzaparin was administered to cells immediately after cell 
seeding; and 6 h, which means cells were let to adhere for 6 hours prior to tinzaparin 
treatment. On the following day, cisplatin was added. 
Heparan sulfate digestion with heparitinase I was performed 6 hours after cell seeding, 
using 10 μL of heparitinase I (0.1 U/mL). On the following day, cisplatin was added. 
Treatment was followed by a logarithmic concentration curve of cisplatin for a final 
volume of 100ul per well. The cisplatin logarithmic concentration curve was obtained 
by diluting 5 mM cisplatin stock solution with PBS into a concentration of 1µmol (103) 
and 3.162µmol (10-2.5) and making sequential 1:10 dilutions from these solutions.  
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Figure 21. Exemplary distribution of a cell cytotoxicity assay. Cisplatin logarithmic dilution series 
starting with DPBS as 0 value and ending with 3.162µmol cisplatin (10-2.5). The outermost row of panels 
contains the DPBS evaporation protection. 
Cells were then incubated, for 72 h, at 37oC, with 5% CO2. Subsequently, the assays 
were developed according to the cytotoxicity assay protocol. In the case of MTT, 20 
µL of MTT reagent solution (5 mg/mL in PBS) was added to each well and incubated 
for 1 h, at 37oC, until formazan crystals were formed. The supernatant was removed, 
and the formazan crystals were solubilized with 100 µL of dimetylsulfoxide. Plates 
were analysed under spectrophotometer at 570 nm, with background subtraction at 690 
nm, using Thermomultiscan EX plate reader. For the alamarBlue™ assay, resazurin 
stock solution (10 mg/mL in DPBS) was diluted to a work solution of 0.15 mg/mL in 
DPBS. After that, 20 µL of this solution was added to each well and incubated for 2 
hours., at 37oC. After that, plates were analysed using FLUOstar OPTIMA fluorescence 
scanner, with a 560 nm excitation / 590 nm emission filter.  
In order to determine cisplatin IC50 and the pIC50 values on the different cell lines, under 
different conditions, results were analysed by generating sigmoidal concentration-
response curves using the software Prism™ GraphPad. IC50 is defined as molar 
concentration of drug, which produces 50% of the maximum possible response, while 
pIC50 is its negative logarithm (pIC50 = -logIC50). pIC50 values were later used for 
statistical analyses using Student's t-test or ANOVA, since the logarithm of IC50 values 
can be regarded as normally distributed (328). 
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The difference between cell lines or treatments can also be evaluated using the 
resistance factor (RF), which is the quotient between the IC50 of treated cells and the 
IC50 of untreated (only cisplatin) as depicted in formula 5: 
𝑅𝐹 =
𝐼𝐶50 (𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠)
𝐼𝐶50 (𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠)
 
Equation 5. Calculation of the resistance factor 
RF values greater than one indicate resistance, whereas values lower than one show 
sensitization of cells. The statistical evaluation of RF mean and SD was carried out 
through one-way ANOVA and Dunnett’s test. The significance level is represented by 
asterisks as follows: * p <0.05; ** p <0.01; *** p <0.001. 
Flow cytometry 
Fluorescence flow cytometry was used to measure changes in the mount and activation 
of surface and internal cell proteins, thus evaluated the cell signalling events, which 
take place in the cell. Proteins can be labelled with specific antibodies that are 
subsequently marked with secondary fluorescence labelled antibodies (329). Since the 
methodology also permits the observation of single cell size and surface condition, it 
enables  the examination of, for example, the vitality of the cell population, or if the 
treatment used gives rise to two separate cell populations (329). 
First, cells are separated by a capillary that allows single cell measurements (329). As 
the laser focus passes through, the apparatus detects both the forward scattered light 
(FSC) and the side scattered light (SSC), which is deflected at an angle of 90° to the 
sample (329). The FSC correlates with the size of the cell, while the SSC describes 
granularity (329). Both parameters are usually displayed against each other in a dot-
plot diagram (Figure 23). 
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The fluorescence generated by the previously labelled cell structures is also measured 
at an angle of 90°, but separately (329). The emitted light is first deflected using 
dichroic mirrors, then, it goes through a specific filter, corresponding to the different 
wavelengths, to adjust the detection of the emission spectrum of the fluorophore used 
(329). Finally, the signals are amplified by means of a photomultiplier and converted 
into electrical signals that can be measured (329). 
 
 
 
Figure 22. Fluorescence flow cytometer (330). Cells enter the equipment and are separated by a capillary 
which allows single cell measurements. As the laser focus passes through, the apparatus detects forward 
scattered light (FSC) and side scattered light (SSC). The fluorescence generated by the previously labelled 
cell structures is first deflected using dichroic mirrors, then, goes through a specific filter, corresponding 
to the different wavelengths; to adjust the detection of the emission spectrum of the fluorophore used. 
Finally, the signals are amplified by means of a photomultiplier and converted into electrical signals that 
can be measured. 
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The fluorescence detected is displayed in a histogram where the shift between the 
maximum fluorescence of the sample can be compared to the corresponding control 
(Figure 23B). 
 
        
Figure 23. A. FSC x SSC dot-plot diagram. The forward scattered light (FSC), that correlates with the 
size of the cell, is displayed against the side scattered light (SSC), which describes cell granularity. B. 
Fluorescence maxima comparison histogram. Cell structures are labelled with fluorophores, which can 
then be excited by specific wave lengths. The emission maxima or fluorescence maxima are displayed as 
a histogram showing the cell count against log fluorescence intensity. The measured value consists of the 
difference between the emission maxima of cells only labelled with secondary antibody (light green) and 
cells labelled with primary and secondary antibodies (dark green). 
To ensure a trustworthy measurement, it is important to set adequate experimental 
parameters, such as threshold value, measuring time, laser intensity and the number of 
cells per measurement (329). The threshold value is of great importance because it 
determines from which size in the FSC a cell is included in the measurement, it is 
appropriate to choose a value that excludes background noise, as effectively as possible, 
without interfering with the readout, which means without excluding cells that might 
be significant (329).  
One advantage of this technique is that it allows the labelling of multiple cell structures 
within the same well. This reduces the number of samples needed to perform the assay, 
but also permits almost direct comparison of a protein and its phosphorylated form 
within the exact same well, at the same time, which is not possible with the western 
blot technique, for example. However, when multiple fluorophores are used within the 
same well, as is in our case, it is essential to ensure that their emission spectra are far 
enough from each other in the light spectrum. A fluorophore overlap would lead to one 
fluorophore influencing the measurement results of other fluorophores, thus making it 
impossible to evaluate the data (329). In such cases, compensation may be beneficial. 
A B 
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When using two or more fluorophores, in some cases, the emitted light of one 
fluorophore radiates into the channel (filter) of another, and creates an overlap (see 
below) (329). Compensating means identifying the overlap region and excluding its 
influence from the measurement (329). The closer the emission spectra of the 
fluorophores used to each other, the more likely is an overlap to occur. Most modern 
equipment have built-in software that can calculate, define and apply the compensation 
required for each fluorophore, however, it is most important to choose fluorophore that 
can be well paired together to minimize the compensating effect.  
 
Figure 24. Fluorescence histogram with compensating area. The absorption spectrum (dotted line), as 
well as the emission spectrum (coloured curve with continuous line) for two fluorophores can be observed 
here, AlexaFluor 405 (blue) and AlexaFluor 488 (green). The overlap of the emission spectra can be 
observed between 473 and 540nm. Image generated using Fluorescence SpectraViewer from 
ThermoFisher (331).  
Finally, the measurements obtained can be further broken down, after the completion 
of the measurements, using regions and gates (329). By means of a gate, a cell 
population can be limited to a specific area on the dot-blot. Subsequently, it is possible 
to consider parameters, such as fluorescence, only for this range (329). Regions, on the 
other hand, can be used to isolate and assess certain areas of the fluorescence histogram. 
So, it is possible to define a respective region for the two emission maxima for a 
fluorophore and thus to display the number of cells in this region. 
Two different protocols were used to prepare cells for the fluorescence flow cytometry, 
depending on the location of the target structure in the cell. In both cases, cells were 
washed with PBS and then detached from cell culture bottles, counted and centrifuged 
as described above. For cell membrane proteins, cell pellets were then resuspended, in 
2 mL wash buffer (BSA solution 0.5%), and centrifuged at 310 g, for 5 min, at 4oC. 
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After the first washing step, cells were resuspended in 3% BSA blocking solution for a 
final concentration of 5 × 105 cells per 90 μL, distributed in a 96-well V bottom plate 
(90 μL per well), and incubated for 15 minutes to block unspecific antibody binding. 
Subsequently, cells were centrifuged at 1370g, for 5 minutes, at 4 °C, and supernatant 
aspirated. Then, 25 μL of specific primary antibody solution (1:100 in 1% BSA) was 
added to each well. Cells were resuspended and incubated with the primary antibody 
for 45 minutes, at room temperature, protected from light. This was followed by a wash 
and centrifugation step, and resuspension in 10 μL / well of secondary antibodies 
solution (1:200 in 1% BSA). Cells were incubated for 35 minutes, at room temperature, 
protected from light. This was followed by centrifugation, two washes and cells uptake 
in 100 μL / well wash buffer, for assessment on the Guava® easyCyte Flow Cytometer. 
The protocol used for labelling intracellular structures was modified from Barbosa et 
al. (332). After detachment, counting and centrifugation, the supernatant was aspirated, 
and pellet resuspended in 5 mL 2% PFA-solution in PBS and fixated for 30 min., at 
room temperature (RT). After fixation, samples were centrifuged, the supernatant 
aspirated, and pellet was washed with 5 mL 0.1 M glycine solution in PBS. Remaining 
pellet was then resuspended and permeabilized with 5 mL 0.001% Triton solution in 
PBS, for 30 minutes, at RT. After permeabilization, cells were centrifuged, the 
supernatant aspirated, and pellet was resuspended with 5 mL 0.1 M glycine solution for 
a final concentration of 5 × 105 cells per 90 μL, distributed in a 96-well V bottom plate 
(90µL / well). Plate was centrifuged at 1370 g, for 5 minutes, at 4° C, glycine was 
aspirated and 25 μL of specific primary antibodies solution (1:100 in 1% BSA) was 
added to each well and incubated for 2 hours, at RT, protected from light. After that, 
the cells were washed once with 1% BSA solution, and incubated for 2 hours, at RT, 
protected from light, with 10 μL / well of the appropriate secondary antibody solution 
(1:200 in 1% BSA). This was followed by a wash and centrifugation step, and cells 
uptake in 100 μL / well wash buffer, before assessment on the Guava® easyCyte Flow 
Cytometer. 
Results were plotted into a graph, where standard deviation (SD) from at least 3 
measurements is given. Statistical analysis was performed using one-way ANOVA and 
Dunnett’s test (* p <0.05; ** p <0.01; *** p <0.001) 
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Western Blot 
To validate the effectiveness of the β1 integrin knock-down, the transduced cells were 
evaluated via western blot. For this purpose, cell protein lysate was obtained using the 
following protocol. First, cells were detached from cell culture bottles with EDTA and 
counted, as described above. After centrifugation, cell pellet was washed once in cold 
DPBS and resuspended in cell lysis buffer, freshly prepared as described in buffers and 
solutions. The volume of cell lysis buffer used varied between 100-1000 μL and was 
determined based on the number of cells in the sample, in order to ensure maximal cell-
lysis and high final protein concentration lysates. Cell lysates were then incubated for 
30 minutes, at 0° C, on a shaker. After incubation, tubes were centrifuged for 10 
minutes, at 20,635 g, 4° C, in order to exclude non-solvated cell constituents, which 
accumulate as pellets. Supernatant was aliquoted in reaction tubes 100 μL / tube and 
stored at -80° C for up to six months. 
The total protein amount of the lysates obtained was determined using Pierce™ BCA 
Protein Assay Kit. This assay is based on a biuret reaction in which molecules with two 
peptide bonds to complex divalent copper ions in alkaline solution. Following this 
principle, the copper (II) ions, contained in a copper sulfate solution, during the BCA 
assay, are reduced to copper (I) ions by the reductive groups of the amino acids of the 
total protein. It could be shown that cysteine, cystine, tryptophan, tyrosine and the 
peptide bond itself act as reducing agents. Bicinchoninic acid (BCA) then complexes 
the copper (I) ions formed into a violet-blue colour (Figure 25), which remains stable 
in an alkaline environment, thus enabling the assessment of protein amounts through 
spectrophotometry. 
 
Figure 25. BCA complex with copper (I) ions 
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To work within the limits of Lambert-Beer's law (< 10 mM), dilutions of 1:20, 1:50 and 
1:100, from the lysate in Purelab® water, were prepared from a 1:10 starting dilution. 
These three dilutions were distributed, in duplicates 20 µL / well, onto a transparent 96-
well flat–bottom plate. In addition, a series of previously prepared references that are 
used to generate a calibration curve of 0 - 400 μg BSA / mL of Purelab® water; and 
three quality controls (QC) (150 μg / mL, 250 μg / mL and 350 μg / mL) were also 
added in duplicates onto the plate. The correlation coefficient of the calibration line 
should be 0.99 and the QCs should not deviate more than ± 5%. 
The copper sulfate solution and the BCA reagent were mixed 1:50, and 200 μL / well 
of this mixture was added to the samples. The incubation was carried out at 60° C, for 
one hour. The plates were then cooled to RT and measured at 570 nm. 
After the protein quantification of the lysates, samples were submitted to protein gel 
electrophoresis, in order to separate proteins according to their sizes, in a polymerized 
SDS gel, using electric current. SDS polyacrylamide gel electrophoresis is based on the 
principle of disk electrophoresis. Disk is the short form for discontinuous and refers to 
the separation of the gel in a wide-pore stacking gel before entering the narrow-pore 
running gel, and to the fact that the buffer in the gel and the electrophoresis chamber 
are different. This allows samples to be collected and concentrated in the stacking gel 
so they can be specifically separated in the narrow-pore gel. The stacking gel has a 
lower concentration of acrylamide, lower pH, and a different ionic content than the 
running gel. This allows the proteins in a loaded sample to be concentrated into one 
tight band during the first few minutes of electrophoresis, before entering the resolving 
portion of a gel. Important for this is the use of a Tris-HCl / Tris - glycine system. 
Typically, the system is set up with a stacking gel of pH 6.8 (Tris-HCl), a running gel 
of pH 8.8 (Tris-HCl) and an electrophoresis buffer at pH 8.3 (Tris - glycine). The 
glycine present in the buffer is negatively-charged at pH 8.3, but upon application of 
an electrical voltage, it is forced to enter the stacking gel, where the pH is 6.8, close to 
the isoelectric point of glycine. So, glycine switches predominantly to its zwitterionic 
state. This loss of charge causes them to move very slowly in the electric field. In 
contrast, the chloride ions contained in the buffer have high electrophoretic mobility 
and create an ion-migrating front ahead of the glycine. This creates the highly mobile 
Cl- front, followed by the slower, mostly neutral glycine front. Since the proteins 
present an intermediate electrophoretic mobility, they form a stack between the two 
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mobility zones. At the transition between collecting gel and separating gel, the 
difference in density leads proteins to concentrate, since the gelatinous nature of the gel 
counteracts the increased resistance of the sample. 
Once in the separating gel, the mobility of the proteins is strongly dependent on their 
molecular size, since the sodium dodecyl sulfate (SDS) denatures and binds to proteins 
to make them uniformly negatively charged. The intrinsic charge of the proteins thereby 
no longer plays a role in the separation. Depending on the size of the targeted protein, 
it is additionally possible to make the pore size of the separating gel variable by 
changing gel density during the polymerization of the acrylamide (usually 7.5 - 12%). 
In order to properly separate the proteins of the sample, it is common to use a Laemmli 
buffer, which reduces the proteins of the sample. This contains β-mercaptoethanol, 
which reductively cleaves the sulphur bridges between the cysteines. In some cases, 
such as ours, it may be necessary to dispense with these reducing properties in order to 
preserve the quaternary structure of the protein and thereby the antibody binding site 
intact. The anti-integrin β1 antibody also acts as an inhibitor of protein activation, for 
this reason, according to the instruction of the antibody manufacturer, non-reducing 
Laemmli buffer was used.  
Non-reducing Laemmli buffer was added to the sample in accordance with protein 
concentration in each sample, samples were diluted 1:1 in Laemmli buffer, and total 
volume was pipetted in each gel pocket, as well as 5 µl of Precision Plus Protein™ 
Unstained Standards. Proteins were then separated via electrophorese at 200 V for 40 - 
60 minutes, depending on gel density. The commercial precast gels were cracked open 
so that western blot could be performed. 
First, proteins were transferred from the SDS acrylamide gel to a polyvinylidene 
fluoride (PVDF) membrane using an electric current. For this purpose, PVDF 
membranes were activated with methanol for 20 seconds, to reduce their hydrophobia, 
then blot sandwiches were assembled, from outside to inside, consisting of two sponges, 
two filter papers, the membrane and the gel. In the presence of the electric current, the 
negatively charged proteins from the gel are pulled to the positively charged anode site, 
where the membrane has been placed. Blot was performed at 100 V for 1 hour, after 
that, membranes were blocked, with 50 ml of BSA blocking solution for 1 hour, to 
avoid antibody unspecific binding. Subsequently, membranes were washed three times 
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with 20 ml TBS-T for 10 minutes, before addition of 10 mL of primary antibody 
solution. After incubation for 1 hour, membranes were washed three times with 20 ml 
TBS-T for 10 minutes, and 10 mL of secondary antibody solution was added for 1 hour. 
The secondary antibody binds to the primary antibody and allows sample detection by 
chemiluminescence since it is coupled to horseradish peroxidase (HRP) that can 
catalyse the chemiluminescence reaction between luminol and peroxide, generating a 
luminescence signal that can be quantified. Cells were washed again, before the 5-
minute incubation with luminol-peroxide reagent. Immediately after incubation, 
membranes were analysed on the ChemiDoc ™ XRS + system.  
Proteome Profiler™ Human Soluble Receptor Array 
The Proteome Profiler™ Human Soluble Receptor Array was used to screen for the 
membrane proteins of the cell lines and analyse the impact of cisplatin treatment on the 
expression of such proteins. It can identify 119 soluble receptors, to which respective 
antibodies are fixated in duplicates on the nitrocellulose membranes present in the kit. 
It essentially works as a dot blot. The preparation and storage of the lysates used for the 
implementation of Proteome Profiler™ Human Soluble Receptor Array was carried out 
as per manufacturer’s instructions, and protein concentration was determined using 
BCA protein assay, as described above. Membranes were incubated with cell lysates, 
then washed and incubated with a cocktail of biotinylated detection antibodies and 
detected with streptavidin-HRP and a chemiluminescent reagent, similar to the western 
blot technique. Membranes were analysed on the ChemiDoc ™ XRS + system.  
As a result, a dot blot was obtained, which was evaluated by pixel analysis, as advised 
by the manufacturer. In order to ensure comparability between the membranes, all 
membranes were evaluated after the same development time. First, all relevant dots 
were marked as a 2.0 mm2 circumference. Then, background noise, based on the mean 
value of the PBS dots on the membrane, was subtracted from each marked dot. 
Membranes also present reference dots, which serve as landmarks, and positive control 
dots, which were used for the normalization value. Mean and standard deviation were 
calculated from each samples’ duplicates, after subtraction of the background noise 
(PBS dot). Results were plotted into a graph, where the SD is represented. Statistical 
analysis was performed using one-way ANOVA and Dunnett’s test and the significance 
level is represented by asterisks as follows: * p <0.05; ** p <0.01; *** p <0.001. 
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Figure 26. Pixel analysis of Proteome Profiler™ Human Soluble Receptor Array membrane. All 
relevant dots are marked as a 2.0 mm2 blue circumference. PBS negative control corresponds to 
background noise, and were subtracted from each sample dot. Reference spots, serve as landmarks, and 
the positive control were used for sample normalization.
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4. Results and discussion 
Evaluation of different melanoma cell lines in our experimental model 
Characterization of NW1539 and Mel_1956 cell lines with Proteome 
Profiler™ Human Soluble Receptor Array 
First, three different melanoma cell lines (MV3, NW1539 and Mel_1956) were 
assessed under experimental conditions with the purpose of determining which was the 
most appropriate cell line with which to continue our studies. Since literature regarding 
the NW1539 and Mel_1956 cell lines was sparse, we submitted these cell lines to 
Proteome Profiler™ Human Soluble Receptor Array, in order to better understand and 
characterize the cells. 
 
Figure 27. Proteome Profiler ™ Human Soluble Receptor Array of Mel_1956 and NW1539 
melanoma cell lines. Cell lysate of Mel_1956 and NW1539 cell lines were incubated overnight with the 
Proteome Profiler ™ Human Soluble Receptor Array, as described above, to quantify the expression of 
specific cell membrane proteins. 
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It was observed that NW1539 cells express more β1 integrin then Mel_1956 cell line, 
whereas Mel_1956 cells were shown to express higher levels of β3 and β5 integrins 
than NW1539. This is in line with reports, discussed in the introduction, that suggest a 
complex regulation and cooperation system between β1 and β3 integrins. Generally, 
these integrins are associated to opposing function in the cell, β1 integrin has been more 
associated with strong adhesion and proliferation, while β3 integrin has been thought 
to lead to metastatic and EMT phenotypes (259–261). However, it has also been shown 
that they can cooperate, normally β3 integrin is not capable to attach to Coll. But the 
interaction between β1 integrin and Coll leads to modifications that  expose the RGD 
binding site of this ECM component enabling β3 integrin to attach (191). Additionally, 
downregulation of β1 integrin has been shown to provoke β3 integrin upregulation in 
breast cancer cells, with the purpose of maintaining the malignant phenotype (260), 
however, not in normal mammary cells. This also impressively demonstrates cancer 
cells plasticity and ability to adapt in relation to normal tissue. To sum up, the results 
observed in the array suggest a more metastatic phenotype for the Mel_1956 cell line 
and a more proliferative and, possibly, CAM-DR associated profile for NW1539.  
Regarding the α subunits, Mel_1956 cells are the only ones to produce α3 integrin, 
while α5 integrin is only produced by NW1539 cells, according to data from the 
Proteome Profiler™ Antibody Array. In this assay, we could also observe the 
expression of several proteins that interact with integrins, thus enhancing 
tumorigenesis, some of which had already been identified as overexpressed in 
metastatic melanoma compared to primary melanomas, such as thrombospondin, 
osteopontin, and NCAM1 (333). 
The results show that thrombospondin 5 is expressed in both cell lines evaluated, 
although with a higher expression in NW1539. Moreover, thrombospondin 1 was only 
expressed in NW1539 cells, while thrombospondin 2 was only expressed in Mel_1956, 
which could indicate a regulation system between subunits similar to the one observed 
for β integrins, which has not yet been investigated. Thrombospondins are extracellular 
matrix molecules formed by glycoprotein subunits, with EGF-like and calcium-binding 
domains. They can bind to other ECM molecules or cell membrane proteins, such as 
chemokines, integrins and growth factors, and thus interfere in cell attachment, 
proliferation and differentiation (334–337). For example, all three thrombospondins 
expressed by the cells studied are involved in enhancing adhesion in an integrin-
dependent way and have been associated with cancer malignancy (337–342). 
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Furthermore, thrombospondin 5, which is known to interact with several ECM proteins, 
such as FN, Coll and proteoglycans, has been shown to co-localize with FN and 
integrins on chondrocytes (343,344). Accordingly, thrombospondin 5 binding to FN is 
significantly enhanced by Mn2+, demonstrating an integrin involvement (343,344).  
Thrombospondin 1 is not expressed in normal melanocytes; however, it has been 
largely studied in melanoma. Its expression is acquired with the malignant progression 
of this type of cancer and acts in an autocrine manner, correlating with invasiveness, 
drug resistance, higher cell proliferation and tumour thickness, as well as reduced 
expression of genes involved in pigmentation (334,335). Thrombospondin 1 binding to 
integrins is mediated by CD47 and shows different cell effects depending on the 
integrin subunit. Interaction with β3 integrin stimulates invasion and metastasis, while 
α4β1 integrin-binding increases cell adhesion and spreading (334,338), which is 
consistent with the reports about cooperation and regulation between these two integrin 
subtypes discussed above and show that the integrins dictate cell fate upon ligation 
(259–261). The combination of thrombospondin 1 and β1 integrin in the NW1539 cell 
line reinforces the proliferative and adhesive profile expected from these cells. In 
contrast, thrombospondin 2 expression on Mel_1956 reinforces the metastatic profile 
suggested by β3 integrin expression, since thrombospondin 2 is usually strongly 
expressed in metastatic melanoma, but not on primary tumours (336). 
Another ECM protein present in our assay, which interacts with integrins leading to a 
poor outcome in tumorigenesis, is osteopontin (OPN), a chemokine-like protein 
secreted by many cells as part of the ECM. OPN has been shown to bind to cells in an 
integrin-dependent manner stimulating adhesion (345–347). Elevated levels of OPN 
expression and secretion have been associated with enhanced malignancy in several 
cancers, including melanoma, and is used as a prognostic marker (333,348,349). This 
is due to the fact that OPN secreted by tumour stroma, or tumour cells themselves, 
promotes tumour progression by interacting with ECM factors and cell membrane 
receptors, such as integrins, activating multiple signalling cascades, which regulate cell 
proliferation, survival, angiogenesis and metastasis (345–349). In this assay, Mel_1956 
cells have been shown to express this protein, which is in accordance with other reports 
that analysed different stages of melanoma, and revealed that enhanced OPN expression 
correlates with metastatic melanoma phenotype (333,348). This has been associated to 
OPN-integrin binding (345–347,350).  
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Mel_1956 also displayed a high and exclusive expression of ADAM9, which is a 
membrane-anchored protein with catalytic activity, such as FN and gelatin 
hydrolyzation, and ectodomain shedding, which helps regulate and remodel the ECM. 
Besides metalloprotease activity, ADAM9 also interacts with different integrins and 
has been implicated in cancer progression (351–354). ADAM9 expression positively 
correlates with tumour progression in several cancers including melanoma (354–357), 
and the inhibition of its expression has been shown to sensitize chemotherapy resistant 
prostate cancer and melanoma (353,357). It is know that ADAM9 can bind to α6β1 and 
αvβ5 integrins, in a Mn2+ and Ca2+ dependent and RGD-independent manner, in 
fibroblast and myeloma cell lines, respectively (353,358), demonstrating that different 
cell types may use different integrins to mediate binding to ADAM9. More specifically, 
Zigrino et al. showed that ADAM9, produced by melanoma cells, mediates interactions 
between these cells and fibroblasts by binding to β1 integrins on fibroblast surface in a 
Mn2+ dependent manner, enhancing metastasis (354). In the case of the Mel_1956 cell 
line it is possible that ADAM9 expression indicates ECM remodelling and an invasive 
phenotype.  
Interleukin-8 (IL-8) was also only expressed by Mel_1956, which also indicates a more 
aggressive behaviour of this cell line, as IL-8 is a chemokine, which is not normally 
produced by melanocytes. However, it is overexpressed by melanoma cells, 
accompanied by the expression of its receptors, CXCR1 and CXCR2 (359,360), thus 
demonstrating not only a paracrine, but also an autocrine effect (359). IL-8 and its 
receptors interact with integrins and correlate with melanoma malignancy and 
metastatic potential through the activation of multiple cell signalling pathways and by 
affecting proliferation, apoptosis resistance and cytoskeletal dynamics (359–361). 
Finally, both cell lines express high levels of galectin 3, an ECM protein, which has 
been associated with several biological processes and pathologies, including cancer 
(362–366). Its overexpression and/or changes in location are indicators of poor 
prognosis, since they affect cell growth and differentiation, chemoattraction, apoptosis, 
immunosuppression, angiogenesis, adhesion, invasion and metastasis. For example, 
galectin-3 binding to integrin αvβ3 can induce angiogenesis (364,365). Moreover, 
galectin-3 has been associated with metastatic behaviour of melanoma, through 
association with FN mediated by α3β1 integrin (362,363,365). According to the data, 
integrins β1 and β3, as well as galectin-3 are expressed by both cell lines tested, which 
shows their malignant potential.  
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Taken together these results show that, even though NW1539 and Mel_1956 cell lines 
are both malignant metastatic melanoma cell lines, they display different profiles; 
Mel_1956 presents a more metastatic phenotype, while NW1539 could be described as 
more adherent and proliferative. These differences are strongly connected to the 
integrin pattern of these cells, as we were able to demonstrate. This shows the 
importance of targeting such integrins and integrin related adhesion events for the 
improvement of anticancer therapy. 
Sensitivity of melanoma cell lines to cisplatin 
Cisplatin was selected as the cytostatic agent for this project in order to investigate a 
potential relation between integrin activity and loss of apoptotic response, in all three 
cell lines. Cisplatin is usually used a second line treatment in extreme cases of 
aggressive tumours, including melanoma, which means that it is implemented when 
other treatments have failed (52). For this reason, this cytostatic drug seamed like a 
suitable system to simulate therapy resistance. Two parameters were taken into 
consideration to select the optimal seeding density of each cell line: first, cisplatin 
impact on cell proliferation, and second the proliferation rate observed for each cell 
line. Thus, the cytotoxicity assays were performed using 5000 cells/well and 10000 
cells/well for the Mel_1956 and MV3 cell lines; and 2500 cells/well and 5000 cells/well 
for the NW1539 cell lines. As mentioned, the MV3 cells are known to display high 
affinity to Coll type I and IV and have high expression of integrin β1 and CD44 
(257,312,313). Furthermore, Maaser et al. were able to demonstrate a hierarchal 
interaction between these two adhesion molecules. They have shown that α2β1, but not 
CD44, is necessary for the interaction of MV3 cells with Coll matrix containing 
hyaluronan (256). The MV3 cell line has also been shown to stimulate pro-coagulatory 
factors, as well as, glycosaminoglycan synthesis by other cell on their surroundings  , 
which demonstrates the ability of these cells to manipulate and adapt to their 
environment (367,368). The data from the Proteome Profiler™ Antibody Array (Figure 
27) together with literature about the MV3 cells show that although all three cell lines 
are derived from highly metastatic human melanomas, they differ in various 
characteristics, such as, expression pattern of integrins and other proteins, and 
proliferative or invasive profile. Accordingly, the cell lines display a slightly different, 
but not statically significant, sensitivity to cisplatin. 
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Figure 28. Melanoma cell lines sigmoidal concentration-response curves. Exemplary curves that 
represent one of at least three measurements. The sensitivity of all three cell lines to cisplatin was 
assessed by quantifying the number of living cells after a 72-hour incubation period with drug logarithmic 
concentration curve, using MTT assay. The data obtained were plotted into sigmoidal concentration-
response curves and used to determine the IC50 values. 
 
Figure 29. Melanoma cell lines sensitivity to cisplatin. Sensitivity of all three cell lines to cisplatin 
represented using the mean value and SEM of IC50 values from at least three MTT concentration-
response curves. ANOVA statistical analysis, asterisks indicate statistical significance in comparison to 
cells treated solely with cisplatin: * P<0.05; ** P<0.01; *** P<0.001. 
Interestingly, even though the cell lines present different protein expression profiles 
and, based on that, diverse phenotypes, only a slight difference between their sensitivity 
to cisplatin was found. The MV3 cells displayed the highest sensitivity, while the other 
two cell lines exhibited similar IC50 concentrations; as expected from their aggressive 
metastatic protein expression Mel_1956 cells were the most resistant.  
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Impact of integrin activation by FN and Mn2+ on cisplatin resistance 
Based on these findings, the melanoma cells were investigated with respect to their 
sensitivity to cisplatin in relation to integrin activation. Since our expression data 
confirmed that multiple integrins were expressed by the cells, fibronectin (FN) was 
used as a universal integrin binding substrate. Thus, cells were either treated with 1 mM 
solution of Mn2+ for a final concentration of 100 µM in each well, which induces 
integrin clustering and a high affinity binding state; or grown on FN coated surfaces. 
Alternatively, a combination of both treatments was used. Cell sensitivity to cisplatin 
was measured using MTT cytotoxicity assay. The Mel_1956 cell line was evaluated 
first. 
 
Figure 30. Mel_1956 sigmoidal concentration-response curves upon integrin activation. Curves 
exemplify results from one of at least three MTT assays. Cells were platted on FN coated plates and/or 
incubated with final concentration in well of 100 µM Mn2+, before a 72-hour incubation with cisplatin 
logarithmic concentration curve. Sigmoidal concentration-response curves were used to calculate the 
IC50 values of each treatment. 
 
Table 1. Cisplatin IC50 on Mel_1956 cell line upon Mn2+ and FN treatment  
Cell Density Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
Cisplatin 5.00 ± 0.05 9.9 
Mn2+ 5.04 ± 0.11 9.1 
Fibronectin 5.05 ± 0.13 8.8 
Mn2+ + FN 5.09 ± 0.05 8.1 
10000 
cells / well 
Cisplatin 5.00 ± 0.18 9.9 
Mn2+ 4.97 ± 0.13 10.8 
Fibronectin 5.13 ± 0.32 7.4 
Mn2+ + FN 5.00 ± 0.13 10.0 
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Figure 31. Integrin activation in Mel_1956 cells. IC50 values of each MTT were used to estimate the 
resistance factor (RF), which consists of the quotient between the IC50 of cisplatin-treated cells and the 
IC50 of cells that received other treatment in addition to cisplatin, in this case FN and/or Mn2+. The data 
displayed here correspond to the mean value and SD of the RF of at least 3 assays. Statistical analysis 
was performed by one-way ANOVA; asterisks indicate statistical significance in relation to cisplatin-
treated cells only: * P<0.05; ** P<0.01; *** P<0.001. 
Contrary to expectations, treatments for triggering integrins barely increased Mel_1956 
sensitivity to cisplatin. Only Mn2+ was able to slightly increase cell resistance factor 
(RF: ratio of IC50 of cisplatin vs. treated cells) in the high cell-density sample. 
Regrettably, however, most treatments decreased cell sensitivity to cisplatin, which can 
be observed by RF lower than 1. Although unfortunate, these results confirm the 
hypothesis that the Mel_1956 cell line is a highly metastatic melanoma cell, which 
concentrates cell effort, most likely on migration, rather than adhesion and CAM-DR 
formation. NW1539 cells were evaluated next. 
 
Figure 32. Sigmoidal concentration-response curves of NW1539 upon integrin activation. The 
curves shown here represent one of at least three MTT experiments. Cells were seeded on FN coated 
plates and/or incubated with 1 mM solution of Mn2+, before incubation with drug logarithmic 
concentration curve for 72 hours. Sigmoidal concentration-response curves were used to determine the 
impact of each treatment on cisplatin IC50 values. 
Results and discussion 
 
117 
 
Table 2. Cisplatin IC50 on NW1539 cell line upon Mn2+ and FN treatment 
Cell Density Treatment pIC50 ± SEM IC50 (μM) 
2500 
cells / well 
Cisplatin 5.03 ± 0.18 9.3 
Mn2+ 5.19  ± 0.22 6.5 
Fibronectin 4.97 ± 0.04 10.6 
Mn2+ + FN 5.12 ± 0.19 7.7 
5000 
cells / well 
Cisplatin 5.07 ± 0.06 8.5 
Mn2+ 5.31 ± 0.09 4.9 
Fibronectin 5.12 ± 0.02 7.5 
Mn2+ + FN 5.18 ± 0.08 6.7 
 
 
Figure 33. Effect of integrin activation on NW1539 cells. Resistance factors (RF) were estimated using 
the IC50 values obtained from MTT sigmoidal concentration-response curves. Mean value and SD of the 
RF of at least 3 measurements can be observed. Data were submitted to one-way ANOVA statistical 
analysis; asterisks indicate statistical significance in relation to cisplatin-treated cells only: * P<0.05; ** 
P<0.01; *** P<0.001. 
Unexpectedly, sensitivity of NW1539 cells to cisplatin increased with almost all 
integrin-activating stimuli. In the case of Mn2+, even showing a statistically significant 
sensitization of cells to cisplatin. This was very surprising, as the Proteome Profiler™ 
Antibody Array (Figure 27) had indicated that these were high proliferative and 
adhesive cells that overexpress several integrin-binding proteins. The difficulty in 
detecting an increase in cell sensitivity to cisplatin in the abovementioned melanoma 
cell line may be a result of the fact that these cells already have highly activated 
integrins and, therefore, cannot be overactivated by the treatments used. 
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Unfortunately, the treatments used to increase integrin-binding, and thus induce 
chemoresistance in Mel_1956 and NW1539, were not able to generate a resistance 
factor greater than 1. For this reason, we carried out our work only with the MV3 cell 
line, which had shown more promising results.  
 
Figure 34. Sigmoidal concentration-response curves of MV3 cells treated with integrin activating 
stimuli, FN and Mn2+. The exemplary curves illustrate one of at least three MTT experiments. Cells 
were seeded on FN coated plates and/or incubated with a final concentration of 100 µM Mn2+ in well, 
then incubated for 72 hours with cisplatin logarithmic concentration curve. Sigmoidal concentration-
response curves were used to calculate IC50 values. 
 
Table 3. Cisplatin IC50 on MV3 cell line upon Mn2+ and FN treatment 
Cell Density Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
Cisplatin 5.42 ± 0.15 3.8 
Mn2+ 5.04 ± 0.25 4.0 
Fibronectin 5.37 ± 0.17 4.2 
Mn2+ + FN 5.35 ± 0.24 4.5 
10000 
cells / well 
Cisplatin 5.22 ± 0.19 5.9 
Mn2+ 5.14 ± 0.26 6.6 
Fibronectin 5.16 ± 0.06 7.0 
Mn2+ + FN 5.07 ± 0.18 8.6 
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Figure 35. Impact of integrin activation by FN and Mn2+ on the resistance factor of MV3 cell line. 
IC50 values obtained from at least three MTT experiments were used to estimate the resistance factor 
(RF) by dividing the IC50 of cells that received other treatment in addition to cisplatin, in this case FN 
and/or Mn2+ by the IC50 of cisplatin treated cells. RD mean value and SD was analysed by one-way 
ANOVA; asterisks indicate statistical significance compared to cisplatin-treated cells only: * P<0.05; ** 
P<0.01; *** P<0.001. 
It can be observed that the MV3 cells showed an interesting response. All integrin-
activating treatments were able to increase RF above 1, in different intensities, 
depending on the number of cells per well. Sensitivity of MV3 cells to CDDP was 
affected by cultivation in contact with FN, a known integrin activator. Additionally, 
integrin activation by Mn2+ also shifted the sensitivity of MV3 cells to higher IC50 
values, indicating an impact of integrin activity on resistance phenomena. Furthermore, 
the combination of FN coating and Mn2+ resulted in higher resistance, especially in the 
10000 cells per well density, thus showing a strong statistic correlation. This is a 
promising set of data that shows a clear dependency of cellular sensitivity towards 
cisplatin and integrin stimulation. This is in obvious accordance with our hypothesis 
that the other melanoma cell lines tested already had highly activated integrins, which 
could not be overactivated by the treatments, the cell line with the intrinsically highest 
cisplatin sensitivity, MV3, showed the most promising results. 
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MV3 melanoma cell line  
Integrin activation in MV3 melanoma leads to decreased sensitivity against 
cisplatin cytotoxicity. 
As discussed in the introduction, another important component of the ECM are 
collagens. Coll type I, specifically, is a known binding partner of the β1 integrin 
subunit, which is abundantly expressed in most cell types, including the MV3 cells, and 
has been often associated with cancer malignancy and chemoresistance (255–257). 
Thus, cells were grown on Coll I-coated surfaces, and, in some cases, treated with Mn2+, 
for a combination of both treatments, before being submitted to the MTT cytotoxicity 
assay.  
 
Figure 36. MV3 cell line sigmoidal concentration-response curves upon integrin activation by Coll. 
One of at least three curves obtained by MTT assay is represented here. Cells were platted on Coll-coated 
plates and, in some cases, incubated with a final concentration in well of 100 µM Mn2+, previously to 
incubation with cisplatin logarithmic concentration curves for 72 hours. Sigmoidal concentration-
response curves were used to determine the IC50 values of each treatment. 
Table 4. Cisplatin IC50 on MV3 cell line upon Mn2+ and Coll treatment 
Cell Density Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
Cisplatin 5.13 ± 0.33 7.4 
Mn2+ 5.11 ± 0.39 7.8 
Collagen 5.02 ± 0.33 9.7 
Mn2+ + Coll 5.04 ± 0.05 9.1 
10000 
cells / well 
Cisplatin 4.93 ± 0.39 11.7 
Mn2+ 4.92 ± 0.45 12.1 
Collagen 4.78 ± 0.12 16.6 
Mn2+ + Coll 4.84 ± 0.12 14.5 
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Figure 37. Resistance factors of MV3 cells as indicators for attenuated cisplatin cytotoxicity upon 
integrin activation by Coll and Mn2+. Cells were submitted to MTT assay, after 72 hours of incubation 
with cisplatin, under integrin activating stimuli 1 mM Mn2+ solution and/or Coll coating. The data 
displayed here corresponds to the mean value and SD of RF (ratio between IC50 of treated vs. untreated) 
of at least three measurements. One-way ANOVA statistical analysis was used; asterisks indicate 
statistical significance compared to cells treated solely with cisplatin: * P<0.05; ** P<0.01; *** P<0.001. 
MTT assay results revealed a consistent decrease in sensitivity of MV3 melanoma cells, 
when subjected to all integrin-activating stimuli. Mn2+ and Coll increased cell 
resistance to cisplatin in both cell densities. The effect of Coll seems to be more robust, 
showing strong statistical significance. Despite the fact that these findings suggest a 
functional axis of β1 integrin activity and loss in chemosensitivity, a synergistic effect 
between the two integrin-activators could not be observed, as it was the case for FN 
and Mn2+. Nevertheless, this clearly indicates that the functional consequences of the 
different integrin activations, integrin clustering and conformational changes by Mn2+ 
vs. ligand-triggered activation, affect the loss in sensitivity differently and deserve 
closer examination. Integrins are known to control cell proliferation through activation 
of different signalling pathways (36,37,38). In order to test the possibility that the lack 
of synergy between the integrin activating stimuli or the resistance effects observed 
were associated with integrins interfering in the cell proliferation rate, cell counts were 
observed microscopically, after 72 hours, in the presence or absence of 7.5 µM 
cisplatin. 
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Figure 38. Evaluation of integrin activators impact on MV3 cell proliferation rate observed by 
microscopy. A. Exemplary microscopy images of MV3 cells cultured for 72 hours without cisplatin, 
under the indicated conditions (control, Coll or/and Mn2+). B. Exemplary microscopic pictures of MV3 
cells, cultured for 72 hours, under the same indicated conditions in the presence of 7.5 μM of cisplatin. 
Pictures were taken at five different growth spots and counted. The graph displays the mean value and 
SD of the cell-count for the different spots. Results were analysed by one-way ANOVA. Statistical 
significance: * P<0.05; ** P<0.01; *** P<0.001. From Piva et al. (369). 
Neither the Mn2+ nor Coll, or the combined treatment increased cell proliferation rate. 
On the contrary, cell growth and density seemed to be slightly reduced, in relation to 
the control cells. In strict contrast, when cells were exposed to a cisplatin for 72 hours, 
the integrin-activated cells displayed a clearly higher proliferation capacity than the 
untreated control cells (Figure 38B). Consequently, the changes in IC50 values 
presented in Figure 37 do not originate from an integrin-activated accelerated cell 
proliferation rate, but it appears to be the first indication of a lower sensitivity to 
cisplatin cytotoxicity in the integrin-activated cells compared to the respective controls. 
These findings show a role for integrins in cisplatin chemoresistance of the MV3 cell 
line. Additionally, as mentioned, β1 integrins are the main ligands for Coll I, and have 
been often associated with cancer malignancy and chemoresistance, which suggests 
they could be the integrin subunit responsible for this process in the MV3 cells as well 
(255–257). 
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Resistance of MV3 cells is mediated by the FAK/PI3K/AKT pathway 
To further elucidate the path of integrin activation, we investigated the downstream key 
effectors of integrin signalling FAK, PI3K, and its direct target of phosphorylation, 
AKT, by flow cytometry adopting the same treatment regimens as used for the MTT 
assays, but without cisplatin, for 72 hours. 
 
Figure 39. Integrin-signalling effector proteins quantified by flow cytometry. A. Total protein levels 
of integrin effectors AKT, PI3K and FAK. B. Levels of phosphorylated (active) AKT, PI3K and FAK 
signalling proteins. MV3 cells were cultivated for 72 hours in uncoated or Coll-coated cell culture flasks, 
and, depending on the treatment, incubated with 2 ml of 1 mM Mn2+ solution for 5 minutes. Presenting 
geomean and SEM of at least three measurements. One-way ANOVA statistical analysis was used to 
calculate statistical significance in relation to control (uncoated), which is indicated by asterisks: * 
P<0.05; ** P<0.01; *** P<0.001. 
It could be observed that the integrin activating treatments induced a statistically 
significant increase only in AKT phosphorylation. Since AKT is the last effector in this 
signalling pathway, this might be a consequence of the time point observed and does 
not exclude the hypothesis of integrin involvement. Moreover, these results show the 
behaviour of untreated MV3 cells and, as discussed above, cisplatin treatment by itself 
can alter expression and activation state of cell proteins (73). In order to investigate if 
this was the case of our experimental model, we would have to analyse the cell in an 
environment that really simulated the MTT assays. For this purpose, cells were 
submitted to the same treatment regimens plus a cisplatin concentration of 7.5 µM, for 
72 hours, before integrin signalling effectors were analysed and this data was compared 
to the expression and activation rates of the untreated cells.  
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Figure 40. Effect of cisplatin on integrin cell signalling assed via flow cytometry. A. Total protein 
levels of AKT, PI3K and FAK. B. Levels of phosphorylated AKT, PI3K and FAK, which indicate 
activation. The MV3 cell line was grown in cell-culture flasks, either coated with Coll type I, or uncoated 
and, depending on the treatment, incubated with 100 µM final concentration of Mn2+, for 5 minutes, prior 
to the addition of 7.5 µM cisplatin. Cells were Collected after 72 hours and submitted to FACS. Graphs 
display geomean and SEM of at least 3 assessments. ANOVA statistical analysis, statistical significance 
in relation to control or only cisplatin: * P<0.05; ** P<0.01; *** P<0.001 
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As expected, the incubation with cisplatin triggered an intracellular survival response. 
It induced a general increase in the expression and activation of FAK, PI3K and AKT, 
which shows the importance of this pathway for the cells. This survival pathway was 
obviously activated in response to cisplatin stress. Interestingly, in the cisplatin treated 
cells, an integrin activation through downstream signalling molecules could only be 
observed under Mn2+ stimulation, but not under Coll treatment, or both treatments 
combined. A significant upregulation of PI3K and phosphorylated PI3K is evident, 
indicating an activation most likely through FAK. Furthermore, PI3K activity was 
confirmed by an upregulation of AKT and an increase in AKT phosphorylation. 
The activation of the PI3K/AKT axis in the presence of cisplatin only under Mn2+ 
treatment is another indicator of the complexity of integrin regulation and activation. It 
shows, once again, that each integrin-activating stimulus provokes a different integrin-
functional consequence, thus triggering distinct mechanisms. This is confirmed by the 
lack of synergistic effect between these two integrin-activators shown in the combined 
treatments. 
 
Sensitization of MV3 cells to cisplatin by inhibition of FAK/PI3K/AKT 
pathway 
Considering the strong upregulation of the FAK/PI3K/AKT signalling pathway in 
cisplatin treated cells, associated with increased expression of PI3K and phosphorylated 
PI3K in the Mn2+ treated cells, we aimed to associate these findings with cisplatin 
sensitivity. Thus, PI3K was blocked, with the PI3K inhibitor BEZ235, in order to 
investigate its impact on sensitivity. BEZ235 binds reversibly and competitively to the 
ATP-binding cleft of PI3K and mTOR, working as potent and selective inhibitor of 
PI3K pathway. BEZ235 presents very low affinity to other down- or upstream effectors, 
such as FAK, and PDK1, but has been shown to interfere in 50% of AKT 
phosphorylation in a reversible manner (308). BEZ235 has been shown to decrease cell 
proliferation and migration, and display synergistic effects to platinum drugs and 
taxanes (325–327).  
First, a MTT cytotoxicity assay with different concentrations of the inhibitor was 
performed to establish the optimal concentration for our cisplatin assays. 
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Figure 41. BEZ235 cytotoxicity curves on MV3 cells. Exemplary curves that represent one of at least 
three measurements obtained by MTT assay. Cells were incubated with a series of concentrations of the 
PI3K inhibitor BEZ235 for 72 hours, to simulate cisplatin assay conditions, before cytotoxicity 
assessment by MTT assay. 
PI3K inhibitor BEZ235 showed an IC50 of approximately 200 nM for the lower cell 
density of the MV3 cell line. Unfortunately, we were not able to observe an IC50 for the 
higher cell count. This is a consequence of the well-established ability of BEZ235 to 
induce a cell cycle arrest with no apoptosis induction, which can be observed by the 
concentration plateau reached in our assay (308,324,370). Based on these results, cells 
were submitted to MTT assay under integrin activating stimuli (Coll and Mn2+) in the 
presence of two concentrations of BEZ235, a non-cytotoxic final concentration in the 
well of 100 nM and a higher final concentration of 500 nM in the well, which induces 
cell cycle arrest, both of which have been shown to inhibit mainly PI3K (308). Cells 
were treated with BEZ235 for a period of 6 hours, before cisplatin was added; 
subsequently, cells were incubated with both compounds simultaneously, for 72 hours. 
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Figure 42. MV3 cell line sigmoidal concentration-response curves. Exemplary curves that represent 
one of at least three experiments. Cells were incubated with integrin activators (1 mM Mn2+ or Coll 
coating) concomitantly with 100 nM of BEZ235, for 6 hours, before the addition of cisplatin. After 6 
hours, cisplatin logarithmic concentration curve was added and cells grown for 72 hours prior to MTT 
assay. Sigmoidal concentration-response curves were used to determine IC50 values. 
Table 5. Cisplatin IC50 on MV3 cell line upon treatment with 100 nM BEZ235 
Cell Density Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
Cisplatin 4.98 ± 0.11 10.4 
100 nM BEZ235 5.27 ± 0.08 5.4 
BEZ235 + Mn2+ 5.40 ± 0.15 4.0 
BEZ235 + Coll 5.12 ± 0.06 7.6 
BEZ235 + Mn2+ + Coll 5.18 ± 0.04 6.6 
10000 
cells / well 
Cisplatin 4.88 ± 0.32 13.2 
100 nM BEZ235 5.22 ± 0.31 6.0 
BEZ235 + Mn2+ 5.25 ± 0.28 5.7 
BEZ235 + Coll 5.12 ± 0.27 7.6 
 BEZ235 + Mn2+ + Coll 5.23 ± 0.31 5.9 
 
Figure 43. Change in resistance factors under PI3K inhibition with 100 nM BEZ235. Cells were 
seeded on Coll and/or 1 mM Mn2+, then incubated for 6 hours with 100 nM BEZ235. After that, cisplatin 
logarithmic concentration curve was added and incubated for 72 hours, prior to MTT assay. Data was 
analysed by ANOVA; statistical significance in relation to control: * P<0.05; ** P<0.01; *** P<0.001. 
Extracted from Piva et al. (369). 
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The non-cytotoxic concentration of 100 nM of BEZ235 greatly increased cell 
sensitivity to cisplatin and reduced MV3 resistance factor to about 50%, which results 
from a synergy with cisplatin and not from the cytotoxic effect of BEZ235 alone. As 
mentioned above, the ability of other drugs to increase BEZ235 cytotoxicity, and even 
overcome the cell cycle arrest provoked by this inhibitor, has been show in previous 
reports (325–327). As observed above, BEZ235 was not only able to increase 
sensitivity to cisplatin, but also circumvent integrin-activating stimuli. On one hand, 
Mn2+ treated cells were slightly more affected, which is in line with their PI3K 
activation status shown by flow cytometry (Figure 40 and Figure 39). On the other 
hand, Coll showed a slightly protective effect against BEZ235, which is in accordance 
with the increase in the RFs observed in Figure 37. This also indicates that other 
signalling pathways, in addition to the PI3K pathway, might be involved in integrin-
signal transduction upon activation by Coll, which has been seen in the flow cytometry 
data (Figure 40). This, associated with the fact that Mn2+ – Coll combination treatment, 
once again, demonstrated an intermediate response, reinforces the theory that these two 
integrin-activating stimuli have different mechanisms of action. In contrast, the 
concentration 500 nM of BEZ showed a high and unspecific cell cytotoxicity when 
combined with cisplatin.  
 
Figure 44. Sigmoidal concentration-response curves of MV3 cells treated 500 nM BEZ235. One of 
at least three measurements obtained by MTT assay is represented here. Cells were platted on Coll and/or 
incubated with a final concentration of 100 µM Mn2+ in well, before addition of 500 nM of PI3K inhibitor 
BEZ235 for 6 hours. Subsequently, cells were incubated for 72 hours with cisplatin logarithmic 
concentration curve. IC50 values were determined using the sigmoidal concentration-response curves. 
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Table 6. Cisplatin IC50 on MV3 cell line upon treatment with 500nM BEZ235 
Cell Density Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
Cisplatin 5.13 ± 0.33 7.4 
500 nM BEZ235 5.52 ± 0.14 3.0 
BEZ235 + Mn2+ 5.44 ± 0.07 3.6 
BEZ235 + Coll 5.70 ± 0.07 2.0 
BEZ235 + Mn2+ + Coll 5.58 ± 0.12 2.6 
10000 
cells / well 
Cisplatin 4.88 ± 0.32 13.2 
500 nM BEZ235 5.29 ± 0.10 5.1 
BEZ235 + Mn2+ 5.30 ± 0.04 5.0 
BEZ235 + Coll 5.36 ± 0.23 4.4 
BEZ235 + Mn2+ + Coll 5.29 ± 0.05 5.2 
 
 
Figure 45. Effect of 500 nM of PI3K inhibitor BEZ235 on the resistance factor of MV3 cells. Cells 
were submitted to integrin activation by Coll or Mn2+ solution (1mM), prior to a 6-hour incubation period 
with 500 nM PI3K inhibitor BEZ235. Afterwards, plates were given a cisplatin logarithmic concentration 
curve, which was incubated with cells for 72 hours, before MTT quantification. ANOVA statistical test 
was performed; asterisks indicate statistical significance in relation to control: * P<0.05; ** P<0.01; *** 
P<0.001. 
Interestingly, even though both cell densities were differently affected by BEZ235 
alone, when associated with cisplatin, cells demonstrated equally high cytotoxicity, 
which demonstrates the advantage of a combination treatment, compared to the 
inhibitor alone. As it has been suggested by many reports, the biggest advantage of 
combinatory therapy is the ability to reduce drug concentration to achieve the same 
effect with lower side effects for the patient. More specifically, the 500 nM 
concentration of the PI3K inhibitor lead to high unspecific cytotoxicity and a massive 
gain in sensitivity in all treatment groups, reducing the RF of MV3 cells by 50-60%, 
independently of cell density. Despite the slight differences between the integrin 
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activation stimuli, the combination of cisplatin and inhibitor clearly overcomes cell 
cycle arrest and prevents the formation of the plateau observed for this concentration 
of inhibitor alone. This is in accordance with several previous reports that establish the 
synergy between BEZ235 and other platinum drugs and taxanes (325–327).  
In summary, this highlights the relevance of PI3K signalling for cells to survive 
cisplatin treatment and suggests the blockade of PI3K to be a highly promising target 
to affect chemosensitivity of melanoma cells. This also impressively confirms the role 
of integrins in steering the cells into a chemoresistant state, the massive sensitization 
showed by the RFs 50% smaller than 1 supports our hypothesis.  
 
Microscopy of β1 integrin-blocking antibody on MV3 cell line 
The protective effect showed by Coll against BEZ235 associated with the fact that 
treatment with Coll was the most effective in increasing the RF, points to the 
involvement of the β1 integrin subunit, which is the main ligand to Coll, in the cisplatin 
chemoresistance phenomena of MV3 melanoma cells. Aiming to test this hypothesis, 
MV3 cells were grown on Coll-coated 24-well plates for 48 hours and then treated with 
1.75µg/ml P5D2 β1 integrin-blocking antibody for 24 hours. Subsequently, cells were 
analysed by microscopy. 
 
Figure 46. Microscopic images of MV3 wt treated with β1 integrin-blocking antibody. Exemplary 
pictures of one of at least three experiments. Cells were cultured for 48 hours, on 24-well plates, in the 
presence or absence of Coll coating. Then, cells were treated with 1.75µg/ml P5D2 β1 integrin-blocking 
anti-body for 24 hours, prior to microscopy analysis. 
Data clearly shows that the antibody had a massive effect on cells platted on the Coll-
coated surface, which corroborates the hypothesis that CAM-DR formation in MV3 is 
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mediated by β1 integrin through activation by Coll binding. This, taken together with 
our previous data which shows that Coll increases cells RF (Figure 37) by impacting 
cell signalling (Figure 39), led us to the conclusion that β1 integrin is one of the main 
factors responsible for cell adhesion-mediated cisplatin resistance in MV3 melanoma 
cell line.  
MV3 β1 integrin kd cell line 
β1 integrin knockdown on MV3 wt cells 
After the promising results shown by the inhibition of β1 integrin by the P5D2 blocking 
antibody, the next logical step was to establish an MV3 mutant cell line with reduced 
expression of this integrin subunit. This was performed as described in the materials 
and methods section by a lentiviral approach and the resulting knockdown (kd) cells 
were called MV3 β1 integrin kd cell line. With the purpose of confirming the efficiency 
of the knockdown cells, they were submitted to western blot, as advised by the plasmid 
manufacturer, to measure the amount of β1 integrin in the kd cells in relation to the wild 
type (wt) MV3 cells. 
 
Figure 47. Western blot of MV3 β1-integrin kd to confirm downregulation. Exemplary picture 
represents one of at least three assessments. MV3 wt, MV3 β1-integrin kd and MV3 scramble cell lines 
were grown to 80% confluence, in uncoated cell flasks, before cell lysates were harvested and prepared 
for SDS page followed by western blot. Membranes were developed by chemiluminescence and analysed 
using ChemiDoc ™ XRS + system. 
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Wild type MV3 cells showed high levels of β1 integrin expression, while the protein 
could barely be detected in the knockdown cells. This confirmed that the cell 
transduction had massively reduced β1 integrin levels in the MV3 β1 integrin kd cells 
without any apparent changes in cell morphology or viability. However, MV3 scramble 
cells showed an unexpected increase in β1 integrin expression when compared to the 
wild type. We believe this to be the result of a random point integration.  
A major disadvantage of delivery systems for stable transfections is that, even though 
constructs are engineered to avoid random integration in the genome of the cell, it can 
still occur and lead to undesirable effects, such as insertional mutagenesis or different 
levels of expression of shRNA, depending on the area of integration (316,371). As 
stated in the materials and methods chapter, the lentiviral particles were commercially 
acquired, thus the construct sequence is protected by intellectual property. The scramble 
lentivirus particles encode a non-targeted sequence, which works as negative control 
for targeted shRNA lentiviral particles, which possess the same construct, but several 
different knockdown targets. For this reason, it is possible that the scramble sequence 
has inserted itself in a different location in the cell genome other than the targeted 
knockdown.  
Other experiments showed that the MV3 scramble cell line presents a completely 
different behaviour and protein expression than the wild type cells (data not shown). 
This associated with the western blot data, that clearly shows that the scramble 
sequence interferes with the expression of our target protein, β1 integrin; led us to the 
conclusion that a comparison between MV3 β1 integrin kd and MV3 scramble would 
not represent an accurate picture of cell behaviour and knockdown effect. For this 
reason, the effect of β1 integrin knockdown will be evaluated considering the wild type 
and not the scramble cells. 
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MV3 β1 integrin kd cell line sensitivity to cisplatin and integrin activating 
stimuli 
To test the new cell line sensitivity to cisplatin, wild type MV3 and MV3 β1 integrin 
kd cells were submitted to MTT cell cytotoxicity assay.  
 
Figure 48. Impact of β1-integrin knockdown on sigmoidal concentration-response curves. Curves 
represent one of at least three MTT assays. The sensitivity of MV3 β1-integrin kd cell line to cisplatin 
was compared to the wild type after a 72-hour incubation period with drug logarithmic concentration 
curve. The sigmoidal concentration-response curves were used to determine IC50 values. 
 
Figure 49. Evaluation of the cisplatin resistance factor of MV3 β1-integrin kd cells. Here represented 
mean value and SEM of IC50 values from each cell line obtained from at least three MTT experiments. 
One-way ANOVA statistical analysis was used; asterisks indicate statistical significance * P<0.05; ** 
P<0.01; *** P<0.001. 
The knockdown of β1 integrin only led to a slight sensitization to cisplatin, compared 
to wild type cells. Since the β1 integrin by the P5D2 blocking antibody only showed an 
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effect when associated to Coll, this could also be the case for the MV3 β1 integrin kd 
cells. With the aim of testing if integrin activating stimuli would have an effect on such 
cells, they were grown on Coll-coated plates or treated with 1µM Mn2+ solution. Since, 
from the beginning, the combination of these treatments had constantly shown an 
intermediated response instead of a synergistic one, combinatory treatments were not 
performed in the knockdown cells. 
 
Figure 50. MV3 β1-integrin kd cell line sigmoidal concentration-response curves upon integrin 
activation by Coll and Mn2+. Curves shown represent one of at least three assays. Cells were platted on 
Coll or incubated with a final concentration in well of 100 µM Mn2+, then incubated for 72 hours with 
cisplatin logarithmic concentration curve. Cell sensitivity to the drug was assessed by quantifying the 
number of living cells using MTT assay. The data obtained was plotted into sigmoidal concentration-
response curves and used to determine the IC50 values. 
 
Table 7. Cisplatin IC50 on MV3 β1-integrin kd cell line upon Mn2+ and Coll treatment 
Cell Density Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
Cisplatin 5.38 ± 0.08 4.2 
Mn2+ 5.42 ± 0.07 3.8 
Collagen 5.42 ± 0.09 3.8 
10000 
cells / well 
Cisplatin 5.24 ± 0.05 5.7 
Mn2+ 5.30 ± 0.02 5.0 
Collagen 5.29 ± 0.16 5.1 
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Figure 51. Resistance factors of MV3 β1-integrin kd after treatment with cisplatin concomitant to 
Coll or Mn2+. Cells were submitted to MTT assay, after 72 hours of incubation with cisplatin under 
integrin activating stimuli 1 mM Mn2+ solution or Coll coating. The data displayed here correspond to 
the mean value and SD of the RF (ratio between IC50 of treated vs. untreated) of at least three 
measurements. One-way ANOVA statistical analysis was used; asterisks indicate statistical significance 
only in relation to cisplatin treated cells: * P<0.05; ** P<0.01; *** P<0.001. 
While wild type cells presented statistically significant increase in the resistance factor 
on Coll-coated surfaces and slight increase upon Mn2+ treatment (Figure 37), MV3 β1 
integrin kd cells were irresponsive to integrin activating stimuli. Even thought, the 
treatment with cisplatin alone had not been able to display a significant difference 
between wild type and β1 integrin knockdown cells, there was a possibility that this 
would change once integrins were activated through Coll coating or Mn2+ treatment. 
Unfortunately, this was not the case, while MV3 wt consistently exhibited an 
augmented cisplatin resistance when treated with integrin activators (Figure 37), we 
were neither able to replicate this in the MV3 β1 integrin kd cells, nor show an increase 
in cell sensitivity to cisplatin. These observations were difficult to accept considering 
that all the experimental evidence from the wild type cells points to a strong β1 integrin–
Coll axis and the involvement of the two proteins in the resistance formation of these 
cells. For this reason, it became clear that further investigation was required, so, first 
we decided to compare the wild type cells and MV3 β1 integrin kd cells under the 
microscope on Coll-coated surfaces to the effects observed in the P5D2 β1 integrin-
blocking antibody by microscopy. 
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β1 integrin kd affects cells differently than β1 integrin-blocking antibody 
Although the previous data obtained with the wild type cells were quite promising and 
strongly indicated that β1 integrin was a key molecule in the chemoresistance of the 
cells upon Coll activation, the reduction in the resistance factor of MV3 β1 integrin kd 
cells was only slightly lower than the wild type MV3, and no response could be 
observed from the integrin activators. In order to gain a better understanding of the 
reasons for these somewhat disappointing data, MV3 β1 integrin kd and wild type cell 
lines were observed via microscopy. Cells were seeded on 24-well plates, with or 
without Coll coating, and grown for 72 hours and analysed via microscopy. Results 
were compared to the effect of the P5D2 β1 integrin-blocking antibody on MV3 wild 
type cells. 
 
Figure 52. Microscopy images of MV3 β1 integrin kd. Knockdown and wild type MV3 cells were 
cultured on 24-well plates in the presence or absence of Coll coating and photographed after 72 hours. 
Pictures represent results observed in of one of at least three experiments. 
It can be observed in the pictures that the considerable reduction of the β1 integrin did 
not provoke any apparent change in cell morphology or viability. Besides, β1 integrin 
kd cells seem to be slightly less confluent on the Coll surface, which could indicate that, 
similarly to the P5D2 β1 integrin-blocking antibody, integrin activation by Coll triggers 
cell signalling pathways that would usually be reinforced or carried forward by β1 
integrin. Since this integrin is not present, the signal cannot be transmitted and it is 
difficult for cells to adhere, thus they proliferate less or die.  
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This is in accordance with above-mentioned literature that has linked β1 integrin to a 
more adhesive and proliferative cell-profile in normal and cancer cells (259–261). 
Nevertheless, the phenotype provoked by P5D2 β1 integrin-blocking antibody 
definitely could not be observed, which is, unfortunately, in accordance with the only 
slight reduction on the RF value of the knockdown cells under cisplatin (Figure 49) and 
irresponsive to integrin activating stimuli observed in the MTT assay (Figure 50). A 
reason for the difference between β1 integrin knockdown and inhibition by antibody 
could be that, on one hand, knockdown cells suffer a genetic change that provokes cell-
signal rewiring, which ensures cell survival. Moreover, these adaptive changes have 
taken place before cells come into contact with Coll. On the other hand, inhibition by 
antibodies is a quick environmental change that demands a rapid adaptive response 
from the cells. More importantly, cells were put into contact with Coll first and β1 
integrin was blocked after a 24-hour adhesion period. This means that cells had been 
activated and were strongly relying on the Coll induced β1 integrin signalling, when it 
was suddenly interrupted, causing cell death. In order to investigate if the 
abovementioned integrin signalling rewiring did occur in the β1 integrin knockdown, 
cells were submitted to flow cytometry assay.  
 
Evaluation of β1 integrin kd on the FAK/PI3K/AKT signalling pathway of 
MV3 cell line by flow cytometry 
The unexpected data obtained from the MV3 β1 integrin kd cell line, more precisely, 
the inability of β1 integrin downregulation to sensitize cells to cisplatin, led us to 
investigate how integrin signalling had been affected by the knockdown. Moreover, up 
to this point, the evidence gathered pointed to the involvement of the FAK/PI3K/AKT 
cell-signalling pathway in the resistance formation of the wild type cells, so this 
pathway was investigated on MV3 β1 integrin kd cells as well, in the presence of 
cisplatin. 
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Figure 53. Changes on integrins signalling triggered by β1 integrin knockdown observed by flow 
cytometry. A. Total protein levels of AKT, PI3K and FAK. B. Levels of active AKT, PI3K and FAK. 
MV3 β1 integrin kd cells were either incubated with final concentration of 100 µM Mn2+ for 5 minutes 
or cultivated in Coll-coated or uncoated cell flasks before treatment with 7.5 µM cisplatin for 72 hours. 
Depicted, geomean and SEM obtained from at least three flow cytometry experiments. Asterisks indicate 
statistical significance calculated by ANOVA: * P<0.05; ** P<0.01; *** P<0.001. C. Representation of 
signalling pathway activation as relative comparison between the total and phosphorylated protein 
amounts in percentage. 
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Interestingly, we could observe a general reduction of total protein expression in the 
MV3 β1 integrin kd, while the phosphorylated forms of AKT and FAK remained the 
same as in the wild type cells. Moreover, the amount of active PI3K, which had been 
significantly increased in MV3 wt, was massively reduced in the absence of β1 integrin.  
This indicates, first that β1 integrin downregulation puts cells under stress, which they 
try to compensate by increasing protein activation, as we can observe in Figure 53C, 
which shows the difference in the activation levels of cell signalling proteins between 
the two cell lines. In the wild type cell only approximately 4% of total FAK, 13% of 
total PI3K, and 12% of total AKT is activated, while in the knockdown cells, a much 
higher activation percentage can be observed: 60% for FAK, 26% for PI3K, 20% for 
AKT. Second, while in the wild cell the signalling is amplified from one effector to the 
other, in the β1 integrin deficient counterpart, the signalling fades, since activation 
decreases according to how downstream the effector is. These results indicate that there 
could be a compensation mechanism involved and that the activation seen could be 
initiated by other integrin subtypes that are unable to efficiently carry the message all 
the way to the nucleus. It has been discussed in the introduction of this work that the 
expression and cooperation between β1 and β3 integrins is a very complex and not 
completely understood cell mechanism; and that breast cancer cells have been shown 
to compensate for the downregulation β1 integrin with increased expression of β3 
integrins (260). Thus, it is possible that this integrin subtype could be responsible for 
this compensation mechanism in MV3 β1 integrin kd cells as well, which was tested by 
submitting cell lysates to western blot.  
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β3 integrin expression on MV3 β1 integrin kd cell line 
As discussed above, literature reports of cooperation and regulation between β1 and β3 
integrins, led us to suspect the involvement of the later integrin subtype in a possible 
compensation mechanism. For this reason, we evaluated the wild type and β1 integrin 
kd MV3 cell lysates via western blot to assess the amount of β3 integrin present in these 
cells. 
 
Figure 54. Expression level of β3-integrin subunit on MV3 β1-integrin kd cells obtained by western 
blot. The image shown represents one of at least three experiments. Cell lysates were obtained from 80% 
confluent cells, cultivated in uncoated cell flasks. SDS page followed by western blot, membranes 
analysis was performed as previously described. 
The western blot data confirmed the increase of β3 integrin in the β1 integrin kd cell 
line, in relation to the wild type MV3. This compensation mechanism has been reported 
in breast cancer cells (260), it is an adaptive survival response that leads to the 
upregulation of a different integrin subunit to compensate for the integrin deficit. This 
explains the only slight reduction in the resistance factor in the knockdown cells and 
demonstrates the importance of β1 integrins for cells. Moreover, even though β3 
integrin displays some protective effect against cisplatin, it does not achieve exact the 
same effect as β1 integrin, since cells were irresponsive to Mn2+ and Coll stimuli and 
PI3K signalling was reduced. This might result from the fact that β3 integrin preferable 
binding partner is vitronectin and not Coll (160). Besides, in order for β3 integrins to 
be able to attach to Coll, there must be an initial attachment made by β1 integrins that 
exposes the RGD binding site of Coll (191). 
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Cisplatin treatment changes protein profile of MV3 cell line  
Alterations in integrin expression pattern of wild type MV3 cells caused 
by cisplatin 
With the intention of looking for other interesting targets that could be involved in 
association with β1 integrin in resistance formation, cells were submitted to the 
Proteome Profiler ™ Human Soluble Receptor Array, which provides a broad view of 
cell membrane proteins expressed. Since cisplatin has been known to alter cell 
expression pattern (51,73,109), we looked into how cisplatin influences the integrin 
status in terms of general toxicity to the cells. Therefore, the assay was performed under 
the influence of cisplatin at a concentration of 7.5 µM. 
 
Figure 55. Impact of cisplatin treatment on the integrin status of MV3 melanoma cell line. Cells 
were incubated for 72 hours in the presence (white) or absence (black) of 7.5 µM cisplatin. Cell lysates 
were then submitted to Proteome Profiler ™ Human Soluble Receptor Array. Results of cisplatin-treated 
cells (white) were compared to untreated cells (black). Measurements were conducted in duplicates. 
Adapted from Piva et al. (369). 
The array revealed a strong decrease in a great variety of proteins (data not shown) and 
a shift in integrin distribution among its subunits representing one of only a few up-
regulations in proteins, under cisplatin treatment. Interestingly, the overall integrin 
expression pattern undergoes a shift in the sub-type expressions, during which there is 
a down-regulation of several of those integrin subunits, which are important for Coll 
binding, such as β1 and α3. All α-chains of integrins investigated were strongly down-
regulated, while the ratio of β-chain containing integrins was, with exception of β1, 
upregulated. Integrin subunits β2, β3, β4, β5 and β6, which are barely detectable in 
untreated cells, were more strongly expressed under cisplatin stress. Cisplatin clearly 
alters the integrin expression pattern of MV3 cells, possibly indicating a direct link to 
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the different responses in cell sensitivity to cisplatin. For example, the decrease of Coll 
binding integrins β1 and α3 and shift to other integrin subtypes serves as first hallmark 
for the differences in integrin activation observed above (Figure 40). 
 
Transformation of the syndecan profile of MV3 wt cells 
Other  proteins present in the Proteome Profiler ™ Human Soluble Receptor Array are 
syndecans-1 and 4. As explained above, cisplatin treatment led to a general 
downregulation of cell membrane proteins, which is an interesting contrast to flow 
cytometry results, presented in Figure 40, that show intracellular proteins upregulation 
and increased activation upon cisplatin treatment, as a survival adaptive response. This 
indicates that, under stress, cell machinery concentrates protein transcription efforts to 
express proteins that are essential to cell survival, mostly intracellular signalling 
molecules, but also a few crucial cell membrane proteins. As it was the case of 
syndecan-1, which was the only protein from the array that exhibited a statistically 
significant increase in expression upon cisplatin treatment. 
 
Figure 56. Cisplatin treatment alters syndecan profile of MV3 melanoma cell line. Cell lysates were 
harvested from untreated cells (white) or cells kept in the presence of 7.5µM cisplatin (black) for 72 
hours. Results obtained with Proteome Profiler™ Human Soluble Receptor Array were analysed by 
comparing cisplatin-treated (black) to untreated (white) cells. Measurements were conducted in 
duplicates. 
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Interestingly, similar to integrin, the syndecan status showed a shift from the expression 
of exclusively syndecan-4, to the expression of about 50% syndecan-1, which 
demonstrates the importance of this proteoglycan for cell survival. As discussed in the 
introduction, both syndecan-1 and 4 have been shown to cooperate with β1 integrin in 
focal adhesions, and their aberrant expression has been associated with tumour 
malignancy respectively (270,273,274,281,282). Specifically, in breast cancer, 
syndecan-1 co-localization with α2β1 integrin enhances integrin-mediated adhesion 
through actin organization on Coll, in a heparan sulfate-dependent manner (247). 
However, syndecan-4 cooperation with β1 integrin in focal adhesion is the most 
understood and has been shown to be the most important combination for ECM-
mediated cell survival (283). Actually, it was not until recently that it could be shown 
that syndecan-1 can also cooperate with several integrins (αvβ3, αvβ5, α2β1 α6β4) to 
form focal adhesions on vitronectin and laminin (273,274,281,282). In comparison with 
the results of the Proteome Profiler ™ Human Soluble Receptor Array, it is evident that 
the shift in syndecan expression pattern is intimately connected with the change in the 
integrin profile, since upregulation of syndecan-1 was followed by upregulation of its 
binding partners β3, β5 and β4 (Figure 55). The contrary being true for syndecan-4 and 
β1 integrin, as well. Thus, these two syndecans would definitely be involved in the 
CAM-DR phenomena triggered by integrins. 
MV3 Syn-4 kd cell line  
Syndecan-4 knockdown on MV3 wt cells 
As observed above, upon cisplatin treatment MV3 cells showed a diversification in 
their syndecan profile (Figure 56). There was a reduction in syndecan-4 expression of 
about 50%, with a simultaneous increase of approximately 50% in syndecan-1 
expression. With the purpose of evaluating if syndecan-1 alone could still trigger cell 
resistance to cisplatin, we used the MV3 syndecan-4 knockdown (MV3 Syn-4 kd) cell 
line, stablished in our group as described in methods. 
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Figure 57. Establishment of MV3 syndecan-4 knockdown cell line and cell functional consequences. 
A. Knockdown confirmation by western blot. MV3 Syn-4 kd cells (aSDC-4 MV3kd) were compared to 
MV3 wt and MV3 negative control (ntMV3) with respect to syndecan-4 expression. SDC-4 monomer 
32 kDa, SDC-4 dimer 68.2 kDa, β-actin 42k Da. B. Flow cytometry data to determine the impact of 
syndecan-4 knockdown on the expression pattern of different integrin subunits and syndecan-1. The grey 
peak represents the secondary antibody control, MV3 wt is represented in black and MV3 Syn-4 kd cells 
in red. Adapted from Gerber et al. (315). 
As demonstrated by our group, syndecan-4 knockdown reduced target protein 
expression without interfering in the syndecan-1 or integrin profile of the cells 
(315,372). As discussed above, syndecans are a known co-receptor for numerous 
integrins, syndecan-4, particularly, has been associated with focal adhesion complexes 
formation and mediating adhesive and migratory capacities (270). For this reason, the 
syndecan profile shift caused by cisplatin seemed strange, but gave us the opportunity 
to investigate if syndecan-1 alone is capable of maintaining the resistant phenotype. 
 
 
B 
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Syndecan-4 kd increases cell sensitivity to cisplatin 
First, MV3 Syn-4 kd cells were submitted to MTT assay aiming to demonstrate their 
response to cisplatin in relation to the wild type cell line and a negative control. MV3 
NT represents the negative control for the MV3 Syn-4 kd cells similar to the MV3 
scramble cell line. NT stands for non-transfecting plasmid. 
 
Figure 58. MV3 Syn-4 kd cell line sigmoidal concentration-response curve in response to cisplatin 
cytotoxicity. MV3 Syn-4 kd cell line sensitivity to cisplatin was assessed in relation to MV3 wt and 
negative control MV3 NT. Exemplary curves that represent one of at least three measurements obtained 
by MTT assay. Cells were left to adhere over night after seeding. In the following day, cisplatin 
logarithmic concentration curve was added and incubated for 72 hours. Sigmoidal concentration-
response curves were used to estimate IC50 values. 
 
Figure 59. MV3 Syn-4 kd cell line sensitivity to cisplatin. Sensitivity of all three cell lines to cisplatin 
is represented using the mean value and SEM of IC50 values from at least three MTT concentration-
response curves. ANOVA statistical analysis was used to calculate statistical significance, which is 
indicated by asterisks: * P<0.05; ** P<0.01; *** P<0.001. 
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The data clearly indicated that the knockdown of syndecan-4 increased cell sensitivity 
to cisplatin treatment. This impressively illustrated, on the one hand, that syndecan-1 
alone cannot maintain the resistant phenotype, and on the other hand, the importance 
of syndecan-4 itself, possibly in triggering integrin activity and the role of integrins in 
the resistance phenomena in MV3. Since the MV3 NT positive control cell line 
consistently presented the same behaviour as the wild type cells in this and other works 
(315,372), we decided it was safe to carry out the integrin activating experiments only 
with MV3 wt and Syn-4 kd cell lines. 
MV3 Syn-4 kd cell line sensitivity to cisplatin upon integrin activating 
stimuli 
The results presented above show that cisplatin treatment induced a change in the 
pattern of syndecan expression in the wild type MV3 cells (Figure 56). Under cisplatin 
stress, cells reduced their expression of syndecan-4 and upregulated the expression of 
syndecan-1, which indicated that this specific proteoglycan sub-type is important for 
cell survival under these conditions. However, we could also show that syndecan-4 also 
plays a role in this phenomenon, since cells deficient in this proteoglycan sub-type were 
more sensitive to cisplatin. Integrin – syndecan cooperation and synergy has been 
discussed throughout this work and is well stablished in literature, the best understood 
example being the cooperation of β1 integrins and syndecan-4 in focal adhesions (283). 
Since our main goal was to investigate the mechanisms of CAM-DR and the role of 
integrins in this process, the next step was to determine the impact of syndecan-4 loss 
in the activation of integrins in cells treated with cisplatin. 
 
Figure 60. MV3 Syn-4 kd cell line response to integrin activation by FN and Mn2+. Sigmoidal 
concentration-response curves are representative of one of at least three MTT experiments. Cells were 
platted on FN and, sometimes, incubated with a final concentration in well of 100 µM Mn2+ previous to 
a 72-hour incubation period with cisplatin logarithmic concentration curve. Sigmoidal concentration-
response curves were used to estimate IC50 values. 
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Table 8. Cisplatin IC50 on MV3 Syn-4 kd cell line upon Mn2+ and FN treatment 
Cell Density Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
Cisplatin 5.24 ± 0.05 5.8 
Fibronectin 5.19 ± 0.05 6.4 
Mn2+ + FN 5.17 ± 0.03 6.7 
10000 
cells / well 
Cisplatin 5.13 ± 0.14 7.5 
Fibronectin 5.10 ± 0.05 7.9 
Mn2+ + FN 5.13 ± 0.16 7.4 
 
Figure 61. Integrin activation by FN and Mn2+ in MV3 Syn-4 kd cells. IC50 values of each 
measurement were used to estimate the resistance factor (ratio between IC50 of treated vs. untreated cells). 
The results shown here correspond to the mean value and SD of the RF of at least 3 assessments. ANOVA 
statistical analysis was used; asterisks indicate statistical significance in relation to cells treated solely 
with cisplatin: * P<0.05; ** P<0.01; *** P<0.001. 
MV3 Syn-4 cells were able to increase their resistance factor to the same levels as the 
wild type cells in almost all cases. The data clearly indicates that the sensitization 
induced by knockdown of syndecan-4 could be reverted, in most cases almost 
completely, by external integrin activating stimuli. This suggests that syndecan-4 is not 
required for integrin interaction, activation and resistance formation in the presence of 
FN, possibly because several different integrin subtypes can bind to FN, and syndecan-
1 has shown to have a more diverse integrin biding profile, than syndecan-4. As 
previously mentioned, syndecan-4 has been shown to cooperate with β1 integrins in 
focal adhesions, including to Coll, which is the main binding partner for these integrin 
subtypes (283,373). In order to investigate the effect of this ligand, the MTT assay was 
performed with Coll-coated plates. 
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Figure 62. Sigmoidal concentration-response curves of MV3 Syn-4 kd cell line in response to 
cisplatin in the presence of Coll and Mn2+. Exemplary curves that represent one of at least three MTT 
assays. Cells were submitted to cisplatin activating stimuli Coll coating and/or incubation with Mn2+, 
before a 72-hour incubation with cisplatin logarithmic concentration curve. The IC50 values were 
calculated from the sigmoidal concentration-response curves obtained. 
Table 9. Cisplatin IC50 on MV3 Syn-4 kd cell line upon Mn2+ and Coll treatment 
Cell Density Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
Cisplatin 4.87 ± 0.08 13.5 
Mn2+ 4.94 ± 0.16 11.5 
Collagen 4.85 ± 0.11 14.2 
Mn2+ + Coll 4.89 ± 0.10 12.8 
10000 
cells / well 
Cisplatin 4.70 ± 0.28 20.1 
Mn2+ 4.61 ± 0.29 24.61 
Collagen 4.66 ± 0.27 22.0 
Mn2+ + Coll 4.68 ± 0.11 21.0 
 
Figure 63. Impact of integrin activation by Coll and Mn2+ on the resistance factors of MV3 Syn-4 
kd cells. IC50 values of each measurement were used to calculate the resistance factor (RF) as indicator 
of sensitivity to cisplatin cytotoxicity. Graph represents mean value and SD of the RF of at least three 
measurements, analysed using ANOVA statistical test in relation only to cisplatin-treated cells; asterisks 
indicate statistical significance: * P<0.05; ** P<0.01; *** P<0.001. 
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Indeed, it can be observed that Coll treatment had an inferior impact on increasing the 
resistance factor of MV3 Syn-4 kd cell. Even though Coll increased knockdown cell 
resistance factors, RFs on Coll were lower than on FN and did not reach the same 
activation levels as MV3 wt. Coll was not able to cause on MV3 Syn-4 kd the same 
effect it has on wild type cells. This might be a result of the integrin pattern shift we 
also observed in the array (Figure 55). It showed that although MV3 cells have a high 
β1 integrin expression, this specific subunit is downregulated upon cisplatin stress. 
Since β1 integrin is the main cell ligand to Coll, its reduction, combined with syndecan-
4 deficiency, makes it harder for this ECM protein to induce resistance.  
Curiously, Mn2+ treatment was only able to compensate for the lack of syndecan-4 on 
the higher cell count, even in the presence of Coll, which is unsurprising, considering 
the results of Mn2+-Coll combinatory treatment observed so far. Most likely, the 
outcome of the higher cell density is not a reflex of Mn2+ itself, but rather of the cell-
cell contacts facilitated by the physical proximity among the cells. As explained before, 
the Proteome Profiler ™ Human Soluble Receptor Array allows for the evaluation of 
many different cell membrane proteins, some of which could be involved in the result 
observed in the higher cell count.  
 
Evaluation of FAK/PI3K/AKT signalling pathway on MV3 Syn-4 kd cell 
line by flow cytometry 
The intriguing data presented above led us to investigate the underlying cell-signalling 
pathways. Flow cytometry experiments were performed aiming to evaluate the cell 
integrin-signalling behaviour of MV3 Syn-4 kd cells under cisplatin stress. 
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Figure 64 Flow cytometry data corresponding to integrin signalling proteins on MV3 Syn-4 kd cell 
line. A. Total protein levels of AKT, PI3K and FAK. B. Levels of phosphorylated AKT, PI3K and FAK, 
active form of the effectors. MV3 Syn-4 kd cells were grown on culture flasks, either coated with Coll 
or uncoated. After that, depending on treatment, incubated with 1 mM Mn2+ solution for 5 minutes, prior 
to addition of 7.5µM of cisplatin and incubation for 72 hours. Flow cytometry results are represented as 
geomean and SEM of at least 3 assays. Statistical significance between treatments was calculated using 
ANOVA and symbolized by asterisks: * P<0.05; ** P<0.01; *** P<0.001. C. Depicts the quotient of the 
total and phosphorylated protein amounts of integrin signalling effectors, which corresponds to 
perceptual activation of each molecule. 
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As expected MV3 Syn-4 kd cells show a lower expression and activation of the 
PI3K/AKT signalling pathway compared to wild type cells. As previously discussed, 
this results from the deficiency of an important integrin-binding partner, syndecan-4, 
that contributes to integrin activation in an outside-in, e.g. integrin clustering, as well 
as, an inside-out manner. From the data gathered so far, we can conclusively state that 
syndecan-4 is an important integrin partner, whose absence impacts the formation of 
cell resistance against cisplatin. The lack of this proteoglycan leads to decreased 
integrin activation and signalling, and consequently, a cisplatin-sensitive phenotype. 
Similar to the β1 integrin knockdown, the amount of phosphorylated FAK is higher in 
Syn-4 kd cells than in their wild type counterpart. This could be observed independently 
of integrin-activating treatment, which indicates that this is a specific adaptive response 
to the Syn-4 deficiency. Moreover, in the wild type cells only a small percentage of the 
expressed FAK is activated, while in the knockdown cells, 100% of the expressed FAK 
is activated into phosphorylated form. This shows that the cells are desperately trying, 
without success, to initiate the FAK/PI3K/AKT survival signalling pathway, through 
integrin activation, with the purpose of enduring cisplatin stress. However, this signal 
cannot be transmitted to the downstream effectors PI3K and AKT, and to the nucleus, 
due to the absence of specific activating kinases such as PDK1 and mTORC2. This is 
because syndecan-4 is responsible for recruiting these kinases to the cell membrane 
where they can interact with AKT and the phosphate donor PIP3, formed by PI3K 
(304,309). As explained in the introduction, for AKT full activation this protein must 
be phosphorylated in two critical residues, namely T308 and S473, by PDK1 and 
mTORC2, respectively. Syndecan-4 mediates the recruitment of these kinases to the 
cell membrane, thus indirectly regulating AKT phosphorylation (286–288). 
Accordingly, when we compare the relative activation of FAK, PI3K and AKT in the 
Syn-4 kd cells, it becomes evident that the integrin survival signal gradually fades away 
at every step of the pathway due to lack of signalling supporting molecules such as the 
above-mentioned kinases. These results are not only in accordance with previous 
reports, but also corroborate what was observed in the previous MTT assay (Figure 63), 
where Coll was not able to re-establish knockdown cell resistance. 
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Impact of PI3K/AKT pathway inhibition by BEZ235 
In face of this data, further investigation into the role of PI3K/AKT signalling pathway 
in these cells was needed. The PI3K inhibitor BEZ235 was used for this purpose. First, 
a cytotoxicity assay was performed to ensure the cells would be treated with the right 
dose of inhibitor. 
 
Figure 65. BEZ235 cytotoxicity on MV3 Syn-4 kd cell line. Representation of one of at least three 
measurements. Cell sensitivity to PI3K inhibitor BEZ235 was obtained by incubating cells for 72 hours 
with a series of concentrations of the inhibitor before MTT cytotoxicity assay. 
Fortunately, MV3 Syn-4 kd cells had a similar response as the wild cells to the PI3K 
inhibitor BEZ235. They showed an IC50 of approximately 200 nM for the lower cell 
count and a plateau at the higher cell count, possibly as a consequence of the ability of 
BEZ235 to induce a cell cycle arrest (308). Therefore, the dose previously used for the 
MV3 wild type cells could be used to treat the knockdown cells. Thus, cells were 
submitted to MTT assay with two different concentrations of BEZ235 (500 nM and 100 
nM) under the same conditions as wild type cells, with Coll and Mn2+ used as integrin 
activating stimuli. Unfortunately, the higher concentration of 500 nM BEZ235 showed 
a high unspecific cytotoxicity when combined with cisplatin, which did not allow 
experiments to be conducted with this dosage of inhibitor. The non-cytotoxic 
concentration of BEZ235, however, showed interesting results. 
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Figure 66. MV3 Syn-4 kd cell line sigmoidal concentration-response curves upon PI3K inhibition. 
One of at least three MTT curves obtained is represented here. Cells were incubated with integrin 
activators (Mn2+ or Coll) concomitantly with 100 nM of PI3K inhibitor BEZ235 for 6 hours, before the 
addition of cisplatin logarithmic concentration curve. MTT assay was performed after 72 hours and 
results used to draw the sigmoidal concentration-response curves used to determine IC50. 
Table 10. Cisplatin IC50 on MV3 Syn-4 cell line upon treatment with 100nM BEZ235 
Cell Density Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
Cisplatin 4.87 ± 0.08 13.5 
100nM BEZ235 4.96 ± 0.14 11.0 
BEZ235 + Mn2+ 4.97 ± 0.16 10.7 
BEZ235 + Coll 5.01 ± 0.17 9.7 
BEZ235 + Mn2+ + Coll 4.97 ± 0.20 10.8 
10000 
cells / well 
Cisplatin 4.70 ± 0.28 20.1 
100nM BEZ235 4.90 ± 0.27 12.6 
BEZ235 + Mn2+ 4.95 ± 0.34 11.3 
BEZ235 + Coll 4.91 ± 0.36 12.2 
 BEZ235 + Mn2+ + Coll 4.84 ± 0.24 14.5 
 
Figure 67. Impact of PI3K inhibition on the resistance factors of MV3 Syn-4 kd cell line. Integrin 
activating stimuli was given to the cells prior to a 6-hour incubation period with 100 nM BEZ235. 
Subsequently, cells were kept on cisplatin logarithmic concentration curve for 72 hours until MTT assay. 
Represented mean value and SD of the RF of at least three experiments. Asterisks indicate statistical 
significance calculated by ANOVA: * P<0.05; ** P<0.01; *** P<0.001. 
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As expected, in spite of the non-cytotoxic concentration of 100 nM of BEZ235 still 
being able to sensitize MV3 Syn-4 kd cells, the reduction of the resistance factors was 
smaller than that of the wild type cells, and greatly dependent on cell density. In the 
previous MTT (Figure 63), the high cell count facilitated the increase of the resistance 
factor in the absence of syndecan-4, due to physical proximity and cell–cell contact. 
This shows that the low cell density was more affected by the reduction of Syn-4. Thus, 
cell seeding at 5000 cells per well showed a lower sensitivity to BEZ235, with a 
reduction of 20-25% in the resistance factors, as a consequence of cell adaptation to 
syndecan-4 deficiency through rewiring of signalling pathways to decrease dependency 
on PI3K/AKT signalling. Conversely, the higher cell count, which was able to partially 
compensate for the low Syn-4 levels due to greater cell-cell contact (Figure 63), still 
depended greatly on PI3K/AKT signalling, thus was more affected by BEZ245 and 
showed a reduction of about 50% in the resistance factor.  
This variation in effect is unsurprising, if we consider that the function of CAM-DR is 
to quickly protect cells from unexpected stress. It is expected that the adaptive changes 
provoked by this phenomenon would be rapid and influenced by many environmental 
factors, including cell count. Furthermore, MV3 cell dependency on syndecan for 
integrin resistance formation; cell-signalling adaptive rewiring to reduced level of 
syndecan-4; and the effect of cell density in this process, could also be observed in the 
following experiment, in which cell surface heparan sulfate (HS) and heparin (Hep) 
were digested with heparitinase. 
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Impact of glycosaminoglycans on sensitivity against cisplatin cytotoxicity 
In summary, the results presented above highlight the importance of syndecans on cell 
signalling and survival by interacting with integrins and regulating their function. 
Additionally, the glycosaminoglycans present in these proteins play an essential role in 
these interactions, as it can be observed in the experiments bellow where wild type 
MV3 and MV3 Syn-4 kd cell lines were submitted to heparan sulfate and heparin 
digestion by heparitinase for 6 hours before cisplatin was added.  
 
 
Figure 68. Sigmoidal concentration-response curves of MV3 wt and MV3 Syn-4 kd cell lines in 
response to HS and Hep digestion by heparitinase. Exemplary curves that represent one of at least 
three measurements obtained via MTT assay. Cells were incubated with 10 μL of heparitinase I (0.1 
U/mL), 6 hours after cell seeding. On the following day, cisplatin logarithmic concentration curve was 
added to all plates and incubated for 72 hours. Sigmoidal concentration-response curves were used to 
estimate IC50 values. 
 
Table 11. Cisplatin IC50 on MV3 and MV3 Syn-4 kd cell line upon heparitinase I treatment 
Cell Density Cell Line Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
MV3 
Cisplatin 4.95 ± 0.42 11.2 
Heparitinase 5.26 ± 0.48 5.5 
MV3 Syn-4 kd 
Cisplatin 5.06 ± 0.08 8.6 
Heparitinase 5.07 ± 0.02 8.5 
10000 
cells / well 
MV3 
Cisplatin 4.80 ± 0.09 15.9 
Heparitinase 5.00 ± 0.12 9.9 
MV3 Syn-4 kd 
Cisplatin 4.92 ± 0.06 11.9 
Heparitinase 4.96 ± 0.05 11.1 
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Figure 69. Resistance factors of MV3 wt and MV3 Syn-4 kd cell lines in the presence of 
heparitinase. IC50 values of each experiment were used to calculate the resistance factors as indicators 
of sensitivity to cisplatin. Results correspond to the mean value and SD of the RF of at least three assays. 
ANOVA statistical analysis was used; asterisks indicate statistical significance compared to cells treated 
solely with cisplatin: * P<0.05; ** P<0.01; *** P<0.001. 
It can be observed that digestion of HS and Hep glycosaminoglycan chains by 
heparitinase affects the wild type cells, more than the knockdown cell line. Moreover, 
in MV3 Syn-4 kd the higher cell density was slightly more affected than the lower cell 
count. Taken together these results confirm the findings that cells undergo cell-
signalling rewiring in order to minimize the effects of syndecan-4 downregulation, and 
that this is dependent on cell density. Besides, this illustrates the importance of HS and 
Hep in the interactions between syndecan and integrin.  
The data obtained so far clearly show the influence of proteoglycans and their GAG 
chains on integrin resistance formation. It has been suggested that LMWH (low 
molecular weight heparins) could sensitize cells to cisplatin by interfering with integrin-
mediated resistance formation by directly binding to specific integrins or inhibiting the 
anti-apoptotic Wnt pathway (374–376). Aiming to investigate if this was the case for 
the MV3 cell line, cells were submitted to MTT in the presence of Tinzaparin, a 
LMWH.  
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Figure 70. The impact of LMWH Tinzaparin on cisplatin cytotoxicity towards MV3 wt cell line 
grown on Coll. Sigmoidal concentration-response curves shown represent one of at least three MTT 
assays. Depending on treatment, cells were platted on Coll-coated plates and/or incubated with 10 µg 
tinzaparin (500 μg/mL), 6 hours after cell seeding, or immediately after (0 hrs). Subsequently, cells were 
incubated with cisplatin logarithmic concentration curve for 72 hours. IC50 values were obtained from 
sigmoidal concentration-response curves. 
 
Table 12. Cisplatin IC50 on MV3 cell line upon treatment with LMWH Tinzaparin 
Cell Density Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
Cisplatin 4.95 ± 0.42 11.2 
Tinzaparin 6 h 4.92 ± 0.14 12.1 
Tinzaparin 6 h + Coll 4.86 ± 0.24 13.7 
Tinzaparin 0 h 4.86 ± 0.16 13.7 
Tinzaparin 0 h + Coll 4.85 ± 0.18 14.0 
10000 
cells / well 
Cisplatin 4.80 ± 0.09 15.9 
Tinzaparin 6 h 4.76 ± 0.06 17.5 
Tinzaparin 6 h + Coll 4.75 ± 0.02 17.6 
Tinzaparin 0 h 4.74 ± 0.09 18.4 
 Tinzaparin 0 h + Coll 4.72 ± 0.05 18.9 
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Figure 71. LMWH Tinzaparin affects cisplatin cytotoxicity towards MV3 Syn-4 kd cell line grown 
on Coll. Sigmoidal concentration-response curves shown represent one of at least three MTT assays. 
Depending on treatment, cells were platted on Coll-coated plates and/or incubated with 10 µg tinzaparin 
(500 μg/mL), 6 hours after cell seeding, or immediately after (0 hrs). Subsequently, cells were incubated 
with cisplatin logarithmic concentration curve for 72 hours. IC50 values were obtained from sigmoidal 
concentration-response curves. 
 
Table 13. Cisplatin IC50 on MV3 Syn-4 cell line upon treatment with LMWH Tinzaparin 
Cell Density Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
Cisplatin 5.06 ± 0.08 8.6 
Tinzaparin 6 h 4.97 ± 0.21 10.8 
Tinzaparin 6 h + Coll 5.08 ± 0.29 8.3 
Tinzaparin 0 h 5.10 ± 0.25 8.0 
Tinzaparin 0 h + Coll 4.97 ± 0.15 10.7 
10000 
cells / well 
Cisplatin 4.92 ± 0.06 11.9 
Tinzaparin 6 h 4.85 ± 0.09 14.1 
Tinzaparin 6 h + Coll 4.94 ± 0.10 11.4 
Tinzaparin 0 h 4.92 ± 0.06 12.0 
 Tinzaparin 0 h + Coll 4.96 ± 0.16 11.0 
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Figure 72. Effect of Tinzaparin on the response of MV3 wt and MV3 Syn-4 kd cell lines to cisplatin 
in the presence of Coll. RFs were calculated based on the IC50 values of each measurement and 
correspond to the mean value and SD of the RF of at least 3 assays. Statistical analysis was performed 
using ANOVA; asterisks indicate statistical significance in relation to cisplatin treated cells: * P<0.05; 
** P<0.01; *** P<0.001. 
Although it has been shown by our group that Tinzaparin is able to sensitize ovarian 
cancer cisplatin-resistant cells (375,376), this could not be shown for the MV3 wt or 
MV3 Syn-4 kd cells. In fact, wild type cells show lower sensitivity to cisplatin when 
treated with this heparin analogue, while the MV3 Syn-4 kd cells display a decrease in 
RF in almost all treatments. The mechanism of Tinzaparin is not fully understood and 
currently under investigation in our laboratory. So far, Schlesinger et al. have shown 
that Tinzaparin binds to α4β1 integrins with lower affinity than the physiological ligand 
VCAM-1, but with a similar dissociation ratio, which causes a weak inhibition of cell 
binding (374). Furthermore, Pfankuchen et al. were able to show that Tinzaparin can 
overcome cisplatin-resistance in ovarian cancer cells by antagonizing the Wnt pathway 
(375,376).  
Taken together, these results confirm our hypothesis of MV3 Syn-4 kd rewiring to 
decrease syndecan dependency. This can be corroborated by the fact that MV3 wt, 
which relies on syndecan for cell survival, show an increase in its resistance factor, 
most likely because Tinzaparin acts as shed syndecan in the ECM. In comparison, MV3 
Syn-4 kd, which underwent signalling rewiring due to syndecan-4 deficiency, are not 
responsive to syndecan shedding, thus showed reduced RFs.  
The only exception was when cells were treated with Tinzaparin alone, 6 hours after 
cell seeding. In this case, resistance factor increased substantially in both cell lines. In 
the case of MV3 Syn-4 kd, this is most likely a syndecan–integrin unrelated effect. Shed 
syndecan can also bind to heparin-binding growth factors, such as fibroblast growth 
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factor (FGF), vascular endothelial growth factor (VEGF) and platelet-derived growth 
factor (PDGF) (377). Once cells have adhered, Tinzaparin can no longer bind to integrin 
and remains free in the ECM and can influence growth factor receptors, which are 
probably responsible for the effect observed. In contrast, Coll prompts signalling 
syndecan-4 - β1 integrin axis, which cannot be supported because of syndecan-4 
deficiency, independent of when Tinzaparin is added. In Conclusion, this shows, first 
the importance of GAG for the interaction between syndecan and integrins. Second, 
how the delicate balance between these cell components can alter cell fate. 
 
3D Model 
After many attempts to generate a 3D Model in our laboratory we opted for embedding 
all three MV3 cell line variants in VitroGel™ 3D - RGD, which is a mixture of many 
different ECM compounds. The results obtained were a bit disappointing, but 
nevertheless interesting.  
 
Table 14. Cisplatin IC50 on MV3 wt, MV3 β1 integrin kd and MV3 Syn-4 kd cell lines on 3D Model 
Cell Density Cell Line Treatment pIC50 ± SEM IC50 (μM) 
5000 
cells / well 
MV3 
2D Cisplatin 4.89 ± 0.33 12.8 
3D Cisplatin 4.98 ± 0.31 10.5 
MV3 β1 integrin kd 
2D Cisplatin 5.01 ± 0.23 9.7 
3D Cisplatin 4.98 ± 0.05 10.5 
MV3 Syn-4 kd 
2D Cisplatin 4.98 ± 0.29 10.4 
3D Cisplatin 5.04 ± 0.08 9.2 
10000 
cells / well 
MV3 
2D Cisplatin 4.57 ± 0.37 27.0 
3D Cisplatin 4.64 ± 0.42 22.8 
MV3 β1 integrin kd 
2D Cisplatin 4.71 ± 0.02 19.5 
3D Cisplatin 4.69 ± 0.15 20.5 
MV3 Syn-4 kd 
2D Cisplatin 4.61 ± 0.40 24.8 
3D Cisplatin 4.76 ± 0.24 17.45 
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We can observe that, the cells that responded well to integrin activating stimuli in 2D, 
MV3 wt and MV3 Syn-4 kd, were sensitized to cisplatin by the matrix embedding in 
comparison with their counterparts, which were grown on 2D surfaces. This is probably 
a consequence of cell adaptation to being grown in layers, the time window for the 
assay (96 hours) is not enough for cells to re-acquire their 3D capacities. 
Curiously, in the case of the MV3 β1 integrin kd cell line, which were unresponsive to 
the Mn2+ and Coll treatments, the 3D matrix demonstrated to be a protective 
environment against cisplatin. As discussed above, the absence of β1 integrin was not 
able to reduce the RF of MV3 cells because of a compensation mechanism that 
triggered the increase in β3 integrin expression (Figure 54). As previously explained, 
β3 integrin is not able to connect to Coll alone. The interaction of β1 integrin with this 
matrix protein is necessary to expose the RGD binding site, where β3 integrin can bind 
(191). However, in a mixed matrix as VitroGel™ 3D - RGD there are many other 
binding partners for the β3 integrins which possess RGD binding sites available, such 
as its preferable binding partner vitronectin (160). For this reason, this more varied 
matrix was able to trigger a protective effect on these cells. 
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5. Conclusion 
In the present work we were able to provide evidence that, first, different cell lines from 
the same cancer type (melanoma) can present completely different protein expression 
profiles, proliferation and response to therapy. Second, we were able to demonstrate the 
importance of the ECM in resistance formation of the MV3 melanoma cell line, 
specifically the effect of Coll I on integrin activation. We showed that the interaction 
between Coll and integrins triggers cell signalling pathways that increase cell resistance 
to cisplatin treatment. This activation can be blocked by using β1 integrin-blocking 
antibody P5D2, which leads to cell death, establishing not only the involvement, but 
also the importance of this integrin subtype, as main Coll ligand in resistance 
development. Moreover, we were able to observe that Mn2+ activation of integrins also 
induces cisplatin resistance, but at a lower level and non-synergistic manner to Coll, 
indicating that more than one signalling pathway might be involved.  
Nevertheless, it could be observed by flow cytometry that both treatments promoted 
activation of the FAK/PI3K/AKT signalling pathway, at different levels. Additionally, 
the inhibition of this pathway by BEZ235, a PI3K blocking molecule, induced massive 
sensitization of cells to cisplatin; and this effect could not be reverted by treatments 
with Coll or Mn2+. This corroborates the involvement of this pathway in the 
transmission of the survival-signal initiated by the contact between β1 integrin and Coll, 
or integrin activation through Mn2+ binding, from the cell membrane, through the 
cytoplasm, into the nucleus, where it will affect protein transcription and lead to cell 
survival. 
MV3 β1 integrin knockdown was also performed and, unfortunately, did not produce 
the expected results. Even though, the knockdown greatly reduced the levels of β1 
integrin in MV3 cells, the new cell line displayed only a slight reduction in the 
resistance factor, when compared to the wild type. Although it might seem that our 
attempt to demonstrate the importance of β1 integrin on MV3 cisplatin resistance failed, 
this is not true. It allowed us to observe the effect of a genetic change, such as a 
knockdown, as a powerful selective tool that leaves only the cells that were able to 
somehow adapt to the genetic modification to be evaluated. In contrast, the antibody 
treatment to block β1 integrin is a rapid environmental change that forces cells to adapt 
quickly. Therefore, knockdown is more similar to the acquired drug resistance, which 
leads to permanent genetic changes, such as the upregulation of β3 integrin observed; 
while the antibody treatment can be compared to environmentally-mediated drug 
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resistance, and, for this reason, is more appropriate to demonstrate our hypothesis. This 
being said, we can at this point state with confidence that the data reported in this work 
illustrates the importance and involvement of β1 integrin in the resistance mechanism 
of MV3 melanoma cells treated with cisplatin. Moreover, this mechanism is mediated 
by integrin activation through Coll Type I. 
Next, the effect of cisplatin on the MV3 cell line was evaluated and a shift in the integrin 
and syndecan profiles could be observed. All integrins α-chains were strongly down-
regulated while the ratio of β-chain containing integrins was, with exception of β1, up-
regulated. In the syndecan profile, we could observe a switch from the expression of 
only syndecan-4, to a 50 – 50 distribution between syndecans 1 and 4. Another 
knockdown was performed to reduce the expression of syndecan-4. The lack of this 
important integrin partner led to increased cisplatin sensitivity; FN was able to restore 
resistant factors even in the absence of Syndecan-4. This was not the case for Coll, 
which demonstrated the importance of this proteoglycan for β1 integrin activation, 
specifically.  
Similarly, in the β1 integrin knockdown, we could observe a massive increase in FAK 
activation in the knockdown cells, as a desperate attempt to initiate survival signalling. 
However, since Syndecan-4 is responsible for the recruitment of kinases that 
phosphorylate AKT to the cell membrane, the signal cannot be transmitted to the 
downstream effectors PI3K and AKT, which was observed by a decreased expression 
and activation of the PI3K/AKT signalling pathway, in comparison to wild type cells. 
Thus, the genetic modification induced by us forced cells to adapt by rewiring and 
becoming less dependent on this pathway and syndecan-4 to survive. Accordingly, 
syndecan-4-deficient cells were less affected by the BEZ235 PI3K inhibitor and HS 
and Hep ablation with heparitinase, than the wild type cells. This confirms that the 
knockdown leads cells to adapt by becoming less dependent on the signalling pathways 
activated by the missing protein, in this case syndecan-4.  
Finally, due to several reports about the benefit of LMWH in sensitizing cells to 
cisplatin, cells were treated with Tinzaparin (374–376). This was the case for syndecan-
4 knockdown cells, but not the for MV3 cell line, which became slightly resistant. This 
is probably also a reflex of the independency of syndecan-4-deficient cells from this 
proteoglycan, which the MV3 cells do not present. However, the Tinzaparin mechanism 
of action is still not completely understood and more investigation is necessary.  
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Taken together, these results demonstrate the importance and complexity of the 
interaction of integrins and syndecans with the ECM in supporting cell adaptation and 
survival. Moreover, they show the plasticity of cancer cells and give some insight into 
the challenges of cancer biology and therapy development. Certainly, extensive 
research is still needed in this field, but hopefully this work will have made a small, yet, 
significant contribution.  
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